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Abstract 
Mus musculus is a human commensal species and an important model of human development 
and disease with a need for approaches to determine the contribution of copy number variants 
(CNVs) to genetic variation in laboratory and wild mice, and arising with normal mouse 
development and disease. Here, the Mouse Diversity Genotyping array (MDGA)-approach to 
CNV detection is developed to characterize CNV differences between laboratory and wild 
mice, between multiple normal tissues of the same mouse, and between primary mammary 
gland tumours and metastatic lung tissue.  
A CNV detection pipeline was used in conjunction with evaluated probe sets, targeting 
925,378 loci at an inter-probe-set median distance of 319 bp, to identify CNVs in a publicly-
available dataset that includes representatives of 114 classical laboratory (CL) strain mice, 52 
wild-derived (WD) mice, and 19 wild-caught (WC) mice. On average, WC and WD mice (~50 
CNVs/mouse) have twice as many CNVs as CL mice. DdPCR confirmed 96% of MDGA-
predicted copy number states. CL CNVs impact gene pathways related to immunity and 
nucleosome-associated functions, whereas olfaction and pheromone detection are impacted in 
WC mice. WD mice share impacted genic pathways with both cohorts. 
In a five-member C57BL/6J inbred mouse family, losses of developmentally-important 
HOXA genes were detected and confirmed in multiple normal tissues. Further confirmation of 
postzygotic Hoxa13 losses in unrelated C57BL/6J, CBA/CaJ, and DBA/2J mice points to a 
widespread phenomenon occurring in mice, involving mutation hotspots and/or programmed 
losses. 
In comparison to normal tissues (25 CNVs/mouse), cancer samples from an MMTV-
PyMT mouse breast cancer model with lung metastasis have 1.6- to 3.2-fold more CNVs. CNV 
size is reduced and CNV recurrence is increased among primary tumours in the absence of the 
hyaluronan-mediated motility receptor, suggestive of altered mechanisms of CNV formation 
and selection for specific phenotypes in the tumour microenvironment, respectively.  
CNVs were found to arise during normal development, producing different CNV 
profiles than with tumorigenesis and metastasis. CNV profiles also differ between laboratory 
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and wild mice. This thesis presents improvements to an array-based CNV detection and 
analysis pipeline which was used to determine the contribution of CNVs to genetic variation 
in M. musculus. 
Keywords 
Mus musculus, Mouse Diversity Genotyping Array, copy number variants, single nucleotide 
polymorphism, somatic mosaicism, de novo genetic variation, cancer, classical laboratory 
strains, wild-derived strains, wild-caught mice. 
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Chapter 1  
1 Introduction to CNVs and Thesis Aims 
1.1 Copy Number Variants (CNVs) 
Copy number variants (CNVs) are a source of genomic variation that contributes to normal 
and pathogenic phenotypes1–4 through the structural alteration of a genome. As a result, 
CNVs can play an important role in fitness for an individual organism and at a population 
level5,6. Improvements to the resolution and sensitivity of CNV detection technology have 
led to the discovery that CNVs are a common genomic phenomenon, with CNV differences 
being found even between individual cells form the same tissue7. Here, high-resolution 
SNP microarray technology is employed to explore and gain a better understanding of the 
CNV landscape across the genome of Mus musculus, a human commensal species8 and 
important animal model of human diseases, from the perspective of adaptation and 
evolution, somatic mosaicism, and disease.  
1.1.1 Defining CNVs  
Copy number variants (CNVs) are defined as large segments of DNA ranging from ~50 bp 
to several megabases in size, that are present in different numbers of copies between 
genomes9. While the lower size limit of CNVs is not clearly defined since it can overlap 
with other structural variant types like indels (small insertions or deletions), the limit has 
decreased from the commonly used 1 kb minimum as the resolution of CNV detection 
technology and computational methods improved9–11. CNV differences between genomes 
can exist at all levels, ranging from the genomes of two cells of an individual to the 
genomes of two different organisms. In a diploid genome, the expected copy number of 
most DNA regions is two. A DNA segment that occurs as a copy state of one in a diploid 
genome, as opposed to the default two copies, is called a loss or deletion while a DNA 
segment that is present in more than two copies is referred to as a CNV gain, duplication, 
or amplification. Since CNVs can span thousands to millions of base pairs in length, many 
CNVs overlap the full spectrum of functional elements in a genome and can impact 
phenotypes if these elements are dosage sensitive. As such, CNVs play important roles in 
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both normal and pathogenic diversity in many organisms including plants, animals and 
unicellular organisms.  
1.1.2 CNVs and natural and artificial selection 
If CNVs alter the expression of genomic elements that determine phenotypes, then positive 
or negative selection of traits can occur if fitness is affected. Trait selection can occur 
quickly through artificial means when humans intentionally breed and select plants, 
animals and other organisms for specific qualities, sometimes following intentional 
mutation induction. Examples of artificial selection by humans are numerous and include 
generation of different dog breeds12, creating ornamental plant cultivars13, and 
improvement of lactic acid bacteria strains used for producing fermented dairy products14. 
Sometimes there are unintended consequences of artificial selection. For example, some 
mutations in livestock and pets produce desirable traits when present in a heterozygous 
state but are deleterious when present in a homozygous state15. Under natural selection, 
traits that confer a fitness advantage to individuals within a population will be positively 
selected while deleterious traits will negatively affect fitness and be under negative 
selection. CNVs are known to impact phenotypes and cause diseases through numerous 
mechanisms including gene dosage changes, gene interruption, gene fusion, position 
effects, unmasking recessive alleles or functional polymorphisms, and potential 
transvection effects16. 
More than 145 CNV genes show evidence of positive selection in humans17. During 
recent human evolution, different human populations gained variation in the copy number 
of the dosage-sensitive salivary amylse gene, AMY1. Gains in AMY1 range from two to 
twenty copies within human populations, have not been observed in Denisovan or 
Neanderthal genomes, and are thought to be associated with the introduction of starch-rich 
foods into the human diet18–20. Individual differences in AMY1 copy number can lead to 
different oral perceptions of starch viscosity, and this in turn may influence individual food 
choices and consumption levels of starch-containing foods21. Because AMY1 is expressed 
in multiple tissues and salivary a-amylase has a limited role in starch digestion, it was 
proposed that additional adaptive advantages may be responsible for retaining AMY1 copy 
number gains in humans18. The spread of prehistoric agriculture not only impacted humans, 
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it also correlates with the copy number expansion of the pancreatic amylase gene, AMY2B, 
in dogs22. Dog breeds which were more likely to have had high starch diets historically, 
have more AMY2B copies on average than do dog breeds who had low starch diets23.  
Positive selection can occur for copy number losses as well as gains. Three genomic 
elements that were deleted or pseudogenized in humans are an enhancer located near the 
growth arrest and DNA damage inducible gamma (GADD45G) gene, the caspase 12 
(CASP12) gene, and an androgen receptor (AR) enhancer. In modern humans, CASP12 has 
nearly reached complete fixation for a null allele that reduces susceptibility to severe 
sepsis24. Deletion of the GADD45G enhancer correlates increased growth of specific brain 
regions while the deletion of the AR enhancer is associated with the loss of sensory 
vibrissae and penile spines25. The loss of penile spines in the human lineage may have been 
in response to a changing reproductive strategy that included pair bonding and 
monogamy26.  
In the modern human genome, 91% of genes that are greater than 10 kb, occur in a 
fixed diploid state27. Almost half of the duplicated genes are not variable in copy number 
between individuals, and of the genes that are variable, 80% do not exceed a copy number 
state of five27. This implies that the majority of the human genome is fairly stable with 
regard to copy number and a limited number of gene families have extreme variation. This 
is consistent with studies of bacteria that have shown gene amplifications to be unstable 
and associated with increased fitness costs28; excess gene copies are quickly being reduced 
to lower copy numbers. After comparing the human data to the gorilla, chimpanzee and 
orangutan genomes, Sudmant et al (2010) were able to identify 53 gene families with 
increased copy number in humans, including eight gene families that appeared to be fixed 
in humans27. The human specific duplications included genes related to brain development 
and function.  
 Similarly, many human CNVs are enriched for genes with chemosensation and 
immune response functions29. Chemosensation genes include olfactory receptor (OR) 
genes, which belong to the largest gene family in humans and are known to undergo gene 
duplication and pseudogenization events30. The rate of OR gene pseudogenization has 
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occurred almost 4-fold faster in humans than in other primates, possibly resulting from a 
lowered dependence on chemosensory perception in humans, relative to apes31. Additional 
support for environmental pressures shaping the OR gene family in humans is provided by 
observations that the number of intact and functional OR genes differs greatly between 
modern human populations32. Although humans have more OR pseudogenes than many 
mammals, research suggests that contrary to popular belief, humans do not have a poor 
sense of smell in comparison to other mammals, like dogs, which are known for their sense 
of smell33.  
CNVs are frequently found to overlap genes with functions important to the human 
immune system. Human antibody heavy chains are produced by immunoglobulin heavy 
chain (IHC) gene families that arose through duplication and diversification, and are 
currently hotspots for CNV formation34,35. The effects of CNVs on innate immunity have 
been difficult to characterize and their impact on disease susceptibility and progress has 
been controversial36. An example of this is the defensin genes, which are commonly studied 
for their antimicrobial functions37. In humans, copy number polymorphisms of defensin 
genes are limited to a subset of defensin genes and do not appear to be a general feature of  
innate immunity genes38. CNVs of defensin genes have been associated with HIV 
progression to AIDS, and susceptibility to numerous disorders including cervical cancer, 
autoimmune disorders like ankylosing spondylitis and lupus, sarcoidosis in females, 
ulcerative colitis susceptibility, and more39–44. Although there are many findings of 
associations between copy number of immunological genes and disease susceptibility, 
confirmation of the biological roles of candidate CNVs in disease susceptibility is 
required36.  
Also relevant to human health, is the role of CNVs in antibiotic resistance. Bacterial 
acquisition of antibiotic resistance is a two-step process involving the initial amplification 
event of dosage-sensitive genes that confers antibiotic resistance and the subsequent 
mutational events that reduce the fitness costs of the amplification45. These bacterial gene 
amplifications are generated and lost at high rates, making them difficult to study. There 
are at least 22 known instances of multiple bacterial species acquiring antibiotic resistance 
through gene amplifications occurring either on plasmid DNA or chromosome DNA45. One 
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such example is the acquisition of tobramycin resistance in multidrug-resistant 
Acinetobacter baumannii, isolated from a patient46. Treatment of A. baumannii isolates 
with increasing tobramycin concentrations results in either moderate tobramycin resistance 
(≤8 μg/ml) with no fitness costs via low amplification of the aminoglycoside resistance 
gene aphA1, or high tobramycin resistance (16 μg/ml) with impaired fitness resulting from 
greater amplification of aphA1. This experiment mimics the selective pressures acting on 
bacteria outside of the laboratory that are created by humans mainly through excessive and 
improper use of antibiotics, as well as other actions related to infection control and 
prevention47. It is important to understand the mechanisms by which resistance to 
antibiotics is conferred since antibiotic resistance has become a serious health concern for 
both humans, and for conventional livestock farming where antibiotics are routinely used 
in a prophylactic manner48.   
In agriculturally relevant animals, CNV studies are often conducted between 
different breeds to identify contributors to different desirable traits. For chickens, CNVs 
have been studied in different breeds to identify breed- or line-specific CNVs and to 
determine if they have an effect on egg production, body size, growth rate, abdominal fat 
content, feather growth and pea-comb phenotype49–52. CNV studies on pigs have been used 
to determine if there is an association between CNVs and coat colour, backfat thickness, 
meat quality, fatty acid composition and growth traits53–56. In cattle, genomes were 
examined for CNV impacts on growth, milk protein and fat traits, meat quality, and health 
traits57–61. CNV research that is primarily aimed at discovering associations with 
phenotypic traits has also been conducted on agriculturally important animals like sheep, 
goats, ducks, turkeys, and horses62–66 and plants, including in maize, rice, barley, wheat, 
grapes, tomatoes, sorghum, foxtail millet and soybeans67–75. For both plants and animals 
important to agriculture, there is a need to understand structural variation that occurs in the 
genome. This knowledge would assist with maintenance and monitoring of genetic 
diversity in crops or livestock, selecting desirable phenotypic traits, improving the 
understanding of and monitoring for health issues, and improving knowledge regarding the 
domestication history of different species.  
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1.1.3 CNVs and human disease 
CNVs have been extensively studied from a human disease perspective. Over 90% of 
pathogenic CNVs contain ohnologs, which are genes that have been retained following 
ancestral whole-genome duplication events76. This is far lower than observations for 
nonpathogenic CNVs (~30% contain an ohnolog), which suggests that the dosage sensitive 
nature of many ohnologs contained in CNVs appears to be an important part of the 
pathogenicity. Following whole-genome duplication, dosage balancing was required, and 
now, this careful regulation of gene expression is disrupted if the ohnologs are duplicated 
or deleted77. Down syndrome (trisomy 21) is an example of a genetic disorder caused by 
gene dosage alteration, in this case an increase in dosage. The majority of genes associated 
with this genetic disorder can be classified as ohnologs76. These findings regarding the 
relationships between CNVs, dosage-sensitive ohnologs, and aberrant phenotypes with 
increased risk to multiple diseases, are valuable since they may help narrow the list of 
candidates involved in certain diseases. However, it is important to recognize that not all 
dosage-sensitive genes are ohnologs.  
Pathogenic CNVs are involved in both simple, single-gene diseases, and complex 
diseases. With simple diseases, a mutation affecting only one gene or other important 
genomic element (e.g. expression regulators) is enough to result in a disease phenotype. 
For example, CNV duplications of peripheral myelin protein 22 (PMP22), lamin B1 
(LMNB1), and nuclear receptor binding SET domain protein 1 (NSD1) cause Charcot-
Marie-Tooth 1A disease, autosomal dominant leukodystrophy, and a growth retardation 
syndrome, respectively78–80. When deleted, PMP22 causes hereditary neuropathy with 
liability to pressure palsies while a NSD1 deletion causes Sotos syndrome78,81,82. When a 
gene is impacted in such a way that it leads to decreased expression and a pathogenic 
phenotype, whether via a CNV deletion or other means, this is called haploinsufficiency. 
CNVs implicated in complex diseases, including neurological disorders like autism, vary 
in nature in regard to size, copy number state, whether they are recurrent or not, or inherited 
or de novo83–86. Complex diseases and traits with CNV associations include Parkinson 
disease, Alzheimer disease, schizophrenia, epilepsy, and HIV-1 infection susceptibility87–
92.  
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1.1.3.1 Disease thresholds, heteroplasmy and pathogenic 
mosaicism 
CNV deletions and duplications of dosage-sensitive genes may not result in an abnormal 
phenotype if a certain threshold of cellular or tissue malfunction is not reached. Disease 
“thresholds” are commonly used when discussing mitochondrial heteroplasmy – the 
presence of more than one mitochondrial genome in the mitochondrial population within a 
cell or individual. The threshold level for when a phenotypic effect is present is dependent 
on the particular mutation and tissue93. Phenotypic threshold levels for mtDNA mutations 
are generally above 60% and deletions generally have lower thresholds than other 
mutations types94.  
Mitochondrial mutations are common in normal cells and likely inherited 
frequently. In 1995, Chen et al. found that approximately 50% of tested oocytes contained 
a frequently occurring 4,977 bp deletion95. This particular deletion is found in a 
subpopulation of people with chronic progressive external ophthalmoplegia, and Kearns 
Sayre syndrome95–97. A likely explanation for why some people with mitochondrial 
deletions develop diseases while others do not is that people who developed a disease 
inherited a higher mutation load or acquired spontaneous de novo mutations earlier than 
people who did not develop a disease. If a mitochondrion acquired a de novo mutation in a 
zygote, that will have a minimal effect on the developing individual compared to a zygote 
where 90% of mitochondria are inherited mutants and the phenotype threshold has been 
surpassed. Although generally thought to occur randomly, some evidence suggests that 
mitochondrial segregation is not always random and heteroplasmy levels can be maintained 
in daughter cells for numerous mitoses98.  
Genotype differences can also occur between the nuclear DNA of somatic cells, in 
a phenomenon called somatic mosaicism. Cancer is a well-known example of somatic 
mosaicism where tumour cell populations are known to have genetic instability and high 
heterogeneity in comparison to adjacent healthy tissues99,100. Cancer-predisposing 
mutations can be inherited or occur de novo in an individual. One group of individuals who 
are predisposed to developing cancer and have high levels of de novo CNVs are people 
with Li-Fraumeni syndrome (LFS)101. They are more likely to have high CNV levels than 
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healthy individuals or individuals who develop the same TP53 mutation spontaneously, 
rather than inherit it. The reason for this is that germline TP53 tumor suppressor mutations 
in individuals with LFS are thought to increase genomic instability, leading to the 
formation of more CNVs and carcinogenic mutations101. The CNV levels were found to be 
even higher once LFS-affected individuals developed cancer when compared to mutant 
carriers not yet affected by cancer. Similar to the idea of a phenotypic threshold, there 
appears to be a dose-response relationship between CNV frequency and cancer phenotype 
severity for LFS101.    
CNVs are commonly implicated in cancer, particularly recurrent copy number 
gains of oncogenes and recurrent losses of tumour suppressor genes102. There are known 
associations between cancer and the copy number duplication and overexpression of over 
70 genes103. With respect to copy number losses, tumour suppressor gene losses can lead 
to decreased gene expression which may subsequently play a role in cancer initiation or 
progression104. Tumour suppressor genes, including phosphatase and tensin homolog 
(PTEN), microcephalin 1 (MCPH1), F-box protein 25 (FBXO25), SMAD family member 
4 (SMAD4), tripartite motif-containing 35 (TRIM35), RB transcriptional corepressor 1 
(RB1), and methylthioadenosine phosphorylase (MTAP), have shown concordance 
between copy number loss and decreased gene expression in multiple tumour samples104. 
MTAP, which is involved in purine biosynthesis, showed this relationship in 14 cancer 
types104. In non-small cell lung cancer, decreased MTAP expression is associated with poor 
overall survival and higher risk of tumour reoccurrence105. The mutation and gene 
expression profile for a given type of cancer can help direct cancer treatments, like using 
trastuzumab for cancers with estrogen-related receptor beta type 2 (ERRB2) amplifications 
or AKT serine/threonine kinase 1 and 2 (AKT1/2) inhibitors if there is no response to 
trastuzumab or lapatinib106. However, the genetic heterogeneous makeup of tumours can 
make cancer difficult to treat because often when a dominant cell subpopulation is targeted 
and eliminated, other tumour cell subpopulations become dominant107,108.  
In spite of tumour heterogeneity, many cancer types were found to have unique 
underlying mutation profiles  or “signatures” that can be used to diagnose tumour types109. 
The collective mutations present across a genome, and their characteristics (e.g. type, size, 
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location, genic content), constitute the mutation “profile” of a sample. Cancer mutation 
signatures commonly involve multiple genes and mutation types109. Soh et al (2017)109 
applied machine learning to tumour DNA sequence data, representative of 28 different 
cancer types, and found that the cancer type of a tumour sample can be correctly identified 
in almost 84% of cases when using SNP and CNV data for 100 genes. The same study 
showed that the accuracy of cancer type identification decreases when fewer genes are used 
and if only SNPs or only CNVs are used as a predictor. CNVs are a better predictor of 
cancer type than SNPs since use of CNV data alone can result in an overall prediction 
accuracy of ~75% while SNP data alone have a much lower prediction accuracy of 
~49%109. 
1.1.3.2 CNV impact on drug metabolism 
CNVs can play important roles in disease treatment since they can influence drug 
metabolism. Cytochrome P450 2D6 (CYP2D6) is an extensively studied human gene that 
encodes an enzyme capable of metabolizing numerous drugs including selective serotonin 
reuptake inhibitors, atypical antipsychotic medications, tricyclic antidepressants, beta 
blockers, opioid pain medications, antimalarial medication, poly (ADP-ribose) polymerase 
inhibitors (anticancer agents), and more110. CYP2D6 is a dosage-sensitive gene which 
causes decreased drug metabolism if copies are deleted, and increased metabolism if the 
gene is duplicated. A study of over 30,000 Americans found that a large minority (12.6%) 
of people have either fewer or more than two copies of CYP2D6111. This minority group 
may be given incorrect medication doses and be more likely to suffer side effects when 
taking drugs metabolized by CYP2D6, if the dosage is not adjusted for CYP2D6 enzyme 
levels. One such example is codeine, which can be lethal to those with CYP2D6 
duplications and the associated ultra-rapid metabolizer phenotype112,113. 
1.1.4 Mouse models of human disease  
While many studies have been performed to study the effects of CNVs in humans, mice 
are also of great importance and help to fill in gaps in human research with respect to 
disease etiology, progression, and treatment. Mice are one of the most commonly used 
animals in human disease research and their value is evident from the fact that in 2002, 
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Mus musculus was the first mammal to have its genome fully sequenced114. By 2011, 
genome sequences were available for 17 inbred laboratory mouse strains115. The popularity 
of the mouse as an animal model comes from the many advantages of working with mice. 
For example, mouse breeding can be controlled to minimize or maximize genetic 
heterogeneity between individuals, family studies can be conducted, studies can be 
conducted at any age, there is no shortage of available tissues, the scale of the experiment 
can be much larger than with humans, diet and environment can be controlled, and the 
genomes can be manipulated to generate specific phenotypes and diseases. Some disease 
mouse models that involve DNA gains and losses are used to study mitochondrial deletion 
disorders116, the contribution of dosage imbalance to complex diseases like Alzheimer’s 
disease117, haploinsufficiency118 and overexpression disorders119, and cancer120. 
Due to the importance of mice in research, it is necessary to gain an understanding 
of the mouse genetics and to develop tools for studying the mouse genome. Determining 
what normal mutation levels are for different mouse strains and tissues will help with 
identification of abnormal genomic alterations, discovery of mouse-, strain-, and tissue-
specific mutation hotspots, and development of appropriate study designs. Although mouse 
studies are invaluable for human research, animal models do not always accurately mimic 
human diseases and study results for the two species are not always concordant, for reasons 
concerning both biological (i.e. species-specific differences) and non-biological aspects 
(e.g. study design quality, availability/suitability of technology, sample availability, cost, 
etc.) 121,122. Mouse genetic studies can be useful beyond human-relevant medical research, 
and have also contributed in the areas of evolution and ecology123,124, and uncovering the 
history of human colonization125.  
1.1.5 Mechanisms of CNV formation 
There are several mutational mechanisms that give rise to CNVs, which can be grouped 
into homology-based and non-homology-based mechanisms126. The breakpoint junctions 
surrounding a CNV, as well as the CNV size, can indicate what mechanism was responsible 
for creating a CNV. Long homologous regions in the breakpoint junctions, like low copy 
repeats, tend to be associated with non-allelic homologous recombination (NAHR). Allelic 
homologous recombination is normally used to repair broken chromosomes with two ended 
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double-strand breaks (DSBs) but mismatches between homologues can occur in repetitive 
regions, leading to recombination between non-allelic homologous regions. When 
occurring between chromatids and chromosomes, NAHR can produce reciprocal 
duplications and deletions, but when occurring within a chromatid, NAHR will produce 
only deletions127.  
In the human male germline, the rate of NAHR-mediated CNV deletions was found 
to be two-fold higher than the duplication rate128. However, the proportion of duplications 
and deletions appears to be similar in healthy humans, suggesting that other mechanisms 
might be biased towards duplications or there is stronger selection against cells carrying 
deletions128,129. NAHR is the most common mechanism for generating recurrent CNVs130. 
Recurrent CNVs are the same length and share fixed (common) breakpoints. Short 
homologous regions enriched for mobile elements like long or short interspersed nuclear 
elements (LINEs and SINEs), are associated with CNV insertion and deletion events that 
can occur via NAHR, nonhomologous end joining (NHEJ) or replication-based 
mechanisms131–133. NAHR breakpoints are also associated with hypomethylation and open 
chromatin134.  Exposed DNA is more susceptible to damage like DSBs than condensed 
DNA is, and DNA is particularly vulnerable when it is in a single-stranded state during 
transcription134.  
In the absence of large homologous regions, NHEJ may be used to repair DNA. 
NHEJ is an important mechanism for repairing DSBs involving blunt ends or short 
microhomologies (1-4 bp), with the repair outcome typically resulting in small insertions 
and deletions ranging from one base pair to a couple hundred base pairs in length135,136. 
When longer terminal microhomologies (>5 bp) are involved in DSB resolution, the 
mechanism is called microhomology-mediated end joining (MMEJ) and it may be used in 
place of NHEJ when some components required for NHEJ are not available136. 
In addition to producing small structural alterations, NHEJ is capable of altering 
large regions of the genome, and producing CNV deletions involving thousands of base 
pairs or more137–140. NHEJ is also associated with large CNV duplications, which 
sometimes occur via a two-step process involving homologous recombination (HR) in 
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addition to NHEJ139,141,142. Unlike NAHR, the NHEJ process requires little to no homology 
and is known to create non-recurrent CNVs, which have unique sizes and breakpoints130.  
DSBs can occur throughout all cell cycle stages, as can NHEJ-mediated repair. 
However, NHEJ is affected by the cell phases with regard to its frequency and repair 
outcomes (e.g. deletions of varying sizes are common in G1)143. HR is an alternative 
mechanism to repairing DSBs and can occur during the S/G2 phase if homologues are 
present near the DSBs144. In comparison to HR, NHEJ repairs DSBs more quickly and 
efficiently in human cells, but also with less accuracy145. Being a DSB repair mechanism, 
NHEJ-mediated CNVs are likely to be found in regions of the genome that are susceptible 
to breakage. For example, LINE-1 causes DSBs via endonuclease activity during 
retrotransposition events, so DSBs are expected to occur in regions containing such mobile 
elements146. Spontaneous DSBs can also occur during DNA replication when replication 
forks collapse and by extension could occur if mutagens interfere with replication 
progress147. However, mechanisms other than NHEJ are involved in DNA repair following 
replication fork collapse since the breaks involve a single double-stranded end with no 
other end to join it to. 
Like NAHR and NHEJ, replication-based mechanisms are important contributors 
to CNV formation and formation of de novo CNVs can be observed when canonical NHEJ 
is blocked in mouse embryonic stem cells148. In the absence of canonical NHEJ, CNVs 
arising during replication were 1.9-fold larger when occurring at mutation hotspots than 
non-hotspots, and more CNV deletions than duplications were observed at both hotspots 
(100% deletions) and non-hotspots (79.5% deletions). Excluding possible alternative end-
joining mechanisms, one replicative mechanism which could have contributed to the 
formation of these CNVs is microhomology-mediated break-induced replication 
(MMBIR), which is involved in repairing one-ended DSBs following replication fork 
collapse149.  
Following replication fork collapse, MMBIR finds microhomologies between the 
broken DNA strand and a DNA template to repair the break. Breakpoint junctions 
following MMBIR repair can often be found near LCRs150,151. Additionally, it was 
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predicted that MMBIR could create LCRs which can later be utilized for NAHR149. 
MMBIR can create large, complex structural alterations where the outcome is dependent 
on the which DNA template is used for repair and how many template switches occur. 
When a sister chromosome or homologue behind the fork breakage is used, a duplication 
will result, whereas the use of a template positioned ahead of the fork breakage will result 
in a deletion. Other outcomes include inversions, translocations, triplication and a rolling 
circle.  
Junctions at the endpoints of MMBIR show microhomology (2-5 bp), sometimes 
leading to confusion as to whether MMBIR or NHEJ was responsible for the repair event, 
although the presence of complexity is more indicative of MMBIR than NHEJ126. Like 
NHEJ, MMBIR creates nonrecurrent CNVs, but in contrast to end-joining mechanisms, 
MMBIR is a favoured mechanism for the production of CNVs arising during replication, 
particularly for CNV amplifications.  
NAHR, NHEJ and MMBIR are important DNA damage repair mechanisms that 
can produce CNVs, although other repair mechanisms exist as well. The outcome of DNA 
repair is dependent on numerous factors including, but not limited to, the type of damage 
(e.g. one or two-ended DSBs), the cell cycle stage, the surrounding genomic context (e.g. 
presence or absence of homologues and repeats), and the availability of key components 
for specific repair pathways.  
1.1.6 CNV mutation rates 
For CNVs greater than 500 bp in length, array-based HapMap data representing 450 
individuals provided a genome-wide CNV mutation rate of 3 × 10−2 per genome per 
generation152. The authors predict that this mutation rate is an underestimate since purifying 
selection against deleterious CNVs was not taken into consideration. A second study 
showed that the general CNV mutation rate based on 4,187 genomic regions from HapMap 
Phase II human populations is estimated to be at an order of 10−5 CNVs per locus per 
generation, but was as high as 10−3 CNVs per generation for 2.5% of 4,187 loci, with 47% 
of these mutation hotspots overlapping genes153. A similar average mutation rate at an order 
of 10−5 was estimated based on 856 CNV loci from HapMap Phase III human 
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populations154. This average CNV mutation rate is consistent with NAHR-mediated CNV 
mutation rates in human sperm155.  
In the human male germline, NAHR deletion rates at a mutation hotspot were found 
to differ greatly between individuals, ranging from 9.82 × 10−6 to 6.96 × 10−5 per 
individual, with an average deletion rate of 3.52 × 10−5 (± 3.04 × 10−6 SEM)155. An earlier 
study examining the same locus observed very similar NAHR deletion rates in male sperm 
(4.20 × 10−5 ± 2.99 × 10−6 SEM)128. For three other mutation hotspots, the average NAHR 
deletion rates were different, ranging from 2.16 × 10−5 to 1.87 × 10−6. The average NAHR 
duplication rates were lower than the duplication rates for all four hotspots and ranged from 
1.73 × 10−5 to 1.73 × 10−7. This finding is consistent with observations from other studies 
where NAHR-mediated deletions were found to be more frequent than duplications128,153. 
In a third study focusing on a region of Chromosome 17, NAHR CNV rates associated 
with male meiosis were also found to be on an order of 10−5 to 10−7 156.  
Contrary to the mutation rates determined above which were determined based on 
a few disease-relevant loci, the frequency of NAHR-mediated CNVs detected across whole 
genomes would suggest that the mutation rates are higher than expected. For a mutation 
rate at an order of 10-5, 0.00324 de novo deletions and duplications per generation, or 0.324 
NAHR-mediated CNVs per individual when separated from the reference genome by 100 
generations would be expected yet 24 NAHR-mediated CNVs per individual were 
observed157.  
Although additional genome-wide studies would be helpful in resolving the NAHR 
mutation rates for CNV formation, NAHR rates have been more extensively studied than 
the difficult to determine NHEJ or MMBIR mutation rates. Identifying NAHR-associated 
breakpoints is simpler because it involves searching for large homologies, while 
mechanisms that generate nonrecurrent CNVs have little to no homology at breakpoints 
and it can be difficult to assign an exact mechanism to a CNV. Little is known about NHEJ 
rates, although the CNV generation rate via NHEJ is predicted to be less than 10-7 per locus 
per generation152. However, based on deletion breakpoints examined from the 1000 
Genomes project data, nonhomologous mechanisms generate more CNVs (61% of 
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detected CNV deletions) than NAHR (13%), with 42% of these deletions predicted to have 
occurred via NHEJ and 58% through template-switching mechanism like MMBIR134.  
Like NHEJ, there is little information regarding MMBIR-mediated CNV rates. 
While MMBIR is associated with replication fork collapse, the rate of replication fork 
collapse in humans is unknown. If recombination frequency during replication is used as a 
measure of replication fork collapse, then replication fork collapse is expected to occur 
multiple times per cell division cycle158. Although not all replication fork collapses are 
resolved with a CNV outcome, the sheer number of replication events required to create an 
adult human from a zygote and to renew cells in tissues provides many opportunities for 
CNV formation. To reach the predicted 3.72 × 1013 cells present in an adult human when 
starting from a zygote, the cell population will have needed to double approximately 45 
times through numerous independent replication events159. These frequent but nonrecurrent 
mutation events would result in high levels of somatic mosaicism in healthy individuals 
that could be difficult to detect if there is insufficient clonal expansion to meet a required 
detection threshold. Mutations that arise early in embryogenesis would have high clonal 
expansions in an adult, assuming there are no fitness costs to the affected cells.  
Aneuploidy mosaicism in blastocysts is known to occur frequently, increasing from 
~50% to ~90% of tested blastocysts, as a woman’s age and meiotic error risk increases160. 
In preimplantation embryos, aneuploidy mosaicism is associated with clinical implications 
like reduced implantation success and increased risk of miscarriage with embryos that have 
aneuploidy in 20%-80% of their cells (in a 5-cell biopsy)160. CNVs are known to arise 
during gametogenesis and embryogenesis and with estimates of the rate of de novo CNV 
occurrence in offspring being placed at 1.2 × 10−2 CNVs per genome per transmission, for 
CNVs over 100 kb in length161. In rare cases, individuals with genomic disorders present a 
CNV mutator phenotype and have an unusually high number of de novo CNVs (5-10 CNVs 
per individual)162. This mutational process appears to be transient, only occurring 
perizygotically, possibly as a consequence of replicative repair. It is hypothesized that 
mutant maternal proteins or transcripts are responsible for driving a CNV mutator 
phenotype in early embryogenesis and the mutation process ceases once zygotic genome 
transcription is activated and wild-type proteins and transcripts are generated162. The 
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mutations that arise early in embryogenesis are likely to have large clonal populations in 
the developed individual and therefore have high phenotypic impact potential.  
1.2 CNV detection 
There are several approaches that can be used for the identification of CNVs. Fluorescent 
in-situ hybridization (FISH) is a commonly used CNV detection technique, and is often 
used for diagnostic purposes in the clinic163–165. With FISH-based approaches, locus-
specific fluorescent probes are hybridized to metaphase or interphase spreads to visualize 
CNVs at a single cell level166. This method provides an absolute CNV count, typically at a 
resolution ranging from tens of thousands to hundreds of thousands of base pairs167, 
although the resolution has been improved with newer methods like Fiber FISH which is 
performed on extended chromatin fibers168. The drawbacks to FISH approaches are that 
they are low throughput in comparison to other CNV-detection technologies like 
microarrays, and CNV discovery is limited to the loci that have sequences complementary 
to the designed probes, meaning a priori knowledge of the target CNVs is required166.  
Higher throughput technologies for CNV detection include array-based 
comparative genomic hybridization (aCGH) and non-CGH microarrays like SNP-based 
oligonucleotide arrays169. In an aCGH approach, sample and reference DNA are 
cohybridized to DNA probes on an array. A sample of interest, for example, may be DNA 
from a disease-affected individual while the reference DNA would come from a healthy 
individual170. The goal would be to identify chromosomal abnormalities in the sample of 
interest compared to the healthy reference and see if there is an association to the disease 
phenotype. The sample and reference DNA are labelled with different fluorescent dyes so 
that for each locus, the ratio between the two fluorescence signals can be used to infer a 
copy number state171. Since aCGH-based CNV detection is dependent on the use of a 
reference genome, absolute counts of DNA copies are not detected like with FISH. An 
advantage over FISH, is that aCGH uses thousands of probes in parallel which allows for 
genome-wide CNV detection. Array CGH has been used in the identification of CNVs 
associated with diseases including but not limited to pancreatic cancer172, metastatic breast 
cancer173, neurodevelopmental disorders or multiple congenital anomalies174, and autism 
spectrum disorder175. Array CGH has also been used in a human evolutionary study, and 
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found copy number expansions in humans when compared to four other hominoid species 
(bonobo, chimpanzee, gorilla, and orangutan) that could account for some of the species-
specific phenotypic characteristics such as brain structure and function176.  
Non-CGH microarrays are an alternative approach to aCGH for CNV detection and 
do not require cohybridization with a reference DNA sample. With SNP-based 
oligonucleotide microarrays, for example, the DNA of interest is hybridized to single-
stranded DNA probes on an array and the overall fluorescence intensity signal of each locus 
is compared to a reference diploid signal to detect CNV gains and losses177. Thus, SNP 
microarray CNV detection is reference based and does not provide absolute copy number 
counts. High resolution SNP microarrays have been used for a variety of different CNV 
studies including but not limited to studies of human anthropomorphic traits178, cross-
species comparisons between humans and rhesus macaques179, fetal alcohol spectrum 
disorder180, autism spectrum disorder181, and thoracic aortic aneurysms and dissections182. 
Overall, both aCGH and non-CGH microarrays that are used for CNV detection come in a 
variety of designs and vary greatly in several aspects including but not limited to their 
resolution and sensitivity, in the type of mutations that they can detect, and the amount of 
DNA required for hybridization183–185.  
A more advanced approach to CNV detection than microarrays, particularly with 
respect to resolution and sensitivity, is the use of sequencing technologies, which provide 
single base-pair resolution. Sequencing technologies, which are rapidly improving and 
developing, are used in high-throughput approaches for genome-wide CNV discovery, 
even for single cells, and they allow for the identification of translocations, rare variants, 
and CNV breakpoint junctions186,187. However, assembling raw sequencing data into a 
useful output is a complex process for numerous reasons that include but are not limited to 
the large quantities of output data, various limitations between the different sequencing 
technology platforms and algorithms, dependence on reference genomes for read 
alignment, and a lack of standardization and simplified workflows188,189. In regard to 
clinical application, many tests that look for structural alterations of the genome are not 
conducted using sequencing since often times more affordable methods like FISH, or PCR-
based techniques are sufficient, especially when testing for known variants and 
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diseases190,191. Microarrays are currently being used in clinics for genetic testing of 
individuals, particularly children, with developmental delays and intellectual disabilities, 
autism spectrum disorders and dysmorphic features with unknown causes192. Microarrays 
are also used in the detection of clinically relevant CNVs in fetuses for prenatal diagnosis 
of cytogenic abnormalities193. Sequencing is of great value for studying complex or 
monogenic diseases where rare structural or sequence alterations that are associated with 
the disease have yet to be discovered194.   
Due to the high demand for products and services for human research, CNV 
detection technology and methodology for the human genome have seen rapid advances. 
However, mouse models are still necessary for many aspects of human-relevant research 
but the costs of some CNV detection methods like whole genome sequencing are 
prohibitively expensive to use on a large scale for mice. Therefore, more affordable 
technologies like high-density microarrays are of value to animal model research, 
particularly when the study requires looking at the whole genome and at many samples. 
One such microarray is the Mouse Diversity Genotyping Array (MDGA; Thermo Fisher 
Scientific Inc, Waltham, MA), a high-resolution, mouse SNP genotyping array that was 
reported in 2009195.  
1.3 Thesis goal and specific aims 
The overall goal of this thesis is to explore and characterize the CNV landscape of Mus 
musculus (house mouse), as detected by the MDGA in order to advance our knowledge of 
an important model organism from the perspectives of adaptation and evolution, normal 
development, and disease. M. musculus was selected as it is the most common mouse 
species used in research, the reference genome has been sequenced and annotated, and it is 
compatible with the MDGA since the array design is based off of the M. musculus reference 
genome195. The MDGA was selected as the detection technology of choice due to its 
affordability and because it was the highest resolution mouse microarray available at the 
time. The chapters in this thesis describe experiments that were conducted with the goals 
of improving the reliability of the MDGA CNV detection pipeline and determining its 
utility for CNV detection in mice. This thesis will also explore how CNVs contribute to 
the genomic landscape in different mouse groups affected by natural or artificial selection, 
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in multiple tissues within an inbred mouse family, and in a mouse model of cancer. The 
specific aims and the rationale for these aims are described below. 
Aim 1: To assist in the development of a reliable, validated, and user-friendly CNV 
detection pipeline for use with the MDGA by 1) identifying probes that are predicted to 
perform poorly and excluding them from computations associated with CNV calling, and 
2) updating probe annotations where necessary, and 3) developing a CNV output 
visualization method to assist with identifying patterns in the number, state, and spatial 
distribution of CNVs within and across the genomic landscapes of multiple samples.  
This aim was necessary due to inconsistencies found in the original probe annotation files 
and a lack of CNV detection software that can generate calls using both the single 
nucleotide polymorphism-based probes and the invariant genomic probes. Results relating 
to MDGA improvements and recommendations for use are presented mostly in Chapter 2, 
and the CNV detection pipeline was used in the experiments described in Chapters 3-5, 
with some stated modifications between different experiments. A method for visualizing 
the CNV distribution across a genome is described in Chapter 3B.  
Aim 2: To use the developed CNV detection pipeline to explore the CNV landscape of 
multiple mouse subspecies and characterize differences between laboratory-bred and wild-
caught mice.  
This aim is used to test the pipeline developed in Aim 1 on a large M. musculus dataset and 
the results of this broad survey have been published. Chapter 3 also includes a mouse cohort 
comparison study that is an extension of the broad survey and has a stronger focus on the 
genetic variation between classical laboratory-bred, wild-caught and wild-derived mouse 
cohorts. 
Aim 3: To study the contribution of CNVs to somatic mosaicism in an inbred mouse family 
and assess the MDGA tool for this objective. 
The goal of this aim is to provide a mutational baseline for what a CNV profile looks like 
across multiple healthy tissues of one of the most commonly used laboratory mouse strains, 
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C57BL/6J, as this would allow for identification of abnormal mutation profiles in future 
mutation studies. The results of this work are presented in Chapter 4.  
Aim 4: To assess the utility of the MDGA in the context of tumorigenesis and metastasis. 
The MDGA was originally used to genotype normal mouse samples. The purpose of this 
aim is to determine if the MDGA can be applied to disease samples like cancerous tissue, 
where there is a high degree of genetic heterogeneity that also includes small size clones 
of de novo mutations. The work from this aim is presented in Chapter 5.  
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Chapter 2  
2 The Mouse Diversity Genotyping Array: Overview 
Parts of this chapter were published in Locke et al, BMC Genomics (2015)1. Probe filtering 
based on BLAST analysis was performed by Nisha Patel. Chloe Rose isolated DNA from 
naked mole-rat samples. 
2.1 Introduction 
2.1.1 Study motivation 
To assist with the fulfillment of Aim 1 in this thesis - the development of a reliable, 
validated and user-friendly CNV detection pipeline for use with the Mouse Diversity 
Genotyping Array (MDGA) - probe lists were filtered according to defined criteria to 
include only probes predicted to perform well in CNV detection. The impact of probe list 
filtering was assessed by comparing SNP genotyping results pre- and post-filtering. The 
MDGA probe design was evaluated in comparison to the Genome-Wide Human SNP 
Array 6.0, which was selected as a standard for high quality. Additionally, the utility of the 
MDGA for rodent samples within and outside of the genus Mus was tested to identify cross-
species hybridization limitations. This chapter provides background on the design of the 
MDGA, and discusses sample selection, the CNV calling process, and data quality 
assessment. 
2.1.2 The Mouse Diversity Genotyping Array design 
The Mouse Diversity Genotyping Array (Thermo Fisher Scientific Inc, Waltham, MA) was 
designed by Yang et al (2009) with the intent to assess genetic diversity in Mus2. It is a 
high-density genotyping array with probe sequences designed based on the sequenced 
C57BL/6J mouse strain reference genome (Mus musculus domesticus)2. The MDGA can 
be used to determine single nucleotide polymorphism (SNP) genotypes and identify CNVs. 
Single nucleotide variants are considered polymorphic if they are present in at least 1% of 
the individuals of a population3. The MDGA has 2,093,288 different probes that interrogate 
two SNP alleles (alleles “A” and “B”) at 623,124 uniformly-spaced loci (~1 SNP per 4.3 
kb)2,4. These probes were designed to target SNPs selected to capture the genetic diversity 
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present in classical laboratory and wild-derived mouse strains. A detailed description of 
how the loci were selected is available in the supplementary information of the Yang et al 
paper2. A second group of probes, called invariant genomic probes (IGPs), target 597,758 
non-polymorphic regions in exons and are used in CNV calling. IGPs were designed to 
target ~93% of known exons in the mouse genome (Ensembl version 49)2. Exon 1 and 
Exon 2 probe types make up the largest group of IGPs on the MDGA at a total of 1,195,516 
probes and are divided into the two exon groups based on Affymetrix-specified criteria for 
meeting probe design standards. CNV calling in this thesis is performed using both SNP 
probes and Exon 1 and 2 probes.  
2.1.3 SNP probes and invariant genomic probes 
For each SNP locus, there are four different probe sequences that make up a probe set – a 
sense and antisense sequence for each of the two alleles. The probes that make up a SNP 
probe are found in a total of eight separate locations or “features” on the array – there are 
two features for each of the four SNP probe sequences. SNP genotyping will result in one 
of four genotype calls being generated per SNP locus: homozygous for allele A (AA), 
homozygous for allele B (BB), heterozygous (AB), or an inability to determine a genotype 
(No Call). The invariant genomic probes (IGPs), Exon 1 and Exon 2 probes, were designed 
so that there are six probe sequences per exon. The IGPs target approximately 93% of the 
annotated exons in the mouse genome2. There are three sense strand probes spaced out 
along each exon in conserved (invariant) regions, and for each sense probe there is a 
complementary antisense probe. These six probes make up an IGP set and unlike the SNP 
probes, there is only one feature on the array per probe sequence. On the MDGA, each 5 
µm x 5 µm feature has approximately 1.66-6 picomoles of copies of a particular probe 
sequence5.  
2.1.4 Fluorescence-based SNP and CNV genotyping 
Prior to hybridization to the MDGA, sample DNA undergoes several preparatory steps, 
including biotin labelling. Biotin-labelled sample DNA that has hybridized to MDGA 
probes can be stained with streptavidin-bound phycoerythrin, a fluorescent protein. The 
fluorescence intensity from sample DNA that is bound to IGPs and SNP probes can be 
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used to determine how many relative copies of that particular DNA sequence are present 
in the sample genome.  
If a feature on the array does not emit light, then no hybridization occurred. This 
could occur due the absence of DNA template or the presence of single nucleotide 
mutations within the DNA template. Depending on the type of variant calling performed, 
a lack of a fluorescence signal would translate into either an inability to detect a SNP 
genotype or a copy number loss. To call a copy number loss, a predetermined number of 
probes targeting consecutive loci would have to emit a similar fluorescence signal. If the 
fluorescence intensity for probes targeting a given genomic region is higher or lower than 
what is expected for a copy number of two, then this would suggest the presence of a copy 
number gain or loss, respectively.  
2.1.5 Generating SNP genotype and CNV calls 
2.1.5.1 SNP genotyping with Affymetrix Power Tools 
Prior to CNV calling, SNP genotyping is performed. SNP genotype calls for the MDGA 
can be generated using the BRLMM-P algorithm with Affymetrix Power Tools’ apt-
probeset-genotype program (APT; Thermo Fisher Scientific)6,7. Data from multiple 
microarrays are genotyped together and any inter-sample variability in the signal intensity 
needs to be corrected. This can be done with an APT normalization step. Quantile 
normalization is typically used for SNP genotyping, with the exception of cancer samples 
where median normalization is recommended8. A median polish summarization step 
follows normalization and is applied to summarize the information from all the probes for 
one allele of a SNP by using the median value. Median polish takes into account both inter-
sample variation and variation in signal intensity arising from sequence-dependent 
hybridization specificity9. 
After genotyping, other APT programs are used to generate log R Ratio (LRR) and 
B Allele Frequency (BAF) values for the SNP probes. The LRR represents the total 
fluorescence intensity signals from each SNP probe set. The BAF values represent the 
fluorescence signal ratio between the B and A allele probes at each SNP locus. The 
clustering of genotype calls into AA, AB, and BB genotypes, and the generation of LRR 
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and BAF values, is assisted by a model clustering file that specifies where each genotype 
cluster for a given SNP is likely to be located. This file can be created by the user or 
downloaded from the product page for the MDGA on the Thermo Fisher Scientific 
website10. Specific information about APT installation and required files for MDGA-based 
SNP genotyping are available online, along with a sample genotyping script11.   
SNP genotyping is not only needed for generating CNV calls, it can be used to 
identify false positive calls for putative CNV losses. A requirement for CNV identification 
in this thesis is that the CNV calls include SNP probes and not only IGPs. SNP probes 
within a CNV with a predicted state of zero should only have “No Call” genotypes since a 
state of zero would mean that no target DNA is present in that region of the genome. 
Heterozygous SNP genotypes (“AB” calls) would not be expected for SNP probes 
underlying a CNV with a state of one since only one copy of the allele would be present.  
2.1.5.2 CNV calling with PennCNV 
Following SNP genotyping, PennCNV software11 can be used to generate CNV calls. 
PennCNV is open source software capable of using both SNP probes and IGPs for CNV 
calling and detect copy number states ranging from zero to four. The SNP genotyping step 
is a necessary step prior to CNV calling because PennCNV requires LRR and BAF 
information to identify CNVs. Before the LRR and BAF files are used for CNV calling, 
the SNP genotyping call rates for each sample are assessed and any unusual outliers are 
removed. The call rate for a sample is the percentage of loci that have a genotype call12. 
After outliers are removed, the genotyping step is performed again and new LRR and BAF 
files are created. SNP genotyping does not have to be repeated if there are no failing 
samples to remove.  Another file necessary for CNV calling is a PFB-formatted file that 
contains the genomic location for all SNP probes and IGPs. For a given copy number state 
to be assigned to a genomic region, consecutively located target DNA sequences must emit 
the same fluorescence intensity after hybridizing to the probes. The MDGA probe locations 
are based on the sequenced Mus musculus genome and need to be updated as the reference 
genome is updated. Probes excluded from the PFB file will not be used by PennCNV when 
it generates CNV calls. 
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PennCNV uses a hidden Markov model (HMM) algorithm to make CNV calls. The 
HMM algorithm determines how likely a probe signal is to represent a particular copy 
number state while taking the inter-probe distance and the fluorescence signal of the 
previous probe into consideration11. CNV calling in PennCNV for a dataset of interest is 
assisted by a trained HMM model file that provides information about probabilities and 
possible copy number outcomes, based on a training dataset. 
Several consecutive probes of the same assigned copy number state are required to 
call a putative CNV. The specific number of consecutive probes required to make a CNV 
call is selected by the user although a minimum of three or more probes is generally used13. 
From a biological perspective, most regions of the genome are expected to be in a copy 
state of two and it is uncommon to have two opposite copy number states next to each 
other, like a loss immediately followed by a gain or vice versa.  
The CNVs called by PennCNV require experimental confirmation to determine if 
the CNVs are biological events, and to locate the exact position of the CNV junctions. 
PennCNV provides start and end positions for each CNV call but the array does not have 
single nucleotide-level resolution, so these positions are rough estimations of the junction 
locations. The true CNV junctions are assumed to lie somewhere between the probes at the 
ends of the predicted CNV and the probes just outside of the CNV ends. Further 
information about the use of PennCNV with microarrays designed by Affymetrix is 
available on the PennCNV website14.  
2.1.6 Discrepancies in annotations for the probe files of the Mouse 
Diversity Genotyping Array  
Following the release of the MDGA, discrepancies were found in the chromosomal 
positions listed in the annotation files for the SNP probes15. Later, the probe annotation 
files were filtered by S.T. Eitutis (2013)16 based on several inclusion criteria including, but 
not limited to, probe length consistency, perfect match genome alignment scores, the 
absence of restriction enzyme recognition sites in the target DNA, presence of only one 
known SNP locus within a probe set, and sufficient genomic distance between target SNPs. 
In this chapter, the probe annotation files for both SNP probes and IGPs are filtered to 
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remove unreliable probes from use in CNV identification. The CNV-specific filtering 
criteria for the MDGA are described in the methods section.  
Although probe filtering can be used to improve CNV calling reliability, the CNVs 
identified by microarrays are putative and require additional experimental confirmation. 
Several computational based methods, discussed later in Section 2.5, can be used to assess 
the quality of the MDGA data prior to experimental confirmation.  
2.1.7 Assessment of probe design for the Genome-Wide Human 
SNP Array 6.0 
Following assessment of the MDGA probe design, probe annotation files from the 
Genome-Wide Human SNP Array 6.0 (SNP Array 6.0; Affymetrix®, Thermo Fisher 
Scientific Inc, Waltham, MA) were assessed for issues in SNP probe design, for 
comparison purposes (see Results section 2.3.1). The SNP Array 6.0, designed by 
McCarroll et al (2008)17, is a human SNP-based genotyping array comparable to the 
MDGA, which was available for use one year after the SNP Array 6.018. The SNP Array 
6.0 contains 1,863,892 different probe sequences that provide SNP genotype calls at 
931,946 loci (full CDF file)19. Each SNP genotype is determined by a set of two probe 
sequences representing two alleles.  
Like the MDGA, the SNP Array 6.0 can provide both SNP and CNV genotype 
calls17. The impact of probe filtering on the two arrays can be assessed and compared by 
looking at the SNP genotyping call rates pre- and post-filtering. An increase in SNP 
genotype call rates is expected if the probe filtering is effective at removing probes that do 
not return a genotype call. In this chapter, SNP Array 6.0 probe filtering is limited to 
inclusion criteria that are relevant to SNP genotype calling. The probe inclusion criteria 
include: probe length of 25 nt, probe sequence uniqueness, and absence of NspI or StyI 
recognition sites in the target DNA. If the target DNA is unable to bind the probes due to 
being digested at the probe target site, then a genotype call cannot be made, and removal 
of these poorly-performing probes should result in an increased call rate.  
SNP genotyping can also be affected by the genotyping algorithm used. The 
Birdseed algorithm is commonly used for the SNP Array 6.0 and there are two versions 
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available (v1 and v2). The two Birdseed versions differ in their use of SNP-specific models. 
For Birdseed v1, a Gaussian mixture model is fitted into two-dimensional A- and B-signal 
space and the SNP-specific models are used as starting points for Expectation-
Maximization algorithm iterations for genotype clustering6. Birdseed v2 is more robust 
than Birdseed v1 in the sense that the clustering is more reliant on SNP-specific priors.  
Here, both Birdseed versions are tested on a HapMap320 dataset of 874 samples, to 
observe the effect on SNP call rates, in comparison to probe filtering effects. The Birdseed 
algorithm is used as opposed to other existing algorithms because Birdseed is used by 
Affymetrix® for array testing and validation21. Two versions of Birdseed are included in 
this study rather than one because they are known to produce slightly different genotyping 
outcomes for the same dataset22.  
2.1.8 Cross-species hybridization and considerations for SNP 
genotyping 
SNP microarrays are generally made for a limited number of organisms that are of 
scientific interest, including humans, model organisms like mice, agriculturally-important 
animals like cows, and companion species like dogs1,21,23,24. These microarrays can 
sometimes be used for organisms for which they were not designed. The hybridization of 
Antarctic fur seal (Arctocephalus gazelle) DNA to a dog (Canis familiaris) array is one 
such example and the study obtained SNP genotype calls for 19.2% of loci targeted by the 
array25. This low percentage of usable SNP loci is expected since, according to this study, 
there are 44 million years of divergence between the seal and dog.  
Cross-species array hybridization has also been used for gene expression studies. 
Some examples include Weddell seal (Leptonychotes weddellii) samples being applied to 
a human gene expression array26, Sordaria macrospora fungus samples being applied to 
an array based on the closely related Neurospora crassa fungus27, and bell pepper and 
eggplant samples being applied to a tomato gene expression array28.  
For cross-species microarray assays, it is expected that if there is low sequence 
divergence between the species being tested and the species upon which an array was 
designed, as is expected with closely related species, then there will be high levels of probe-
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target hybridization. Sequence divergence as small as 1% will have a detectable decrease 
in hybridization levels29. Fish gene expression array experiments have shown that gene 
expression results are most consistent for species that diverged from each other less than 
10 million years ago30. The same study showed that some results, although more limited, 
can be generated by expression arrays for species that diverged from the array reference 
species more than 200 million years ago. A similar observation was found for the MDGA, 
where increased genetic distance of Mus musculus samples from the C57BL/6J reference 
strain was associated with an increase in heterozygous SNP calls and No Calls31.  
CNVs are identified by collective calls of an altered copy number state using 
consecutive uninterrupted markers. Therefore, unlike SNP genotyping, the ability to 
identify CNV events is heavily dependent on knowing the genomic position of probe 
targets, relative to each other. In  order to use the MDGA for CNV calling in a different 
species, the MDGA probe sequences would have to be reannotated based on the sequenced 
reference genome for the species of interest, given the likelihood of genomic 
rearrangements over evolutionary time. To ensure that only consecutively located probes 
are used to identify CNVs, probes with sequences that occur more than once in the genome 
should be excluded from CNV calling and the probes need to be annotated so that they are 
assigned a genomic position.  
2.1.9 General goal, specific objectives, and predicted outcomes 
Overall, the filtered probe lists and recommendations for MDGA use and data quality 
assessment described in this chapter are expected to assist in the improvement of the 
MDGA as a tool for SNP genotyping and CNV detection in mice. 
The specific objectives of this chapter are:  
1. To identify MDGA probes that are predicted to perform poorly in CNV detection 
based on defined criteria for probe design, and to generate a list of probes 
recommended for use CNV detection. 
2. To assess the impact of filtering probe lists to contain valid probes only, with 
filtering success being evaluated in terms of increased SNP genotype call rates. 
 
 
49 
 
3. To compare the impact of MDGA probe list filtering on SNP genotype calling to 
the impact of Genome-Wide Human SNP Array 6.0 probe list filtering. 
• The Genome-Wide Human SNP Array 6.0 is predicted to have a better 
probe design and is used here as a standard for comparison. 
4. To evaluate the applicability and hence the utility of the MDGA for rodent species 
other than Mus musculus. 
5. To make recommendations for study design considerations to ensure that reliable 
and useful MDGA data is generated. 
6. To discuss approaches for assessing quality of MDGA data. 
The filtering of probe annotation files for the MDGA is expected to result in improved SNP 
genotype calling and help create a more reliable list of probes for use in CNV calling. SNP 
Array 6.0 probe filtering is also predicted to result in improvements to SNP genotype 
calling. However, the greater use and earlier development of human versus mouse 
microarray technologies may have resulted in a better designed microarray for humans, 
requiring fewer probes to be excluded from genotyping. It is expected that the MDGA can 
be used for cross-species hybridization studies of SNP-based genetic diversity and that the 
array will be most informative for samples closely related to Mus musculus.   
2.2 Materials and methods 
2.2.1 Probe filtering and SNP genotyping for the Mouse Diversity 
Genotyping Array 
MDGA annotation files for IGPs and SNP probes were filtered using criteria relevant for 
CNV calling, and these filtered probe lists were used to identify CNVs described in 
multiple projects in subsequent chapters of this thesis. IGP annotation files were 
downloaded from the Center for Genome Dynamics website32. IGPs that were classified as 
Exon 1 and Exon 2 were locally run through BLAST to ensure that the probe sequences 
were found only once in the mouse haploid genome (UCSC:mm9) and to verify the 
annotated position (Fig. 2-1). Inclusion criteria for probe sequences required a length of 25 
nt, one probe ID per probe sequence and the presence of complementary sense and 
antisense sequences. 
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In-house scripts removed probe sets likely to contribute to background noise and 
false positives, including those containing palindromic NspI or StyI recognition sites within 
a given probe sequence and its 12 nt flanking region (as the genomic target sequence is 
digested by these restriction enzymes prior to hybridization to the array) as well as probe 
sets overlapping other probe sets based on genomic position, as these would compete for 
genomic DNA template (Fig. 2-1). This filtered list was used to identify CNVs in the broad 
survey discussed in Chapter 3. Following the completion of CNV calling and analyses, the 
SNP and IGP annotation files were further filtered to create a more stringent probe list (Fig. 
2-1), which was used in the mouse cohort comparison study of Chapter 3. The additional 
filtering included removing overlapping probes because they would compete for the same 
DNA template, which could affect the fluorescence intensity of that genomic region. The 
check for overlapping probes included all probe types on the MDGA. It is important to 
note that overlap was determined based on the reference genome locations 
(UCSC:mm9/NCBI Build 37) and that which probes are overlapping each other may 
change with updates to the reference genome. The probe identifiers for the stringently 
filtered probe list are provided in Locke et al. (2015)33. 
For 351 mouse .CEL files downloaded from the Center for Genome Dynamics at 
The Jackson Laboratory website34, SNP genotype calls were generated using the APT 
BRLMM-P algorithm and default parameters. The three probe lists used for SNP 
genotyping were the unfiltered MDGA probe list, the filtered list provided by S. T. Eitutis 
(2013) and the stringent list recommended for CNV calling in Locke et al16,33.  
2.2.2 Probe filtering and SNP genotyping for the Genome-Wide 
Human SNP Array 6.0  
SNP Array 6.0 probe sequence, flanking sequence, probe annotation, and library files were 
downloaded from the Thermo Fisher Scientific website35. SNP probe sequences with 
“SNP_A” identifiers were filtered, using in-house scripts, based on probe length, sequence 
uniqueness among other SNP probes, and restriction enzyme recognition sites (Fig. 2-2; 
Appendix 2A). If one probe sequence in the set of two failed to meet inclusion criteria, the 
whole probe set was removed from analysis. SNP probes were not filtered based on probe 
overlap criteria which would remove probes competing for the same target DNA. Unlike 
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CNV calling, SNP genotyping is not dependent on the fluorescence intensity levels relative 
to an expected diploid intensity, which can be affected by probe competition for shared 
DNA targets. After filtering was applied to the 25 nt probe sequences, restriction enzyme 
recognition site filtering was applied to the annotation files containing flanking sequence 
information for each probe (Appendix 2B). Flanking sequences contain the 25 nt probe 
sequence and eight additional nucleotides.  
SNP genotype calls were generated using Affymetrix® Power Tools with the 
Birdseed (version 1 and version 2) algorithm and default parameters6, and 874 HapMap3 
CEL files (Appendix 2C) that were downloaded from NCBI’s HapMap ftp site36. This 
dataset represents individuals from various ethnic backgrounds including African ancestry, 
Gujarati Indian, Han Chinese, Japanese, Luhya, Maasai, Mexican ancestry, Toscani, 
Utah/Mormon and Yoruba. Sample APT scripts are provided in the supplementary 
materials (Appendix 2D). 
Graphical images were generated using R37. Sample numbers in Figure 2-3 
correspond with the “Sample_Number” column in Appendix 2C and sample numbers in 
Figure 2-4 correspond with the “Sample_Number” column in Appendix 2E.  
2.2.3 Cross-species hybridization with SNP genotyping 
The Mus subgenera sample set includes a total of 27 Mus, Pyromys, Coelomys, and 
Nannomys samples (Table 2-1). MDGA CEL files for Mus samples were downloaded from 
the Center for Genome Dynamics website38. H. glaber tail tissue samples were provided 
by Dr. Melissa Holmes (University of Toronto Mississauga). DNA was extracted according 
to the Wizard® Genomic DNA Purificaiton Kit protocol (Promega, Madison, Wisconsin, 
USA), with two modifications: 1) tissues were digested by proteinase K for 24 to 48 hours, 
and 2) RNAse disgestion was used for all tissues. DNA quantity and purity were assessed 
using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). MDGA hybridization was performed at the London Regional 
Genomics Centre (Robarts Research Institute, Western University, London, ON). SNP 
genotyping was performed for combined Mus and H. glaber samples as well as separately 
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for each of these two groups. Genotype calls were generated using the stringent filtered 
MDGA probe list (Section 2.2.1), APT BRLMM-P algorithm, and default parameters.  
Table 2-1. Mus species and Heterocephalus glaber samples. 
CEL ID Mus Subgenus Species Sex 
SNP_mDIV_D7-473_012209.CEL Coelomys Mus pahari Male 
SNP_mDIV_D6-472_012209.CEL Mus Mus caroli Male 
SNP_mDIV_D7-644_101509-redo.CEL Mus Mus caroli Male 
SNP_mDIV_D7-644_91809.CEL Mus Mus caroli Male 
SNP_mDIV_D3-639_101509-redo.CEL Mus Mus castaneus Female 
SNP_mDIV_D3-639_91809.CEL Mus Mus castaneus Female 
SNP_mDIV_D8-646_101509-redo.CEL Mus Mus cervicolor Male 
SNP_mDIV_D8-646_91809.CEL Mus Mus cervicolor Male 
SNP_mDIV_A2-645_102109.CEL Mus Mus cookii Male 
SNP_mDIV_D9-647_101509-redo.CEL Mus Mus dunni Male 
SNP_mDIV_D9-647_91809.CEL Mus Mus dunni Male 
SNP_mDIV_D4-640_101509-redo.CEL Mus Mus famulus Male 
SNP_mDIV_D4-640_91809.CEL Mus Mus famulus Male 
SNP_mDIV_D8-474_012209.CEL Mus Mus famulus Male 
SNP_mDIV_D5-642_101509-redo.CEL Mus Mus fragilicauda Male 
SNP_mDIV_D5-642_91809.CEL Mus Mus fragilicauda Male 
SNP_mDIV_D6-643_101509-redo.CEL Mus Mus fragilicauda Male 
SNP_mDIV_D6-643_91809.CEL Mus Mus fragilicauda Male 
SNP_mDIV_A7-654_102109.CEL Nannomys Mus mattheyi Male 
SNP_mDIV_D11-653_101509-redo.CEL Nannomys Mus minutoides Male 
SNP_mDIV_D11-653_91809.CEL Nannomys Mus minutoides Male 
SNP_mDIV_D10-652_101509-redo.CEL Nannomys Mus orangiae Male 
SNP_mDIV_D10-652_91809.CEL Nannomys Mus orangiae Male 
SNP_mDIV_A3-648_102109.CEL Pyromys Mus platythrix Male 
SNP_mDIV_A4-649_102109.CEL Pyromys Mus platythrix Male 
SNP_mDIV_A5-650_102109.CEL Pyromys Mus saxicola Male 
SNP_mDIV_A6-651_102109.CEL Pyromys Mus saxicola Male 
DNA3337.CEL N/A Heterocephalus glaber Female 
DNA3338.CEL N/A Heterocephalus glaber Female 
DNA3339.CEL N/A Heterocephalus glaber Male 
DNA3340.CEL N/A Heterocephalus glaber Male 
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2.3 Results 
2.3.1 Mouse Diversity Genotyping Array and Genome-Wide 
Human SNP Array 6.0 probe filtering 
Following filtering of MDGA probe sequences, 94% of SNP probe sequences and 71% of 
exon probe sequences remained (Fig. 2-1). In total, approximately 4.79 million unique 
probes targeting 915,195 loci are available for use in CNV calling. In comparison to the 
original, unfiltered SNP probe list, SNP genotype calling improved for 100% of tested 
samples when using both the filtered list by S.T. Eitutis (2013)16, and the filtered list in this 
study (Table 2-2). The average percent by which the call rates increased is similar for the 
two filtered probe lists.  
The SNP Array 6.0 probe files were filtered for the purpose of determining if SNP 
genotyping call rates would improve or not following filtering. SNP probe filtering left 
95% of SNP probes available for genotyping (Fig. 2-2). For this array, the SNP call rate is 
most improved when using a different calling algorithm with the original probe list and not 
by filtering the probe list (Table 2-2). When using the unfiltered human array probe list, 
174 probes fail to call a genotype in any of the 874 samples (Appendix 2F). Filtering the 
probe list does not result in the removal of any of the 174 probes and they continue to 
provide No Call genotypes. The call rate improvement following probe filtering proved to 
be minimal for the human array, with an average call rate increase of 0.009% (Birdseed 
v1) or 0.0093% (Birdseed v2), and a maximum individual sample increase of 
approximately 0.06% (Table 2-2).  
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Figure 2-1. Impact of application of probe list filtering criteria for SNP, Exon 1 and Exon 2 Mouse Diversity Genotyping Array 
probes.  Non-bolded criteria were used to construct the probe list used in the broad survey in Chapter 3. Bolded criteria were used to 
construct the stringent probe list used in the mouse cohort comparison study in Chapter 3. SNP probe filtering was performed on a probe 
list previously filtered by S. T. Eitutis (2013)16. The Exon probe list had not been filtered previously. 
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Table 2-2. Changes in SNP genotyping call rate when changing algorithm version and SNP probe lists. 
Array 
Algorithm and 
probe lista 
Percentage of samplese with 
improved call rates (%) 
Average call rate 
increase (%; range) 
Average call rate 
decrease (%; range) 
Mouse Diversity 
Genotyping Array 
BRLMM-P, S. T. 
Eitutisb 100 0.538 (0.16-1.08) N/A 
BRLMM-P, Locke 
et al b 100 0.536 (0.16-1.08) N/A 
Genome-Wide Human 
SNP Array 6.0 
Birdseed (v1), 
filteredc 72.65 0.009 (0-0.061) 0.0044 (2x10
-5-0.018) 
Birdseed (v1), 
flankingc 31.24 0.011 (8x10
-5-0.051) 0.013 (5x10-5-0.061) 
Birdseed (v1), 
original listd 95.88 0.083 (6.7x10
-4-0.17) 0.018 (3.3x10-4-0.065) 
Birdseed (v2), 
filteredd 74.37 0.0093 (3x10
-5-0.057) 0.0044 (3x10-5-0.018) 
Birdseed (v2), 
flankingd 29.98 0.011 (5x10
-5-0.045) 0.013 (5x10-5-0.064) 
 
a ‘Filtered’ refers to the probe list filtering applied to only the 25 nt probe sequence. ‘Flanking’ excludes “Filtered” probes whose flanking 
regions contain NspI or StyI recognition sites.  
b Compared to original MDGA list with BRLMM-P 
c Compared to original SNP Array 6.0 list with Birdseed (v1) 
d Compared to original SNP Array 6.0 list with Birdseed (v2) 
e Genotyping was performed for 351 MDGA CEL files and 874 HapMap3 CEL files for the MDGA and SNP Array 6.0, respectively. 
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Figure 2-2. Impact of application of probe list filtering criteria for Genome-Wide Human SNP Array 6.0 SNP probes. Probe 
sequences representing both SNP alleles of a locus were excluded if at least one probe sequence did not meet the inclusion criteria. 
When Birdseed (v1) is used instead of Birdseed (v2) as the genotyping algorithm, the call rate improves for 96% of samples 
(Table 2-2). However, the change in call rate is small. The average call rate across samples increases by 0.083%, and the highest increase 
in an individual sample’s call rate is 0.17%. For samples where the call rate decreases, the average decrease in call rate is 0.018%. When 
looking solely at call rates, the differences in call rates between different algorithms is very small. At an individual sample level, some 
call rates are not greatly affected by changes in algorithm version or probe list used, while other samples are more affected (Fig. 2-3).  
25 nt probe length 
Remaining loci 
 
931,946 
 
931,932 
 
903,296 
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Figure 2-3. Call rates for 351 Jackson Laboratory samples, generated with different 
probe lists. Black lines connect the call rates for individual samples and represent the call 
rate difference.  
The difference in effect of probe filtering on SNP genotype call rates for the mouse 
and human arrays can be best observed in Figures 2-3 and 2-4. The average call rate 
increase following filtering for the MDGA is approximately 0.54%, which is nine times 
higher than the maximum call rate increase for an individual human sample following 
filtering (~0.06%). The highest call rate increase for an individual mouse sample post-
filtering is 1.08%.
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Figure 2-4. Call rates for HapMap3 samples, generated with Birdseed (v1), Birdseed 
(v2), and filtered probe lists. Black lines connect the call rates for individual samples and 
represent the call rate difference. 
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2.3.2 Cross-species hybridization 
The average SNP genotyping call rate is highest for members of the subgenus Mus while H. glaber has the lowest average call rate at 
approximately half the call rate of the Mus subgenus group (Table 2-3). The H. glaber call rate almost doubles when it is genotyped 
together with Mus samples.  
Table 2-3. SNP genotype call rates for Heterocephalus glaber samples genotyped together with and without a set of 27 samples 
representing four Mus subgenera: Mus, Pyromys, Coelomys, and Nannomys. 
Samples Divergence time from Mus musculus domesticus Sample size 
Genotyped with or 
without other samples Average call rate 
Heterocephalus glaber 
(Naked mole-rat) 
73.1 million years ago39 4 
Without 44% 
With Mus set 86% 
Mus set  ≤ 7.6 million years ago40 
Mus (17) 
Pyromys (4) 
Coelomys (1) 
Nannomys (5) 
Without 
Mus (90%) 
Pyromys (85%) 
Coelomys (83%) 
Nannomys (86%) 
With four H. glaber samples 
Mus (91%) 
Pyromys (88%) 
Coelomys (86%) 
Nannomys (88%) 
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2.4 Discussion 
2.4.1 Impact of probe filtering for the Mouse Diversity Genotyping 
Array and the Genome-Wide Human SNP Array 6.0 
MDGA probe filtering improved overall SNP genotype call rates, as predicted, and it did 
so for all tested mouse samples. Therefore, filtered probe lists are recommend for use in 
variant detection with the MDGA, particularly for SNP genotyping. Testing the effect of 
probe filtering on CNV calling is more challenging as it would require algorithms to be 
tested on samples where the CNVs have been previously identified so that the copy number 
state and genomic location are known.  Although not tested here, probe filtering is expected 
to improve CNV detection so filtered probe lists will be used for CNV detection in the 
studies described later in this thesis. CNV calls are directly affected by SNP probe 
performance. If a probe does not bind its target efficiently, then the fluorescence intensity 
of that region will be lower than the fluorescence intensity of the neighbouring probes and 
may break up a larger CNV gain, making it falsely appear to be two separate CNV events. 
False negatives can occur when minimum marker requirements are used for CNV calling 
and poorly performing probes in a CNV region prevent the cut-offs from being met. For 
example, a CNV spanning a required minimum of three probe loci may not be identified 
as a CNV because one of the probes is providing false signal information due to poor target 
DNA binding.   
SNP Array 6.0 data indicate that probe filtering based on NspI and StyI recognition 
sites does not greatly improve the average call rate, particularly when compared to the 
effect of using algorithm versions on call rate. Furthermore, a group of 174 probes that 
produced No Call genotypes in all tested samples, were not removed by probe filtering. 
This implies that there are factors other than restriction enzyme digestion involved in 
preventing hybridization. No combination of probe list and algorithm resulted in an 
increased call rate for all samples. The highest call rates overall were observed when using 
the unfiltered probe list and the Birdseed (v1) algorithm. This suggests that the SNP Array 
6.0 is well-designed with respect to the location of restriction enzyme recognition sites and 
does not appear to benefit from the use of a filtered probe list. The difference in the average 
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call rate was very minor (<0.1%) between algorithm versions and this finding is consistent 
with previous algorithm comparisons when genotyping using the Genome-Wide Human 
SNP Array 6.022. However small the differences may appear to be, the algorithm choice 
does still impact the genotyping results and selection of the wrong algorithm can result in 
variants going undetected or being incorrectly associated with a biological event or 
phenotype. The importance of algorithm selection is supported by Bucasas et al41, who 
found that the CRLMM algorithm yielded higher call rates than the Birdseed (v2) algorithm 
but also showed decreased tolerance to low quality samples. Users selecting algorithms for 
variant detection should be aware that some outcomes may be algorithm-specific. The 
reasons for why Birdseed (v1) yields higher call rates than Birdseed (v2) would need to be 
investigated in a future study.  
2.4.2 Cross-species hybridization and considerations for SNP 
genotyping 
Like other microarrays, the MDGA can also be used for cross-species hybridization but the 
call rates are heavily influenced by how the genotyping is performed. For instance, naked 
mole-rat samples applied to the MDGA yield very different genotyping call rates 
depending on whether or not the samples are genotyped along with Mus samples or 
independently. By genotyping the naked mole-rat samples along with Mus samples, the 
call rates are artificially increased so that they are more similar to the mouse samples. 
Genotyping Mus samples with naked mole-rat samples results in a slight increase, up to 
3%, in the average Mus call rate. These results suggest that when conducting cross-species 
hybridization analysis, it is important to perform the genotyping for the different species 
separately. 
Aside from technical issues, low call rates can occur if a sample’s genome is 
distantly related to the reference genome that the probe design was based on. In this case, 
sequence divergence between species means that there are hybridization incompatibilities 
between the target DNA and the array probes. The MDGA probes can hybridize with SNP 
probes to a degree that is associated with the time of species divergence from Mus musculus 
domesticus. Mus subgenus samples have the highest call rates among the Mus genus 
samples tested, likely due to having a closer genetic relationship to M. m. domesticus42 and 
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therefore more sequence complementarity between the MDGA probe sequences and the 
target DNA. The subgenra Pyromys, Coelomys, and Nannomys have call rates in the 80s 
and are more distantly related to the M. musculus species42. Heterocephalus glaber (naked 
mole rat) samples, which have the lowest call rates, are also the samples that are the most 
distantly related to M. m. domesticus39.  
Unlike SNP genotyping, it is more difficult to apply cross-species hybridization for 
CNV detection. This is because accurate CNV detection requires high genomic coverage 
by probes that are contiguously located in the genome. If an organism is distantly related 
to the organism whose genome was used to design the array, then it is likely that many 
probes will not have a target to bind to due to sequence divergence or if they do bind a 
target, the locations may not be contiguous due to low synteny. When choosing to perform 
cross-species hybridization, it is advisable to check the array probe sequences against a 
reference genome (if available) to determine if the sequence is present in the genome and 
where it is located. This will provide the user with an idea of how many probes should 
return a genotype call and which part of the genome is being targeted. The naked mole rat, 
for example, has 41,225 syntenic regions with the mouse genome, covering ~83% of the 
naked mole rat genome43. In comparison, there are 24,999 syntenic regions between the 
naked mole rat and human genomes, covering ~92% of the naked mole rat genome43. This 
means that both mouse and human microarrays could be used for CNV detection in the 
naked mole rat, provided that there is sufficient sequence similarity between the microarray 
probes and the sample DNA.  
2.5 Computation-based assessment of MDGA data quality 
CNV results generated by microarrays require experimental confirmation to ensure that the 
calling methods are reporting biological events. Even if the microarray probes are designed 
well, false positive and negative calls can occur. Some CNV calling errors can result from 
hybridization problems while other errors result from the CNV calling methods or 
algorithms employed44,45. A study comparing multiple algorithms on SNP microarray data 
found less than ~50% concordance in detected CNVs, between any two algorithms tested46. 
The study’s authors advised, based on findings in multiple studies, that the use of multiple 
algorithms for a dataset can reduce false negative calls but will also increase false positive 
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calls. Typically, PCR-based methods are used to experimentally confirm putative CNVs. 
In studies where a large number of CNVs are detected, it is not practical or cost-effective 
to confirm every putative CNV. Therefore, a targeted approach to confirmation can be 
used. With a targeted approach, computational assessment of the data quality can be used 
first to evaluate if the CNV call quality is sufficient to move forward with wet lab 
confirmation. The following chapter sections discuss computational methods of data 
quality assessment.  
2.5.1 Assessing MDGA data quality through visualization of 
fluorescence intensity data 
One of the simplest ways of checking the quality of microarray hybridization for newly 
generated data or unfiltered, publicly available data, is to generate coloured images 
showing the hybridization signal for each array feature. Some arrays can have regions of 
abnormally low or high hybridization signal, which can result from an unequal application 
of the DNA solution, precipitate formation, and poor sample preparation47. Once array 
hybridization has been assessed visually for the presence of artifacts, and problematic 
arrays have been removed from the dataset, SNP genotyping and CNV calling can be 
performed. Depending on the software used for interpreting the fluorescence intensity data 
and the size of the artifacts, artifact reduction may be possible. For small artifacts, the 
probes in those regions can be identified and excluded from analysis. Normalization may 
help in cases were the overall array fluorescence intensity is lower or higher than expected 
unless the signal is too low for detection or the array is oversaturated.  
2.5.2 Assessing quality of SNP genotype output 
SNP genotype call rates are an indicator of the array quality and sample suitability. For a 
call to be generated, the probes have to bind sufficient DNA template so that a hybridization 
fluorescence signal can be detectable. Errors affecting DNA preparation and inappropriate 
hybridization conditions can reduce probe-target binding48, leading to low SNP genotype 
call rates. 
For samples closely related to the reference genome, hybridization success may be 
reduced if off-target mutations (when nucleotide mismatches occur at sites other than the 
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SNP locus) are present. The expected MDGA SNP call rate for a Mus musculus domesticus 
laboratory strain is 97% or higher7. Lower call rates are expected for other subspecies of 
mouse like M. m. musculus, M. m. castaneous and M. m. molossinus, and different species 
of mouse like M. spretus and M. spicilegus are expected to have call rates in the low 
nineties1. To ensure the highest call rates possible for MDGA samples, probes that are 
predicted to perform poorly with regards to hybridization, or cannot be annotated, should 
be excluded from genotyping.  
The SNP genotyping output is important for CNV calling when using PennCNV 
software because PennCNV requires information about the frequency of the B allele (BAF) 
and the Log R ratio (LRR)11,49. The LRR represents the normalized, total fluorescent 
intensity signals from each SNP probe set and is related to the amount of sample DNA 
bound to the probes. BAF values represent the normalized fluorescent signal ratio between 
the B and A allele probes at each SNP locus. The amount of deviation of BAF values from 
the expected BAF values for AA (0.0), AB (0.5) and BB (1.0) clusters, is called the BAF 
drift. Commonly, a filtering step is applied to the LRR standard deviation (LRR_SD) and 
BAF drift values to determine if a sample is suitable to use for CNV calling. Low LRR_SD 
and BAF drift values are desirable and PennCNV uses cutoffs of 0.30 for LRR_SD and 
0.01 for BAF drift50. Exclusion criteria based on the waviness factor (WF <0.05) are used 
as well50,51. The waviness factor describes the dispersion in the signal intensity; low 
amounts of dispersion are desirable and are an indicator of DNA quality. Lower or higher 
LRR_SD, BAF drift, and WF cutoffs can be used depending on the type of array used and 
user preference for cutoffs. Affymetrix arrays, for example, tend to produce more noise 
than Illumina arrays so less stringent cutoffs should be used for Affymetrix array data52.  
2.5.3 Assessing MDGA data quality by examining the nature of 
CNV calls 
There are several indicators that are helpful in predicting the reliability of CNV calls. In 
the case of CNV losses, state-zero losses should not overlap SNP probes with genotype 
calls other than No Call genotypes and state-one losses should not overlap SNP probes 
with heterozygous genotype calls. The reason for this is that if there is only one copy of a 
DNA segment that contains SNP loci, only one allele should be present which would result 
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in the generation of a homozygous genotype call. If there are no copies of the DNA 
segment, SNP probes would not bind target DNA, so it would not be possible to generate 
a genotype call.  
CNV losses are less likely to occur and be maintained in genomic regions 
containing functional elements, in particular for genes vital for cell survival53,54. Although 
it is possible for such losses to be present in subpopulations of cells in cases of mosaicism, 
these losses are unlikely to have been inherited or to have arisen early in development. 
There are over 700 genes and noncoding elements, overlapping MDGA probes, that are 
known to cause deleterious phenotypes when copies are lost, or are highly conserved and 
unlikely to vary in copy number (Appendix 2G). Most of the genes listed in Appendix 2G 
come from the International Mouse Phenotyping Consortium (IMPC)55. The IMPC’s 
purpose is to generate and characterize 20,000 knockout mouse strains, and it a useful 
source for determining the phenotypic impact of gene deletions in mice. The remaining 
genes in the Appendix 2G come from independent studies and were compiled as resource 
in Locke et al33. These genes are expected to overlap very few putative CNVs detected in 
normal healthy tissues, with the exception of some mosaicism events, and can therefore be 
used to assess the MDGA data quality.  
When generating CNV calls for a dataset with mice of different backgrounds, it is 
expected that the number of CNVs will differ between mice and there will be a mix of copy 
number losses and gains called13,33,56. Excessive CNV calls in one sample may indicate 
poor array quality or an unusually high mutation load in that individual. Similarly, 
detecting only gains or only losses in a dataset may be an indicator of either technical issues 
or true mutational events (e.g. from exposure to a mutagen or disease models). Based on 
Locke et al.’s33 study which uses the MDGA, Mus musculus subspecies have an average 
of 29 CNVs per mouse, although the number of CNVs can differ greatly depending on the 
mouse genetic background and health. To determine what is a normal CNV profile for a 
single healthy mouse of a specific background, comparisons should be made to CNVs from 
samples from multiple individuals of this background. For these comparisons, the CNV 
detection approach used should be the same. 
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The size of the CNVs detected is dependent on the probe density and spacing across 
the genome. CNVs that are most likely to be biological events are expected to be those that 
are detected by many, closely-spaced probes since the resolution would be higher. A 
consequence of low resolution is that a large detected CNV may actually be multiple CNVs 
that have been called as one event due to low probe density or uneven probe spacing that 
includes large gaps13. CNV calls can be excluded based on the number of probes used to 
make that call as well as the probe density. The probe density is calculated by dividing the 
CNV length by the number of probes underlying a call, so it does not take into account 
probe spacing within the CNV region. Therefore, large CNVs should be assessed for probe 
spacing to ensure that the call does not include probe “deserts”, which can affect the 
accuracy of the call.  
Confidence in the putative CNVs calls is greater if the CNVs have been detected 
before in multiple, independent studies. Recurrent CNVs can be found in mutation hotspots 
or they may be mouse strain- or species-specific as a result of an inherited mutational event 
in a common ancestor. One such example, is the presence of duplications of the insulin-
degrading enzyme (Ide) gene in some C57BL/6J mice from The Jackson Laboratories 
colony, which is thought to have arisen sometime after 1994 and spread throughout the 
colony via breeding57. The Ide duplication may have an impact on disease models but does 
not appear to be under negative selection in the general C57BL/6J population57. The 
support for recurrent, strain- or species-specific CNVs being true events is increased when 
the same CNVs have been observed the same mouse strain or species in previous studies.  
2.5.4 Probe annotation: Providing genomic context 
Updating the genomic positions of SNP probe and IGP sequences to the latest mouse 
genome build is required when using updated annotation information from databases like 
Ensembl and UCSC genome browser58–60. Probe annotation updates are also important for 
CNV calling accuracy, which is heavily dependent on knowing which probes target 
consecutively located DNA regions. Updated genomic positions for the MDGA can be 
downloaded from the Thermo Fisher Scientific website9. It is not uncommon, however, for 
there to be compatibility issues between the genome version used to specify probe locations 
and the genome version for genomic information downloaded from various databases.  
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2.5.5 Assessing MDGA data quality with pairwise genetic distance 
comparisons 
The genetic distance between samples can be used as an indicator of microarray data 
quality. Closely related individuals are expected to have a smaller genetic distance between 
them than unrelated or distantly related individuals. Likewise, samples taken from the same 
individual would have a smaller genetic distance value than samples coming from different 
individuals. If pairwise genetic distances calculated for a sample set does not reproduce the 
known relative relationships between those samples, then there may be a problem with the 
array data or there was not sufficient genetic variation at the loci that were used for the 
calculations. 
Genetic distance can be calculated using SNP or CNV genotypes. The pairwise 
genetic distance values generated for a sample set can then be used to create distance 
matrices. The following calculation is used to produce a pairwise SNP genetic distance 
value for two samples: 
!"#"$%&	(%)$*#&" = ,-$*.	/01	2"#-$34"	5%66"7"#&")	8"$9""#	$9-	)*:4."),-$*.	#;:8"7	-6	/01	.-&%	&-:4*7"5  
There are multiple definitions for what constitutes a SNP difference. One definition 
includes counting any genotype (AA, AB, BB, No Call) difference between the two 
samples, at a given locus, as a difference. Alternatively, No Calls can be excluded from 
this calculation since a genotype could not be determined. Using this formula, the pairwise 
genetic distance value will range from 0 to 1. If two samples have no SNP genotype 
differences, the value will be 0. The more similar two samples are genetically, the closer 
the value will be to 0.  
A matrix containing the pairwise SNP genetic distance values for a sample set can be used 
to construct a phenogram. A phenogram depicts the degree of similarity between 
individuals, based on selected characteristics, without including measures of evolutionary 
time or defining common ancestors.  
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CNVs can also be used to calculate genetic distance. For CNV calls, the probes 
underlying a CNV are assigned the copy number state of that CNV as a genotype. Then a 
formula similar to the one for SNP genetic distance can be used to calculate CNV genetic 
distance between two samples:  
!"#"$%&	(%)$*#&" = ,-$*.	<0=	2"#-$34"	5%66"7"#&")	8"$9""#	$9-	)*:4."),-$*.	#;:8"7	-6	.-&%	&-:4*7"5  
SNP- and CNV-based genetic distances will not necessarily show the same 
relationship between the same samples and SNP-based distance is more likely to reiterate 
known genealogy13. Cutler et al.13 attribute these differences to the nature of CNV 
inheritance from parents as well as the smaller numbers of CNVs, compared to SNPs, 
which leads to greater intergenerational fluctuations in CNV content. However, CNV-
based genetic distance can be informative about relatedness and ancestry when population-
specific copy number variable regions61 or fixed deletions and duplications in different 
species’ lineages62 are used.  
2.5.6 Considerations for Mus musculus sample set size and sex of 
mice 
When designing an experiment, it is important to select the mouse species, number of 
samples and tissue type, with considerations of MDGA detection limits in mind. The 
MDGA is best suited for detecting genetic variation in Mus musculus subspecies. When 
using a BRLMM-P algorithm for SNP genotyping of MDGA data, it is recommended that 
at least 60 samples are genotyped together for the data to cluster properly63. However, other 
sources using a different microarray found that high performance BRLMM-P clustering 
can be achieved with 44 samples or fewer64. In genome-wide association studies (GWAS) 
using SNP microarrays, thousands of disease and control samples may be required if rare 
variants are involved65. Increasing sample size generally has a greater effect than increasing 
microarray genome coverage with regards to identifying disease-associated SNP variants66.  
In addition to sample size, the sex of the mice for the samples in the dataset should 
be given consideration. Ideally, the user will know the sex of the samples and input this 
information into PennCNV. Where the sex of the sample is unknown, PennCNV will use 
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B allele frequency (BAF) values from the X chromosome SNPs to generate CNV calls for 
the X chromosome – information regarding the sex of the samples is not required when 
using PennCNV for the autosomes, which are run separately from the X chromosome67. 
From a SNP genotyping perspective, greatly skewed sex ratios in a dataset might 
negatively affect clustering and the BAF values for the X chromosome. Datasets using only 
females can have three genotype clusters (AA, AB, and BB genotypes) while male samples 
are expected to lack a heterozygous genotype cluster.  
2.5.7 Considerations for tissue type  
The MDGA, like other microarrays, is more likely to detect CNVs that are in the majority 
of cells of the tissue sample. When using a microarray, a consensus result will be generated 
for all the genomes present within a sample. Rare losses or gains may not influence the 
florescence signal sufficiently to be detected. Genome mosaicism has been detected at 
levels as low as <5% using a SNP-based microarray, although detection limits are generally 
higher68. Another study found that mosaicism is readily detectable at 20%, although the 
threshold can be lowered to 10% following additional statistical calulations69. It would be 
expected that a detection threshold will differ based on the specific microarray and 
computational detection method employed.  
The implications of microarray sensitivity limitations are that the MDGA may not 
be suitable for identifying rare mosaicism events in diseased or normal tissue. Tumour 
samples for example, tend to have high amounts of genetic heterogeneity due to genomic 
instability70. While low level tumour mosaicism may be not be detected by microarrays, 
SNP microarrays have been of use in cancer research71–73 since many mutations are 
detectable. In normal tissues, genetic variation can arise spontaneously during development 
or later in life and is a commonly occurring phenomenon74. The clonal size of a genetic 
variant in an individual will vary based on factors including but not limited to the when the 
variant arose and the phenotypic impact of the variant75–78. To identify cell lineage-specific 
variants, variant detection should be conducted on isolated cell types or subpopulations 
within a tissue if it is comprised of heterogeneous cell populations78–81.  
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2.6  Conclusion 
When compared to the Genome-Wide Human SNP Array 6.0, the MDGA has more probes 
that are predicted to perform poorly. However, these probes can be identified and excluded 
from analyses to improve the overall performance of the MDGA, which was assessed using 
SNP genotype call rate in this study. The generation of good quality array data is also 
dependent on having study designs that incorporate appropriate sample sets and variant 
detection methods. It is important to design studies that are suitable for MDGA’s sensitivity 
and resolution limits. For example, the MDGA cannot be used to detect very rare variants 
or to find the exact locations of CNV junctions. 
Well-designed studies do not guarantee the production of good quality data since 
sample preparation or hybridization errors can occur. Several computational methods are 
available for assessing the quality of MDGA data. These include visualizing the array to 
look for hybridization abnormalities and assessing the SNP genotyping and CNV calling 
results using metrics like SNP call rates, the presence of heterozygous SNP calls underlying 
CNV losses, the presence of CNVs in genes unlikely to vary in copy number, and BAF 
drift, LRR SD, and WF values. Ultimately, even if computational assessment indicates 
good quality data, experimental confirmation is necessary to ensure that true genomic 
alterations were identified. Preferably, non-hybridization-based methods would be used for 
confirmation to avoid similar errors that occur with hybridization-based methods like 
microarrays.
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Chapter 3   
3 CNV Diversity in Inbred and Wild Mice Detected by the 
Mouse Diversity Genotyping Array 
A version of this chapter’s broad survey of mouse genomes for CNVs has been published 
in Locke et al., BMC Genomics (2015)1.  
3.1 Background 
The house mouse, Mus musculus, has a long history linked with humans as a commensal 
species2,3 and as a valuable animal model of human biology and disease4–6, yet there are 
many aspects of its basic biology left to uncover. One such aspect, which is explored in 
this chapter, is the contribution of copy number variants (CNVs) to mouse genetic diversity 
and to phenotypic traits important for species adaptation, evolution, and use as a model 
organism. M. musculus is known to be a phenotypically and genetically diverse species 
being comprised of three major subspecies in the wild3 and including numerous laboratory 
strains which were genetically manipulated and bred to express specific traits7. M. 
musculus subspecies are sufficiently diverse genetically that hybrid sterility and reduced 
fertility have been known to occur8–11. One of the contributors to the genetic diversity in 
M. musculus is CNVs12,13. CNVs can alter phenotypes by modifying expression levels of 
protein-coding genes and regulatory or noncoding elements14,15. Deleterious phenotypes 
will be selected against in a mouse population while phenotypes that confer an advantage 
to fitness are more likely to remain or expand within a population. An exception to this is 
the intentional introduction and maintenance of deleterious variants in mice by humans, to 
create a variety of genetically and phenotypically different mouse models of human 
biology  and disease4,16,17. The genetic diversity of a mouse model can be increased by 
using wild-derived strains, which capture the genetic diversity of the three major mouse 
subspecies in natural populations, or by breeding wild-derived strains with classical 
laboratory strains (usually domesticus) of interest18.  
An important part of understanding why there are genetic differences among 
members of the M. musculus species is understanding its history. The musculus, 
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domesticus, and castaneus subspecies of M. musculus diverged sometime around ~350-
500 thousand years ago19,20. Ancestral M. musculus populations are thought to have lived 
in the north of the Indian subcontinent and dispersed to other parts of the world from there3. 
Today, this species can be found world-wide with different subspecies being predominant 
in certain regions. After M. musculus subspecies divergence, the subspecies are thought to 
have independently evolved commensalism following the rise of human agrarian 
societies7. As a human commensal species, M. musculus movement often followed human 
movement and this allowed for the establishment of populations where none would be 
expected due to large natural barriers such as oceans. During the Viking Age for example, 
mouse stowaways travelled with European colonizers, and this resulted in the 
establishment of M. m. domesticus populations in Iceland and Greenland (later replaced by 
Danish M. m. musculus)2.  
M. m. musculus is commonly found in a region ranging from central Europe to 
northern China and in Greenland, while M. m. castaneus is common in southeast Asia3,21. 
M. m. domesticus has the greatest range and can be found in western Europe, the 
Mediterranean basin, Africa, North and South America, and Australia21. Another mouse 
subspecies was thought to be present in Japan, M. m. molossinus, until DNA studies 
showed that Japanese mice have mostly M. m. musculus DNA along with some M. m. 
domesticus and M. m. castaneus DNA22,23. Mice in New Zealand are hybrids of all three 
mouse subspecies representing mouse populations from different regions of Europe and 
Asia24. Subspecies hybrids can be found in hybrid zones where the subspecies ranges meet 
and overlap. Isolated populations of house mouse subspecies can be found where there are 
natural barriers between the subspecies. One such example is the Himalayan mountains 
which separate M. m. musculus and M. m. castaneus populations21.  
 In addition to natural barriers isolating mouse subspecies, there are also biological 
barriers that can interfere with hybridization of subspecies. M. m. musculus and M. m. 
domesticus, for example, were found to have divergent urinary odors occurring in allopatric 
European populations and the divergence was more pronounced in regions where the two 
subspecies come in contact with each other25. It is suspected that the urinary odors play a 
role in mating and that the presence of different proteins in the mouse urine is responsible 
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for the divergent odors. This may suggest that genetic differences between the mouse 
subspecies are contributing to differences in odor production and detection, and 
preferences for certain odors, leading to interference with hybridization.   
Although mating can occur between subspecies, genetic incompatibilities can affect 
the offspring fitness by causing hybrid sterility8.  Hybrid mating experiments between M. 
m. musculus and M. m. domesticus reveal that hybrid males are sterile if they inherit a M. 
m. musculus X chromosome while hybrid females are not affected26. Sex chromosome 
incompatibilities are not the only genetic contributors to infertility. The autosomal PR-
domain containing 9 (Prdm9) gene was found to play a role in hybrid sterility with fertility 
levels being affected by which alleles are present and the number of copies of Prdm927. 
Prdm9 is highly polymorphic in M. musculus populations28. During meiosis, Prdm9 
initiates meiotic recombination by promoting double strand break (DSB) formation near 
its DNA binding sites29.  Sterile mouse hybrids have defects in meiotic prophase following 
the DSB formation and different Prdm9 alleles influence each other’s behaviour regarding 
DSBs, but the defects causing sterility can be reversed by introducing altered Prdm9 alleles 
into the mouse hybrids30. In all, it has been found that multiple genomic loci can 
independently impact hybrid fertility due to genetic differences between subspecies at 
those loci.  
 Within the same subspecies, genetic variation was found between different wild 
populations of house mouse, with CNVs being a large contributor to this variation12. When 
multiple mice have a CNV overlapping the same genomic region, that region is referred to 
as a CNV region (CNVR). CNVRs that overlap large segmental duplications have been 
found to vary more in copy number in mice than those that do not overlap segmental 
duplications, and they are enriched for nonessential, environmentally-responsive genes 
including those with functions related to olfaction, production of urinary proteins, as well 
as production of proteins with unknown functions12. CNVRs that do not overlap segmental 
duplications are thought to be under stronger selective constraints, since these CNVRs 
contain CNVs that are smaller, less frequent, and linked to Mendelian disease genes.  
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With inbred mice, many classical laboratory strains share a predominantly M. m. 
domesticus background but their genome has been modified through generations of 
inbreeding and selection for specific traits. Many laboratory mice have been selectively 
bred for traits related to human health with numerous strains being used as models of 
cancer, complex and single gene diseases, and for determining gene function (e.g. gene 
knockouts)31–33. Genetic differences among laboratory strains also contribute to differences 
in non-pathogenic traits like taste thresholds and macronutrient selection preference 
(related to taste)34,35.  
CNVs are known to contribute to some genetic differences in laboratory mice. For 
example, an Ide (insulin-degrading enzyme) gene duplication can be found segregating in 
C57BL/6J mice36. Likewise, a-defensin gene diversification occurring through tandem 
duplication has been observed specifically in C57BL/6 mice and results in an increased 
variety of antimicrobial peptides24. CNV studies of laboratory mice have found CNVs that 
are enriched for genes with functions related to the immunity, olfaction, and pheromone 
detection38,39.  
Due to inbreeding over numerous generations and having a small founding 
population, classical laboratory mice do not capture the extent of genetic diversity 
occurring in wild populations of mice7. Thus, wild-derived mouse lines were established 
to introduce greater genetic variation and novel phenotypes40. The genetic variation among 
lines, particularly from a single nucleotide polymorphism perspective, has been shown to 
be greater in wild-derived strains than classical laboratory strains17,41. Similarly, the 
contribution of CNVs to genetic diversity is expected to be greater in wild-derived mice 
than classical laboratory mice.  
In this study, the CNV landscape is characterized in hundreds of M. musculus 
individuals from a variety of genetic backgrounds. CNV differences within and between 
multiple mouse cohorts are identified using the Mouse Diversity Genotyping Array42, with 
an aim of gaining insight into potential phenotypic impact and relevance to adaptation and 
evolution in natural and laboratory environments. This chapter is divided into two studies, 
1) a broad survey of mouse genetic diversity and 2) a comparison of genetic diversity 
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between mouse cohorts. The broad survey tests a CNV detection pipeline on a large mouse 
dataset and assesses its variant detection capabilities by experimentally confirming putative 
CNVs. This survey will characterize the CNVs in a diverse group of M. musculus samples 
that includes multiple subspecies, a variety of inbred laboratory mice, and wild mice. 
Reported here, is the CNV analysis of 351 mice, representing 290 strains that have not been 
studied for CNVs previously.  
The mouse cohort comparison study uses a refined dataset that focuses on the 
comparison of three mouse cohorts: classical laboratory (CL) strains, wild-derived (WD) 
inbred strains, and wild-caught (WC) mice. These cohorts were selected to study how 
differences in genealogy, breeding schema, origins of genetic diversity, and housing shape 
the CNV landscape of a mouse genome. In comparison to the broad survey, the mouse 
cohort comparison study uses 10 addition WD samples and 14 additional WC samples. CL 
strain duplicates were excluded for a total of 114 CL strains selected for study, each with 
different breeding and phenotype selection histories but all are predominantly M. m. 
domesticus. In this study, there is a greater emphasis on the differences between classical 
CL, WD, and WC mouse cohorts with respect to CNV characteristics (e.g. number, length, 
state, hotspots, genic content), and the potential implications for adaptation and evolution.  
Genetic variants that are recurrent in CL cohort are predicted to be associated with 
the shared M. m. domesticus background, husbandry practices, and adaptation to living in 
a laboratory environment. Since the WC cohort includes multiple M. musculus subspecies 
from different geographical regions, WC diversity is predicted to be associated with the 
inclusion of different subspecies and the different geographic environments. Recurrent 
CNVs that are either subspecies-specific or geographically-specific may be observed for 
the WC cohort. The WD cohort also includes multiple subspecies, but unlike with WC 
mice, WD mice are inbred laboratory strains. The CNVs in this cohort are likely shared 
with mice in the CL and WC cohorts, resulting from inheritance given common ancestry 
or from selection pressures given similar environments. The WC and WD cohorts are 
predicted to have the greatest genetic diversity due to greater diversity in environments and 
the inclusion of different subspecies. The WC and CL cohorts are expected to have the 
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fewest CNVs in common given their histories in different environments and the different 
genealogies for the two cohorts.  
3.1.1 Research goal, central hypothesis, and specific objectives 
Research goal: The overall goal of this study is to broadly characterize the CNV landscape 
of Mus musculus using the MDGA, and to expand on this initial study by identifying CNV 
differences within and between mouse cohorts that can be further studied to gain insight 
into the CNV origins, phenotypic impact and relevance to adaptation and evolution in 
natural and laboratory environments.  
Central hypothesis: First, given that CNVs are heritable, different mice of different strains 
and origins will have different CNV profiles reflecting similarities and differences in 
genealogy. Second, given evidence of the phenotypic impact of CNVs, the profile of CNVs 
will differ between mouse cohorts that differ in environment and phenotypic selection. 
The specific objectives of the board survey are: 
1. To identify CNVs, using a filtered probe list containing both SNP probes and IGPs, in 
Mus musculus samples from different lines, subspecies and geographic locations. 
2. To use genes that are unlikely to vary in copy number as a measure of false CNV 
discovery. 
3. To characterize CNV differences and impacted gene pathways between CL and WC 
mouse cohorts. 
4. To evaluate the reliability of the candidate CNV detection method via confirmation of 
select genic CNVs by ddPCR.  
The specific objectives of the mouse cohort comparison study are: 
1. To identify CNVs in CL, WD, and WC Mus musculus samples using the stringently 
filtered probe list recommended in Locke et al1. 
2. To use genes that are unlikely to vary in copy number as a measure of false CNV 
discovery. 
3. To characterize CNV differences and impacted gene pathways in and between CL, 
WD, and WC cohorts. 
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3.2 Materials and methods 
3.2.1 Samples 
Publicly available Mouse Diversity Genotyping Array CEL files were downloaded from 
the Center for Genome Dynamics at The Jackson Laboratory43. The CEL files for the broad 
mouse survey contain raw array intensity data for mouse tail samples from 120 CL strains, 
58 WD strains, 10 consomic strains, one congenic strain, 44 BXD recombinant inbred 
strains, 40 CC-UNC G2:F1 strains, 55 F1 hybrids of inbred strains and 23 WC mice, for a 
total of 351 samples (Appendix 3A). Consomic strains are inbred mice that contain one 
entire chromosome from a different mouse strain44. Congenic strains are generated to 
contain a particular marker from another mouse strain44. BXD recombinant inbred strains 
contain approximately equal amounts of genetic material from a C57BL/6 and DBA/2 
strain background44. CC-UNC G2:F1 mice are the first generation of collaborative cross 
mice generated at the University of North Carolina by breeding eight extant and genetically 
diverse laboratory strains together to create recombinant inbred lines45,46. For the mouse 
cohort comparison study, CEL files for 110 CL strains without strain duplicates, 37 WC 
mice, and 68 WD mice were selected for analysis (Appendix 3B).  
3.2.2 CNV identification 
The probe list provided in Additional file 2 of Locke et al.1 was used for SNP genotyping 
and CNV calling in the broad survey while the more stringently filtered list, provided in 
Additional file 7 of Locke et al. was used for the mouse cohort comparison study. Genotype 
calls were generated using the BRLMM-P algorithm implemented in Affymetrix® Power 
Tools47 using default parameters as specified by Genotyping Console48, which includes 
quantile normalization. To pass SNP genotype call rate requirements, CL mouse samples 
in the mouse cohort study, but not the broad survey, were required to have an overall call 
rate greater than 97%. Low call rates are expected for WD and WC samples1,49, so call rate 
was not used as an exclusion criterion for these samples.  
A canonical genotype clustering file was generated and used to calculate Log R 
Ratio (LRR) and B allele frequency (BAF) values using the PennAffy package50. 
PennCNV was used to generate PFB (population frequency of the B allele) reference files 
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from the dataset for each study51. A GC model file, containing the percent GC content of 
the 1 Mb region surrounding each marker (or the genome-wide average of 42% GC 
content, if this could not be calculated) was generated using KentUtils52 and an in-house 
script based on the reference genome used for the broad survey (UCSC:mm9) and the 
mouse cohort study (UCSC:mm10).  
CNVs were detected with PennCNV using default parameters and GC model 
correction53. CNVs on the X chromosome were detected in a separate run of PennCNV 
using the –chrX option. Calls were filtered to be 500 bp to 1 Mb in length, have at least 
three markers, have a marker density of 0.00013 markers/bp, have a log-R ratio standard 
deviation below 0.35 and have a B-allele frequency drift below 0.01. CNV data for the 
broad survey are provided in Appendices 3C-E. CNV calls for the mouse cohort study are 
provided in Appendices 3F and 3G.  
For the mouse cohort study, CL samples failing to meet the inclusion criteria, based 
on their autosomal CNV calls, were excluded from all subsequent analyses (five samples 
failed: MA/MyJ, NONcNZO10/LtJ, C57BL/10ScSnJ, C57BL/10ScNJ, GR/J). The failing 
samples were included in the phenogram section for comparison to the SNP data since the 
SNP genotyping threshold was met. The MDGA cannot always capture the diversity from 
wild-type samples and is therefore more likely to fail to meet inclusion criteria for WD and 
WC samples than CL strains. As such, WD and WC failing samples were not excluded 
from analysis. Mouse samples were also not excluded from subsequent analysis if their 
Chromosome X CNV calls failed quality controls because X chromosome calling requires 
special treatment51 so the CNV calls for the X chromosome may less reliable than autosome 
calls.  In addition, sex prediction by PennCNV is more suitable for Illumina arrays when 
using default parameters than for Affymetrix arrays54.  
3.2.3 Figure construction and statistical analysis 
Boxplots were generated in R (v3.2.4) using the Boxplot function. Figure 3-2 was 
generated using the ggplot2 (v3.1.0) package and the geom_point and geom_density 
functions. Wilcoxon and Kruskal-Wallis tests were performed with R using the 
stat_compare_means function from the ggpubr (v0.2) package.  
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3.2.4 CNV recurrence and CNV landscape plot visualization 
Recurrent CNVs were identified using the default overlap percentages (40% for a merge, 
and 99% for a family) and reciprocal overlap in HD-CNV55. Recurrent CNVs must be 
found in at least two mice within a dataset, regardless of cohort, and they are not required 
to share the same copy number state. Genomic regions containing recurrent CNVs are 
referred to as CNV regions (CNVRs) in this chapter. Appendix 3C lists broad survey CNVs 
as unique (also known as singleton CNVs) or recurrent. For the mouse cohort study, the 
number of CNVRs detected by HD-CNV, was represented with a Venn diagram generated 
in R with the venneuler package (v1.1.0). Each CNVR count includes multiple CNVs and 
CNVs can be included in more than one CNVR.  
3.2.5 Concordance with previous studies 
Data for concordance analysis for the broad survey were downloaded from the Database 
of Genomic Variants56 or from supplementary tables depending on availability1. Overlap 
analysis at 20% reciprocal overlap was performed using the intersect function of Bedtools 
(version 2.17.0)57. The copy number state of the call was not considered; the presence of a 
call in a previous study was considered evidence that variability occurs in this region. 
Chromosome X was excluded from analysis since many studies did not have CNV data for 
this chromosome.  
To identify CNVs in the mouse cohort study that were observed in the broad survey, 
the genome coordinates from the Locke et al.1 CNVs were converted to the newer genome 
build (GRCm38/mm10) using the UCSC Genome Browser LiftOver tool. Nine positions 
could not be updated due to sequence additions or deletions within the region. CNVs that 
overlapped by at least 1 bp with the Locke et al. CNVs were labeled as “previously 
observed”. Overlapping CNVs were identified using in-house Python scripts.  
3.2.6 Genes unlikely to harbour copy number losses 
In-house scripts were used to determine if CNVs overlapped “control” genes unlikely to 
vary in copy number (Appendix 2G). The genes used in overlap analysis in the broad 
survey from the list in Appendix 2G can be identified by “Locke et al” and “Gatesy et al” 
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in the source column. All genes in Appendix 2G were used for overlap analysis in the 
mouse cohort study. A CNV to be considered to be overlapping a control gene if there was 
an overlap of at least 1bp between the CNV and a control gene.  
3.2.7 Confirmation of select CNVRs by droplet digital PCR 
(ddPCR) 
For the broad survey, nine genic CNVRs found in C57BL/6J mice were selected for CNV 
confirmation by ddPCR in five C57BL/6J, five CBA/CaJ and four DBA/2J inbred mice 
(Appendix 3H). C57BL/6J and CBA/CaJ mouse samples came from Dr. Kathleen Hill’s 
laboratory (Appendix 3I) and DBA/2J mice were provided by Dr. Shiva Singh. For 
C57BL/6J mice, DNA was extracted from tail samples, with the exception of C57BL/6J 
mouse 2, where ear clip tissue was used. DNA was extracted from the cerebellum for 
DBA/2J mice and tail samples for CBA/CaJ mice. For each CNVR, one TaqMan® Copy 
Number Assay (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was selected 
for a gene overlapping that CNVR. Overall, nine gene assays were conducted for the 14 
mice with inclusion of two technical replicates per DNA sample. A TaqMan® Copy 
Number Reference Assay (Thermo Fisher Scientific, Waltham, Massachusetts, USA) for 
the transferrin receptor gene (Tfrc) was used as a reference with an expected copy number 
of two. Negative controls lacking DNA template were included for each gene assay, 
including the reference gene. 
Prior to ddPCR, DNA samples were extracted using the Wizard® Genomic DNA 
Purification Kit (Promega, Madison, Wisconsin, USA), assessed for quantity using a 
NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) and diluted to approximately 8 ng/μl. The DNA was then fragmented by centrifuging 
140 μl of DNA sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo, 
Limburg, Netherlands) to prohibit inaccuracies in copy number detection due to tandem 
duplications not efficiently sorted in the ddPCR assay58. 
Each 20 μl PCR reaction contained 8 μl of DNA template (~4 ng/μl), 10 μl of the 
ddPCR™ Supermix for Probes (Bio-Rad, Hercules, California, USA), 1 μl of the FAM™ 
dye-labelled TaqMan® assay for the gene target of interest, 1 μl of the VIC® dye-labelled 
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TaqMan® reference assay. Droplets were generated by a QX200™ droplet generator (Bio-
Rad, Hercules, California, USA). A C1000 Touch™ thermal cycler (Bio-Rad, Hercules, 
California, USA) was used to perform PCR using the following program: 1 cycle at 95°C 
for 10 min, 45 cycles of denaturation at 95°C for 30 s, annealing and extension at 60°C for 
1 min and enzyme deactivation at 98°C for 10 min. Droplets were read using a QX200™ 
droplet reader and analyzed with QuantaSoft™ software (Version 1.7.4.0917; Bio-Rad, 
Hercules, California, USA). 
3.2.8 Gene analysis 
Gene annotations consistent with the broad survey reference genome (UCSC:mm9)  and 
the mouse cohort study reference genome (UCSC:mm10) were downloaded from Ensembl 
BioMart59,60. Genes found in CNVs were identified using in-house scripts. The Database 
for Annotation, Visualization and Discovery (DAVID) Functional Annotation tool was 
used to identify gene ontology (GO) term enrichment for genes overlapping CNVs61,62. 
DAVID versions 67 and 68 were used for the broad survey and the mouse cohort study, 
respectively. DAVID automatically excludes redundant genes from its analysis. The three 
GO categories “GOTERM_BP_FAT”, “GOTERM_CC_FAT”, and 
“GOTERM_MF_FAT” were used to identify the most relevant GO terms for each broad 
survey gene list. Occasionally, pseudogenes can be “resurrected” and produce translated 
products63. For this reason, pseudogenes classified as having a protein-coding biotype by 
Ensembl were included in the gene analysis. For the mouse cohort study, the default 
“GOTERM_BP_DIRECT” category was used to identify the most relevant biological 
process GO terms for each gene list. The gene lists were comprised of genes that were 
completely encompassed by CNVs in the mouse cohorts.  
Ingenuity® Pathway Analysis’ Core Analysis64 was used to determine disease and 
biological function networks for genes overlapping CNVs from the broad survey. Direct 
and indirect relationships with a maximum of 35 focus molecules per network were 
included. Human, mouse and rat genes were included. The confidence level was set to 
include experimentally observed relationships between focus molecules as well as 
predicted relationships that have a high confidence. Molecule relationships with 
endogenous chemicals were excluded. 
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3.2.9 Genetic distance matrices and phenogram generation 
SNP genetic distance was calculated based on pairwise genotype differences at SNP loci. 
All four genotype categories were used in the calculations:  AA, AB, BB, and No Call. To 
calculate pairwise CNV genetic distance, probes underlying a CNV call were assigned the 
state of that CNV, while probes not underlying a CNV call were assigned a default state 
value of two. Distance matrices were generated using R (v3.2.4). From the distance 
matrices (Appendix 3J), phenogram files were constructed in R using the BIONJ function 
in the APE package (v3.4) and saved in Newick format. The Newick files were uploaded 
to Figtree (v1.4.2) to generate coloured phenogram images.  
3.3 Results 
3.3.1 Broad survey  
3.3.1.1 CNVs detected 
For 334 samples passing quality control criteria, a total of 9,634 CNVs were identified on 
the autosomes, with an average of 29 CNVs per sample (Table 3-1). On the X chromosome, 
1,218 CNVs were found (Appendix 3D), with an average of four CNVs per sample. Calls 
across all samples affect 6.87% (169.9 Mb) of the autosomal genome or 8.15% (215.2 Mb) 
when including calls on the X chromosome.  
Strains classified as CL strains have a mean of 0.065% (1.6 Mb) of the autosomes 
affected by CNVs, 0.065% (1.7 Mb) when the X chromosome was included. The mean 
autosome and genome percentage affected for the WD strains (0.15% or 3.6 Mb and 0.14% 
or 3.8 Mb, respectively) and WC mice (0.14% or 3.5 Mb and 0.14% or 3.8 Mb, 
respectively) were significantly different than the CL strains (P < 0.01, Mann–Whitney 
test). 
The CNVs on the autosomes have an average length of 54,037 bp, with a median 
length of 26,340 bp. The majority (81%) of CNV calls are between 1 kb and 100 kb. Gains 
are significantly larger than losses (P < 2.2 × 10−16, Mann–Whitney test), where gains have 
a median length of 36,708 bp compared to losses at 20,091 bp. Copy-state-zero losses are 
significantly smaller than copy-state-one losses (P < 2.2 × 10−16, Mann–Whitney test), 
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where copy-state-zero losses have a median length of 13,766 bp compared to copy-state-
one losses at 26,980 bp. Losses outnumber gains by a ratio of 1.42:1 on the autosomes 
(Table 3-1) and only the CL cohort has more gains than losses. Unlike the CL and WC 
cohorts which have roughly twice as many state-one CNVs as state-zero CNVs, the WD 
cohort has approximately twice as many state-zero CNVs as state-one CNVs.   
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Table 3-1. Autosomal CNV losses and gains in laboratory strains and wild-caught mice. 
Sample Group Number of Samples 
Number of 
CNV calls 
 
Copy Number Stateb 
Loss/Gainc 
0 1 3+ 
All Mice 334 9,634 (29)a 1,995 (6) 3,661 (11) 3,978 (12) 1.42 
Classical Inbred 114 2,824 (25) 424 (4) 867 (7) 1,533 (13) 0.84 
Wild Derived 52 2,611 (50) 1,214 (23) 594 (11) 803 (15) 2.25 
Wild Caught 19 969 (51) 231 (12) 491 (26) 247 (13) 2.92 
C57BL/6J 8 90 (11) 0 (0) 38 (5) 52 (6) 0.73 
C57BL/6NJ 6 46 (7) 5 (1) 23 (4) 18 (3) 1.56 
 
a Values in parentheses are the average number of CNVs per sample. 
b Copy number is determined in reference to the diploid standard with 0 indicative of loss of paternal and maternal copies; 1 and 3+ 
indicate single copy loss and the occurrence of duplication events respectively. 
c Loss/Gain is the total number of deletions (0 and 1 copy-state call counts) divided by the number of gains (3+ copy-state call counts) 
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3.3.1.2 Genic content and analysis 
A majority (65.7%) of CNVs within the dataset entirely encompass at least one gene, are 
entirely encompassed by a gene, or partially overlap with at least one gene. The three main 
Ensembl classification types, excluding regulatory elements, for regions that overlap CNVs 
are protein-coding genes (76%), pseudogenes (11%) and multiple classes of RNAs (10%). 
The percentage of CNVs containing protein-coding genes in the CL mice (76.7%) is higher 
than in the WC mice (54.2%).  
Overall, protein coding genes were found in a higher percentage of gains (88.8% 
of gain calls overlapped a protein coding gene region) than losses (55.6%). Pseudogenes 
were also found to overlap a higher percentage of gains (18.0%) than losses (13.9%), as 
were RNAs (18.2% vs 7.1%) and antisense gene regions (5.1% vs 2.6%).  
The most common CNV (when considering events with the same start and end 
position in each sample) is in 66 mice on Chromosome 17 and contains the Tmem181c-ps 
pseudogene (Table 3-2). Almost all (93%) CL mice with this CNV have a gain, while all 
WC mice have a single-copy loss. The second most common CNV (Table 3-2) contains 
two pseudogenes, Ear-ps7 and Ear-ps10, as well as two protein-coding genes, Ang5 and 
Ang6. This CNV was observed only as a copy number state of either zero or four and both 
states existed in CL and WC cohorts. This CNV occurred most frequently in the BXD 
cohort. 
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Table 3-2. Most common CNVs detected by the Mouse Diversity Genotyping Array in a set of 334 Mus musculus samples. 
Genomic location of CNV 
Number of 
mice with  
the CNV 
CNV 
state Gene name (Gene symbol; Gene type)
a 
chr17:6635443-6646618 66 Mixed Transmembrane protein 181 C, pseudogene (Tmem181c-ps; ps) 
chr14:44540155-44579921 43 Mixed 
Angiogenin, ribonuclease A family, member 5 (Ang5; pc), Eosinophil-
associated, ribonuclease A family, pseudogene 7 (Ear-ps7; ps), 
Eosinophil-associated, ribonuclease A family, pseudogene 10 (Ear-
ps10; ps), Angiogenin, ribonuclease A family, member 6 (Ang6; pc) 
chr17:35383895-35392718 41 Gain DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B (Ddx39b; pc), 
histocompatibility 2, Q region locus 4 (H2-Q4; pc) 
chr11:116603748-116629092 40 Mixed 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 (St6galnac1; pc), 
Predicted gene 11735 (Gm11735; ps) 
chr4:122366514-122382286 38 Loss RIKEN cDNA 9530002B09 gene (9530002B09Rik; pc) 
chr7:111681502-111683670 35 Mixed Tripartite motif-containing 30E, pseudogene 1 (Trim30e-ps1; ps) 
chr4:111790559-111972640 35 Gain 
Selection and upkeep of intraepithelial T cells 4 (Skint4; pc), Predicted 
gene 12820 (Gm12820; ps), predicted gene 12815 (Gm12815; ps), 
selection and upkeep of intraepithelial T cells 3 (Skint3; pc) 
chr17:30593663-31058945 34 Gain 
BTB (POZ) domain containing 9 (Btbd9; pc), predicted gene 9874 
(Gm9874; pc), glyoxalase 1 (Glo1; pc), dynein, axonemal, heavy chain 
8 (Dnahc8; pc) 
chr5:114856193-114895051 34 Gain 
Ubiquitin protein ligase E3B (Ube3b; pc), methylmalonic aciduria 
(cobalamin deficiency) cblB type homolog (human) (Mmab; pc), 
mevalonate kinase (Mvk; pc) 
chr14:20443929-20587951 34 Gain Predicted gene 17030 (Gm17030; ps), nidogen 2 (Nid2; pc) 
 
a Gene names are as in Mouse Genome Informatics Symbol. Gene types are one of: Protein coding (pc), RNA type as listed, or 
pseudogene (ps)
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CNV differences were observed in samples from the same mouse strain. Six of 
eight C57BL/6J mice have an extra copy of the insulin-degrading enzyme (Ide) gene and 
half of the C57BL/6J mice have an extra copy of the fibroblast growth factor binding 
protein 3 (Fgfbp3) gene. None of the C57BL/6NJ mice have the Ide or Fgbp3 gain. All 
eight C57BL/6J mice in this study also have CNV gains overlapping most of Skint4, NLR 
family, pyrin domain containing 1B (Nlrp1b), and solute carrier family 25, member 37 
(Slc25a37), although none of these genes were encompassed completely by a CNV like 
Ide and Fgfbp3. Single-copy losses overlapping predicted gene 9765 (Gm9765) and Btbd9 
are also common (found in > 50% of samples). The Skint4 two-copy gain is also in all six 
C57BL/6NJ mice.  
When only considering genes completely encompassed by CNVs and CNVs 
completely encompassed by genes (complete overlap), the top gene enrichment terms 
differed between WC and CL mice (Table 3-3). Across CL mice, only the gene ontology 
(GO) terms for gains are significant, while in WC mice, GO terms for both losses and gains 
are significant. The most significant GO term across classical laboratory mice is “antigen 
processing and presentation of peptide antigen” (Padj = 3.26 × 10−10). Most of the top GO 
terms for CL mice are related to immunity or structural organization of the genome. Across 
WC mice, GO terms related to olfaction are significant for losses while GO terms related 
to pheromone response are significant for gains. 
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Table 3-3. Top DAVID Gene Ontology terms for genic CNVs detected in classical laboratory and wild-caught mice.  
Mouse 
cohort 
CNV 
state Gene Ontology term (Category
a) Involved genes  (% total) 
Fold 
enrichment 
Padj 
(Benjamini-
Hochberg) 
Classical 3+ Antigen processing and presentation of peptide antigen (BP) 16 (1.95) 13.08 3.26E-10 
Classical 3+ Antigen processing and presentation (BP) 22 (2.68) 7.23 1.24E-09 
Classical 3+ MHC protein complex (CC) 17 (2.07) 9.19 5.60E-09 
Classical 3+ Nucleosome (CC) 16 (1.95) 7.25 5.12E-07 
Classical 3+ Nucleosome assembly (BP) 17 (2.07) 6.66 1.81E-06 
Classical 3+ Protein-DNA complex assembly (BP) 17 (2.07) 6.4 2.02E-06 
Classical 3+ Nucleosome organization (BP) 17 (2.07) 6.4 2.02E-06 
Classical 3+ Chromatin assembly (BP) 17 (2.07) 6.48 2.06E-06 
Wild caught 1 Sensory perception of chemical stimulus (BP) 71 (26.59) 5.16 1.46E-30 
Wild caught 1 Sensory perception (BP) 72 (26.97) 4.44 1.74E-27 
Wild caught 1 Neurological system process (BP) 78 (29.21) 4.02 2.25E-27 
Wild caught 1 Cognition (BP) 72 (26.97) 4.21 3.88E-26 
Wild caught 1 Olfactory receptor activity (MF) 62 (23.22) 4.81 1.10E-24 
Wild caught 1 Sensory perception of smell (BP) 61 (22.85) 4.73 8.03E-24 
Wild caught 1 G-protein coupled receptor protein signaling pathway (BP) 76 (28.46) 3.5 4.46E-23 
Wild caught 1 Cell surface receptor linked signal transduction (BP) 79 (29.59) 2.74 1.50E-17 
Wild caught 3+ Pheromone binding (MF) 13 (5.39) 15.33 9.35E-09 
Wild caught 3+ Odorant binding (MF) 13 (5.39) 14.17 1.20E-08 
Wild caught 3+ Response to pheromone (BP) 13 (5.39) 13.92 1.03E-07 
Wild caught 3+ Pheromone receptor activity (MF) 13 (5.39) 11.13 1.36E-07 
 
a BP, Biological Process; CC, Cellular Component; MF, Molecular Function 
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Ingenuity Pathway Analysis (IPA) gene groupings into top diseases and functions 
networks show differences between WC and CL mice for CNVs completely within or 
completely containing a gene, although the distinction is not as clear as with DAVID 
(Appendix 3K). A total of 45 networks with an IPA score not less than 10 were identified. 
More networks are affected by gains (28) than by losses (17) and, in particular, by gains 
across the CL strains (22). “Lipid metabolism” is among the top biological functions for 
an IPA network associated with gains across WC mice and is not found for CNVs in CL 
mice. Conversely, CL mice have a network associated with “carbohydrate metabolism” in 
gains, as well as “amino acid metabolism” in one-copy losses.  
Development terms were found in 23 of the 45 networks associated with CNV 
regions and included cellular development, tissue development and the development of a 
variety of systems (e.g. neurological, hematological, gastrointestinal). For all genes present 
in the mouse (Ensembl:67), 34 out of 50 of their associated networks when analyzed as a 
whole with IPA include development terms. 
Across mouse strains, networks involved in “endocrine system development” are 
associated with gains in WC mice and with state-zero losses in CL mice. Networks 
involved in “cardiac system development” are only associated with gains in CL mice and 
not associated with CNVs in WC mice. Networks involved in “inflammatory response” are 
associated with CNVs (both in losses and gains) in the CL mice, but not in the WC mice. 
Networks involved in “cell mediated immune response” were found to be associated with 
gains in both CL and WC mice. 
3.3.1.3 Genes unlikely to harbour copy number losses 
Mouse CNVs  that were detected by the MDGA did not overlap 26 gene regions that are 
conserved in copy number across mammalian species (Appendix 2G)65. For autosomal 
genes that are unlikely to contain losses, a partial loss of one copy of Col7a1 was detected 
in three mice. Two male mice are partially missing the Cask gene on the X chromosome 
(approximately 33% and 6.5% missing). 
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3.3.1.4 Droplet digital PCR confirmation of select genic CNVRs 
For a total of 252 ddPCR confirmation assays, 242 (96%) were in agreement with MDGA 
predictions (Appendices 3H and 3L). There was no discordance between ddPCR technical 
replicates. Predicted intra-strain differences in Fgfbp3 copy number were also confirmed 
by ddPCR assays, for the C57BL/6J samples. Inter-strain differences in copy number state 
for CNVRs affecting haloacid dehalogenase-like hydrolase domain containing 3 (Hdhd3), 
selection and upkeep of intraepithelial T cells 3 (Skint3), and glyoxalase 1 (Glo1) genes 
were also confirmed by ddPCR. Three of nine ddPCR gene assay results (B4galt3, 
Ide and Fgfbp3) matched the predicted state for all three mouse 
strains. Skint3 and Trim30e-ps1 copy number states were zero for all CBA/CaJ and 
DBA/2J mice when a state of two was predicted. However, the MDGA predicted a copy 
number difference of two for Skint3 and Trim30e-ps1 when comparing CBA/CaJ and 
DBA/2J to C57BL/6J, so ddPCR results were considered to confirm MDGA predictions. 
The gains predicted for Hdhd3 in CBA/CaJ and DBA/2J mice were detected by ddPCR 
and called as a state of six in both strains. Skint3 ddPCR copy number states were found to 
be increased by one for all three mouse strains when compared to the predicted states. 
Contrary to array-based predictions, ddPCR targeting intelectin-1 (Itln1) determined that 
copy number states did not differ from two, in the five C57BL/6J mice tested. 
3.3.2 Mouse cohort comparison study 
3.3.2.1 CNV number, state and length in three mouse cohorts 
In total, 4,718 autosomal and 683 Chromosome X CNVs were detected, and passed 
filtering criteria, for 210 mouse samples (Appendices 3F and 3G). For autosome CNVs, 
WD mice had the highest median number of CNVs, which was two-fold higher than the 
CL strain median while there was no difference for the median number of X chromosome 
CNVs between WD and CL cohorts (Table 3-4). WC mice had a three-fold lower median 
number of X chromosome CNVs than the WD and CL cohorts and an intermediate 
autosome CNV median. WC mice had the greatest range in the total number of CNVs 
detected per mouse (7-98 CNVs) when compared to WD mice (12-75) and CL mice (4-80; 
Fig. 3-1).  
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Table 3-4. Summary statistics for autosome and Chromosome X CNVs detected in classical laboratory, wild-derived, and wild-
caught mice. 
Genomic 
location 
Mouse 
cohorta 
Total 
number of 
samples 
Samples with 
at least one 
CNV 
Total 
number of 
CNVs 
Average 
number of 
CNVs 
Median 
number of 
CNVs 
Min, max 
number of 
CNVs 
CNV 
gains 
(%) 
Autosomes 
CL  105 105 1706 16  15 4, 67 54 
WD 68 68 2098 31 30 9, 72 34 
WC 37 37 914 25 21 7, 90 3 
Chr. X 
CL 105 95 361 3 3 0, 15 92 
WD 68 65 240 4 3 0, 11 75 
WC 37 25 82 2 1 0, 8 54 
 
a CL, Classical laboratory strains; WD, wild-derived strains; WC, wild-caught mice 
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Figure 3-1. Number of CNVs detected for classical laboratory, wild-derived, and wild-
caught mice. The box plots show the median number of CNVs with the quartiles, 
minimum and maximum non-outlier values, and outliers. Asterisks indicate significant p-
values of <0.001 (***) or <0.0001 (****) for Wilcoxon tests performed following a 
Kruskal-Wallis test (p = 7 x 10-16).  
CL mice have a higher ratio of gains-to-losses than do either WD or WC mice, by 
1.6- and 1.8-fold respectively (Fig. 3-2). All cohorts have a higher proportion of CNV gains 
on the X chromosome than on the autosomes and the greatest difference is seen in the WD 
mice, which have a 2.2-fold increase in CNV gains on the X chromosome when compared 
to the autosomes (Table 3-4). WC and CL mice both have 1.7-fold more gains on the X 
chromosome than on the autosomes. 
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Figure 3-2. Number of CNV gains and losses for classical laboratory, wild-derived, 
and wild-caught mice. Individual data points represent a single sample within the classical 
laboratory (pink circle), wild-derived (light green), and wild-caught (dark green) mouse 
cohorts. The center dotted line indicates where a data point will lie if a sample has an equal 
number of CNV gains and losses. The dotted lines above and below the center line indicate 
where data points will lie if the sample has 75% losses with 25% gains and 75% gains with 
25% losses, respectively. The top density plot shows the distribution of CNV gains for each 
cohort while the right-side density plot shows the distribution of losses.  
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For all cohorts, the median length is longer for autosomal CNV gains than the 
median length for CNV losses (Fig. 3-3). The WD cohort has the greatest fold difference 
in length between gains and losses where gains are 2.2-fold longer in median length. CL 
and WC cohorts had a similar length difference between gains and losses, at 1.6- and 1.5-
fold respectively. The same pattern for median length was observed between gains and 
losses for Chromosome X CNVs, except the fold difference was much higher at 4.9-, 7.7-
, and 8.5-fold for CL, WD and WC mice, respectively. Significant differences in the mean 
CNV length were observed for all autosomal intra- and inter-cohort comparisons while for 
the X chromosome CNVs, there were significant differences observed only at the intra-
cohort level. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
103 
 
 
 
Figure 3-3. Length of CNV gains and losses for the autosomes and X chromosomes of 
classical laboratory, wild-derived, and wild-caught mice. Classical laboratory, wild-
derived, and wild caught mouse cohorts are represented by CL, WD, and WC, respectively. 
CNVs are groups by autosomal gains (dark blue), autosomal losses (light blue), 
Chromosome X gains (dark yellow), and Chromosome X losses (light yellow). The box 
plots show the median number of CNVs with the quartiles, minimum and maximum non-
outlier values, and outliers. P-values of > 0.5 (ns), £ 0.01 (**), £ 0.001 (***), and £ 0.0001 
(****) are indicated for Wilcoxon tests performed following a Kruskal-Wallis test for the 
autosome (p < 2.2 x 10-16) and X chromosome data (p < 2.2 x 10-16). 
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3.3.2.2 Regions with recurrent CNVs and singleton CNVs 
When considering all cohorts combined, 67% of CNVs were recurrent (Fig. 3-4). For a 
CNV from one mouse sample to be considered recurrent, it must reciprocally overlap a 
CNV from at least one other mouse sample by at least 40%, and the copy number states of 
the overlapping CNVs are permitted to differ. A genomic region containing recurrent 
CNVs is defined here as a CNV region or CNVR. WD mice had 3.2 times more cohort-
specific CNVRs than WC mice and 1.2 times more CNVRs than CL mice. A similar 
number of CNVRs were shared between the WD and WC cohorts, and the WD and CL 
cohorts. In contrast, 3.1 times fewer CNVRs were shared between CL and WC mice. The 
CNVRs are not uniformly distributed across the mouse genome. 
A total of 1,783 singleton CNVs (<40% reciprocal overlap) were identified (Table 
3-5). WD mice have double the number of singletons CL mice have (1.97-fold more) and 
more than double the number of singletons WC mice have (2.2-fold more). When a more 
stringent singleton cutoff of 0% reciprocal overlap is applied, the majority of CL (91.1%), 
WD (90.4%), and WC (89.0%) CNVs that were singletons at the 40% overlap, remain 
singletons. At 0% and 40% reciprocal overlap respectively, CL strains had the fewest 
singletons as a cohort (20% and 22%), the WC cohort had the greatest (38% and 41%) and 
the WD cohort had slightly fewer singleton CNVs than the WC cohort (35% and 39%).  
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Figure 3-4. CNVRs in classical laboratory, wild-derived, and wild-caught mice. 
Classical laboratory, wild-derived, and wild-caught mouse cohorts are represented in pink, 
light green, and dark green colours, respectively. A CNV is considered to be recurrent if it 
has at least 40% reciprocal overlap with another CNV of any state in a different sample. 
Genomic regions containing recurrent CNVs are CNV regions (CNVRs). CNVs include 
autosome and Chromosome X CNVs.  
Table 3-5. Number of singleton CNVs present on the autosomes and X chromosome 
for classical laboratory, wild-derived, and wild-caught mouse cohorts, as determined 
using <40% reciprocal overlap and 0% overlap criteria. 
Mouse 
cohort 
 
Autosomal 
Singletons 
(<40% overlap) 
Chr. X 
Singletons  
(<40% overlap) 
Autosomal 
Singletons  
(0% overlap) 
Chr. X 
Singletons  
(0% overlap) 
Classical  438 24 399 22 
Wild derived 868 44 788 36 
Wild caught 385 24 351 23 
53 Wild caught 
Wild derived 
Classical 
laboratory 
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3.3.2.3 Genetic distance 
The CNV-based genetic distance between mouse pairs groups some mice with common 
ancestry together but it does not recapitulate known genealogy as well as SNP-based 
genetic distance does (Fig. 3-5). The SNP-based genetic distance shows a clear division in 
genetic distance between the CL samples and the WD and WC samples, which do not have 
clear cohort divisions. The MOR/RkJ WD mouse is genetically most similar to the C57BL 
strains according to SNP-based genetic distance calculations, but this is not unexpected 
because MOR/RkJ contains some C57BL/6J ancestry66. CNV-based genetic distance does 
not show any clear cohort grouping.  
 
Figure 3-5. Phenograms depicting relationships between mice, as determined using 
pairwise genetic distances calculated for all autosomal CNVs in 210 mice and 
autosomal SNPs in 215 mice. The mouse samples are coloured by cohort where pink 
indicates classical laboratory strains, light green represents wild-derived mouse strains and 
dark green is used for wild-caught mice. Samples C57BL/6NCr, C57BL/6NCrl, and 
C57BL/6NTac are listed as C57BL/6NCl, C57BL/6Crl, and C57BL/6Tc, respectively, in 
Appendix 3B. 
CNV SNP 
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When looking at CNV-based genetic distance values, the average intra-cohort 
genetic distance is lowest within the CL cohort, although it is very similar to the WD and 
WC cohorts (Table 3-6). The average inter-cohort genetic distance is similar when 
comparing the CL and WD cohorts and the CL and WC cohorts. The average inter-cohort 
genetic distance is slightly greater between the WD and WC cohort samples. SNP-based 
genetic distance shows that the average genetic distance within the CL cohort is two times 
lower than the average intra-cohort genetic distance for the WD and WC cohorts. The 
greatest average inter-cohort genetic distance is between CL and WC mice and lowest 
between CL and WD mice. The minimum and maximum genetic distance values indicate 
that CL mice are genetically more similar to each other than to mice in other cohorts. In 
contrast, some mice in the WD and WC cohorts are more genetically similar to mice from 
other cohorts than to mice within their cohorts. In comparison to CNV-based genetic 
distance values, the SNP distance values are greater by 100-fold indicating that there are 
more SNP differences between samples than CNV differences.  
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Table 3-6. Average CNV- and SNP-based genetic distances within and between classical laboratory, wild-derived, and wild-
caught mouse cohorts. 
Variant type used 
for genetic distance 
calculations 
  
Mouse cohort 
Average intra-cohort 
genetic distance 
(min, max) 
Average inter-cohort genetic distance (min, max) 
Classical Wild derived Wild caught 
Copy number variant 
Classical 
2.57´10-3  
(1.06´10-4, 1.45´10-2) 
- 
2.85´10-3  
(3.20´10-4, 1.71´10-2) 
2.90´10-3  
(3.78´10-4, 1.75´10-2) 
Wild derived 
2.97´10-3  
(4.91´10-4, 1.20´10-2) 
- - 
3.07´10-3  
(5.64´10-4, 2.03´10-2) 
Wild caught 
2.92´10-3  
(2.11´10-4, 1.86´10-2) 
- - - 
Single nucleotide 
polymorphism  
Classical 
1.89´10-1  
(1.84´10-3, 2.36´10-1) 
- 
3.84´10-1  
(2.54´10-2, 5.58´10-1) 
4.67´10-1  
(2.50´10-1, 5.72´10-1) 
Wild derived 
3.86´10-1  
(2.17´10-2, 5.91´10-1) 
- - 
4.01´10-1  
(1.33´10-1, 6.00´10-1) 
Wild caught 
3.91´10-1  
(3.03´10-2, 5.68´10-1) 
- - - 
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3.3.2.4 Genes unlikely to vary in copy number 
Of the 5401 detected CNVs, 99% did not overlap, to any degree, with genes that were 
unlikely to vary in copy number. The full list of genes checked for CNV overlap used can 
be found in Appendix 2G. Of the 47 CNVs that did overlap these genes only four had a 
copy number state of zero (Appendix 3M). However, none of the four CNVs completely 
overlapped these genes with the percentage of gene overlap ranging from 0.5-20.5%.  
3.3.2.5 Concordance between mouse cohort comparison study 
and broad survey 
Of the autosomal CNVs detected in this study, 522 (11%) CNVs, were not observed in the 
broad survey. However, the majority of these novel CNVs (68%) were found in samples 
not used in the study. When only comparing the same samples from both studies, 167 
autosomal CNVs from 94 mice, were novel in the mouse cohort comparison study. For the 
X chromosome CNVs, 15% of CNVs were not found in the broad survey. However, unlike 
for autosomes, the majority (68%) of these novel CNVs were detected in samples used in 
both studies. In total, 71 novel CNVs were detected in 39 mouse samples in the mouse 
cohort comparison study.  
3.3.2.6 Genic content  
Within the WD and WC mouse cohorts, there were fewer CNVs overlapping at least one 
complete gene (Table 3-7). The CL cohort has an equal number of genic and non-genic 
CNVs. The majority of genic CNVs in the CL and WD mouse samples were gains while 
approximately the same proportion of WC genic CNVs were gains and losses. The top 
ranked gene ontology (GO) terms for genes overlapping CNVs differ between CL and wild 
mouse samples (Table 3-8). CL mice had CNV losses and gains in genes with terms related 
to epigenetics, like nucleosome assembly and methylation. CL CNV losses were found in 
genes with antigen-related functions. Nucleosome assembly is also found as a top GO term 
in WD CNV gains. Unlike with the CL cohort, the WD cohort has gene enrichment for 
sensory perception of smell, also found in the WC cohort. The WC cohort genes are also 
enriched for pheromone response in both CNV losses and gains.  
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Table 3-7. Genic CNV gains and losses in classical laboratory, wild-derived, and 
wild-caught mice.  
Mouse  
cohort 
 
Genic CNVsa Non-genic CNVs 
Genic CNVs 
(% of total) Gain Loss Gain Loss 
Classical 773 (73%) b 286 (27%) 482 (48%) 526 (52%) 51 
Wild derived 529 (57%) 399 (43%) 363 (26%) 1047 (74%) 40 
Wild caught 224 (49%) 236 (51%) 108 (20%) 428 (80%) 46 
 
a Genic CNVs overlap at least one whole gene 
b Percentage of gains in genic CNVs 
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Table 3-8. Top Gene Ontology terms for CNV gains and losses in classical laboratory, wild-derived, and wild-caught mouse 
cohorts.  
Mouse 
cohort 
 
CNV 
states GO term (biological process) 
Number of 
genes P-value 
Padj 
(Benjamini-
Hochberg) 
Classical 
laboratory 
Losses 
Nucleosome assembly 25 1.40E-16 2.00E-13 
Antigen processing and presentation 16 4.30E-12 3.90E-09 
DNA methylation on cytosine 13 1.10E-11 6.60E-09 
Gains 
Nucleosome assembly 25 9.40E-18 1.60E-14 
DNA methylation on cytosine 13 2.70E-12 2.20E-09 
Positive regulation of gene expression, epigenetic 13 4.20E-12 2.30E-09 
Wild 
derived 
Losses 
Sensory perception of smell 105 1.40E-69 6.50E-67 
G-protein coupled receptor signaling pathway 109 2.00E-56 4.70E-54 
Detection of chemical stimulus involved in sensory 
perception 
16 1.40E-08 2.10E-06 
Gains 
Sensory perception of smell 71 3.80E-17 4.60E-14 
G-protein coupled receptor signaling pathway 83 7.80E-14 4.80E-11 
Nucleosome assembly 17 3.10E-10 1.30E-07 
Wild 
caught 
Losses 
Sensory perception of smell 67 1.50E-33 5.20E-31 
G-protein coupled receptor signaling pathway 74 4.70E-29 8.30E-27 
Response to pheromone 18 2.70E-16 2.60E-14 
Gains 
Response to pheromone 10 2.60E-04 2.90E-01 
Cell adhesion 23 3.80E-04 2.20E-01 
Glutathione metabolic process 7 4.40E-04 1.80E-01 
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3.4 Discussion 
3.4.1 Broad survey 
3.4.1.1 CNVs detected  
The percentage of the reference mouse genome affected by CNVs detected in this study 
(6.87-8.15%) falls within the range found in other studies which found between 1.2%67 and 
10.7%68 of the reference genome affected by SVs and CNVs, respectively. In comparison 
to WD (0.15%) and WC (0.14%) mice in this study, the percent of the genome affected 
was higher in other studies for WD mouse samples (3.4%)67 and WC samples (10.7%)68. 
CL mice had a lower percentage (0.065%) of the genome affected by CNVs than WD or 
WC mice, which would be expected with inbreeding practices leading to reduced inter-
strain and intra-strain genetic diversity. These values are all affected by the sample size, 
capture technology and diversity of samples, which differ between studies. The amount of 
the mouse genome affected by CNVs is greater than that reported for dog (1.08%)69, cattle 
(1.61–4.60%)70,71 and swine (4.23%)72 but is similar to that reported for humans (3.7%, 
7.6%, 12%)73–75. 
The higher ratio of CNV losses to gains observed in this study is consistent with a 
previous study76. The larger median CNV length of gains, compared to losses, is consistent 
with the idea that large genomic gains are less likely to be deleterious than losses and thus 
more likely to be present in the genome, particularly for genic CNVs77. Similarly, a 
significant size difference between copy-state-zero and copy-state-one losses was 
observed, where the median length of copy-state-one CNVs is approximately double that 
of copy-state-zero CNVs. A complete loss of a genomic region is more likely to be 
deleterious if it is large because it is more likely to overlap regions that code for important 
biological functions.  
3.4.1.2 Genic content and analysis 
While reduced genetic diversity is expected in CL mice, CNVs can arise even in well-
established strains like C57BL/6J mice. Watkins-Chow and Pavan78 found dosage-
sensitive Ide and Fgfbp3 copy number gains segregating in the Jackson Laboratory 
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C57BL/6J colony with the occurrence of the gains having increased in the colony since the 
mutation was predicted to have arisen, sometime after 1994. The Ide and Fgfbp3 gains in 
C57BL/6J samples were confirmed by ddPCR in our study as well. The intra-strain CNV 
differences that were detected by the array continue to support intra-strain CNV differences 
as important contributors to divergence from isogeneity53. This divergence from 
isogeneity, however, can only occur in certain regions of the genome and is dependent on 
the mutation type. For example, few losses were expected to occur in regions important for 
biological function as they are likely to be deleterious79. Thus, to some extent, dosage 
sensitive genes can be used to assess the quality of CNV calls.  
Recurrent detection of specific CNVs by different research groups may indicate a 
mutation hotspot in a region of the genome or inheritance through relatedness (e.g. same 
supplier), but it is also important to consider the reference genome used when generating 
CNV calls. The C57BL/6J strain is commonly used as a reference. CNV gains that overlap 
with Skint4, Nlrp1b, Slc25a37, Ide and Fgbp3 in the study were called as CNV losses in 
non-C56BL/6J laboratory strains in previous studies38,39,68,80–84. Similarly, the CNV losses 
in Btbd9 were called as CNV gains in previous studies38,76,81–84. Gm9765, which appears 
as a loss in this study’s C57BL/6J mice, appeared as an gain in inbred mice in six other 
studies38,76,81–84, while one study found a mix of losses and gains in this region68. This may 
indicate that the CNVs overlapping with these six regions (excluding Gm9765) are 
widespread in some C57BL/6J mouse stocks and using this mouse strain as a reference 
(expected copy number state of two) may result in incorrect CNV states reported in other 
strains. 
Gene ontology analysis, using DAVID, showed differences in gene enrichment 
between mouse cohorts. Laboratory mouse strains are frequently bred to display specific 
immunity or disease phenotypes85 and this may in part explain the GO term enrichment 
across the CL mouse strains for immunity-related terms. Olfaction- and pheromone-related 
genes, which can assist mice with social interactions and gaining information about their 
environment86, are not highly enriched in analysis of GO terms for CL mouse strains, 
consistent with their laboratory breeding history and less diverse ancestry. Similar to copy 
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number variation, SNP variation in pheromone receptors is lower in CL mice when 
compared to WD mice87.  
Using IPA, an overrepresentation of lipid metabolism genes has been shown in 
CNV regions in WC mice68. Different sets of metabolism genes were overrepresented in 
CL mouse CNVs: carbohydrate metabolism genes in gains and amino acid metabolism 
genes in losses. This difference may indicate copy number variation as an adaptive change 
to diet between WC mice and CL strains. In humans and dogs, the copy number of the 
amylase (AMY1, AMY2B) gene was found to vary and in dogs is also found to be amplified 
over wolves, conferring adaptation to a starch-rich diet88,89. Across all of the samples, there 
is only one gain in the mouse ortholog to these genes (Amy1, Amy2), found in the YBR/EiJ 
CL strain, so there is no evidence for an adaptive change to diet involving CNVs in the 
mouse amylase genes within this sample mouse population. 
Since many development-related genes are present in the mouse genome, it is not 
unexpected for development-related IPA networks to appear for the detected CNVs. The 
types of developmental genes that are overrepresented differ between mouse cohorts 
although it is not clear if the differences result from factors including but not limited to 
environmental influences and sampling biases (e.g. sample size, inter-cohort differences in 
subspecies composition, and genetic relatedness).  
Some CNV calls may differ by strain due to strain-specific SNPs preventing the 
hybridization of probes and the target DNA. As a result, a bias in gene enrichment may be 
present depending on how closely related a mouse is to the probe design reference. Biases 
in gene enrichment can also occur with large gene families or if there are many genes 
associated with specific Gene Ontology terms. These biases can be overcome in programs 
like DAVID by inputting all of the genes in the mouse genome as a “background” for 
statistical analysis.   
3.4.1.3 Genes unlikely to harbour copy-number losses 
The autosomal genes A disintegrin and metallopeptidase domain 17 (Adam17)90, cyclin-
dependent kinase 8 (Cdk8)91, collagen type VII alpha 1 (Col7a1)92, delta like canonical 
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Notch ligand 1 (Dll1)93, DNA methyltransferase 3B (Dnmt3b)94, dual-specificity tyrosine-
(Y)-phosphorylation regulated kinase 1a (Dyrk1a)95, embryonic ectoderm development 
(Eed)96, elastin (Eln)97, enhancer of zeste 2 polycomb repressive complex 2 subunit 
(Ezh2)98, insulin-like growth factor 1 (Igf1)99, laminin alpha 5 (Lama5)100, mediator 
complex subunit 1 (Med1)101, mediator complex subunit 21 (Med21)102, mediator complex 
subunit 24 (Med24)103, mediator complex subunit 30 (Med30)104, peroxisomal biogenesis 
factor 7 (Pex7)105, Pbx/knotted 1 homeobox (Pknox1)106, 3-phosphoinositide dependent 
protein kinase 1 (Pdpk1)107, solute carrier family 2 (facilitated glucose transporter) member 
1 (Slc2a1)108, SUZ12 polycomb repressive complex 2 subunit (Suz12)109,110, VPS35 
retromer complex component (Vps35)111, and transferrin receptor (Tfrc)112 are known to 
cause deleterious phenotypes when gene expression levels are reduced and may be lethal 
when inherited at a zero-copy state or one-copy state, depending on the gene. Therefore, 
losses in these gene regions, particularly state-zero losses, are not expected to be inherited 
or arise early in development and be present in the adult mouse. Although three mice appear 
to have partially lost one copy of Col7a1, unlike a zero-copy loss, a single-copy loss 
of Col7a1 is not lethal92. Mice in this latter case are expected have a normal phenotype if 
gene expression levels are high enough92. As expected, no losses were detected in any of 
the other autosomal genes listed above. 
A number of genes on the X chromosome cause deleterious phenotypes when 
deleted or inactivated113, including apoptosis-inducing factor mitochondrion-associated 
1 (Aifm1)114, aminolevulinic acid synthase 2 erythroid (Alas2)115, APC membrane 
recruitment 1 (Amer1, synonyms Wtx and Fam123b)116, BCL6 interacting corepressor 
(Bcor)117, calcium/calmodulin-dependent serine protein kinase (MAGUK family; Cask)118, 
cullin 4B (Cul4b)119, phenylalkylamine Ca2+ antagonist (emopamil) binding protein 
(Ebp)120, filamin alpha (Flna)121, glucose-6-phosphate dehydrogenase X-linked 
(G6pdx)122, glycerol kinase (Gyk)123, inhibitor of kappaB kinase gamma (Ikbkg)124, methyl 
CpG binding protein 2 (Mecp2)125, mediator complex subunit 12 (Med12)126, X-linked 
myotubular myopathy gene 1 (Mtm1)127, NAD(P) dependent steroid dehydrogenase-like 
(Nsdhl)128, OFD1 centriole and centriolar satellite protein (Ofd1)129, phosphatidylinositol 
glycan anchor biosynthesis class A (Piga)130, and porcupine O-
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acyltransferase (Porcn)131,132. The partial loss of the Cask gene in two mice may be a true 
biological event because although a knockout of Cask is lethal, mice are still viable even 
if Cask expression has been reduced by ~70%118. Losses up to 4761 bp in length have been 
found in Cask67 and a large CNV loss covering the entire Cask gene was identified in an 
aCGH study133. As long as some degree of the functioning Cask gene is maintained in the 
mouse it is possible for Cask to acquire mutations or be lost in a cell population. 
There are several possible explanations for observing gene losses that contribute to 
deleterious phenotypes. The losses could be false positive calls or could be due to off-target 
mutations in the samples that prevent the sample DNA from binding to the array probes. 
In other cases, a potentially deleterious genic loss could have arisen in a mouse, but it is 
not harmful to the individual because it occurred after a specific developmental time point, 
in a tissue where it is not vital for proper function, or it is present in a clonal size insufficient 
to produce a negative phenotype. The following genes were also reported to overlap losses, 
over 500 bp in size, in previous studies67,68,83,134: Adam17, Cdk8, Dnmt3b, Dyrk1a, Eed, 
Ezh2, Lama5, Med21, Pdpk1, and Pex7, as well as on the X chromosome38,67,83: Aifm1, 
Bcor, Cask, Cul4b, Ebp, Flna, G6pdx, Gyk, Ikbkg, Mecp2, Nsdhl, and Porcn. The reports 
for the genes listed above do not provide an integer copy number state, so it is likely that 
the reported losses in these gene regions are one-copy-state losses since single-copy losses 
or minimal expression of each of these genes can be tolerated in mice.  
3.4.1.4 Droplet digital PCR confirmation of select genic CNVRs 
Biological validation, such as qPCR, would normally be performed using the same DNA 
samples. Since we did not have access to those exact samples, strain-matched mice were 
used instead since mice of the same strain are related and there is a possibility that the 
CNVs selected for confirmation may have been inherited in the lineage. Confirmation of 
select genic CNVs in classical inbred strains is a first step toward biological validation and 
future work could be expanded include more CNVs and to evaluate their phenotypic 
impact. 
The high rate of CNV confirmation (96%) in mouse samples that differed from 
those used on the array, can be partially attributed to the occurrence of strain-specific 
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CNVs. For example, two of the CNVRs selected for confirmation are known to contain 
genes Ide and Fgfbp3 that vary in copy number within the C57BL/6J mouse strain78.  
Alternatively, not all strain-specific CNVs are found in every individual of that strain, so a 
copy number state of two (“default” state) is also considered to be an acceptable alternate 
state for confirmation purposes, thereby increasing the probability that a CNV state can be 
“confirmed”. In the case of Skint3 in DBA/2J mice, a copy number state of two was 
predicted by the array, but ddPCR results showed a state of zero. Complete losses of Skint3 
have been previously observed in DBA/2J mice135. Notably, any differences from the 
predicted copy number states are not necessarily indicative of MDGA performance given 
that different mice were used for the microarray and ddPCR-based determinations. 
3.4.2 Mouse cohort comparison study 
3.4.2.1 CNVs detected  
Among the three cohorts, WD mice had the greatest number of CNVs, which is consistent 
with findings in the Locke et al1 study, which includes ~85% of the samples used in the 
mouse cohort comparison study. WD mice are laboratory strains that have greater inter-
strain genetic heterogeneity than CL strains, so the increased number of CNVs may have 
artificially resulted from breeding practices intended to maintain higher genetic diversity 
than CL mice136. At the same time, sibling mating has occurred with WD mice, leading to 
reduced heterozygosity, and the WD mice may also be gaining CNVs common to CL 
strains, as a result of positive selection for variants with higher fitness in mouse facility 
environments136. Further genomic studies would be required to determine if the increased 
number of CNVs in WD mice is due to animal husbandry, the genetic diversity of the 
founding wild animals and animals used in maintaining the stock, or some other reason.  
In general, inbreeding is associated with reduced genetic diversity and CL strains 
have been maintained through inbreeding for many generations. Inter-line genetic 
relatedness can be attributed to founder effects and a small number of related founders. 
Intra-strain homogeneity can be valuable in that it helps reduce confounding factors arising 
from genetic variation in research studies. Many CL strains are known for having specific 
traits and were intentionally bred to study disorders caused by different mutations4. Some 
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mouse strains are used to model diseases that are known to have genomic instability, such 
as cancer and therefore could have a number of structural alterations that is higher than 
expected with other disease models or with normal development137–139. This may have been 
the case with CL samples which are outliers in the cohort with respect to number of CNVs 
detected. The MRL/MpJ sample for example, which had the highest number of CNVs in 
the mouse cohort study (80 CNVs; 100 CNVs in the broad survey), is prone developing 
lupus and differences in anergic B cell gene expression have been identified between the 
MRL/MpJ strain background and the C57BL/6J strain, which is not prone to developing 
lupus140. The differentially expressed genes were involved in functional networks relating 
to the regulation of cell growth, signalling and apoptosis140. It has yet to be determined if 
the high number of CNVs in the MRL/MpJ sample is characteristic of this strain as a result 
of genetic background or if it is disease-associated, or both.  
Given that CNV gene gains are generally thought to result in milder phenotypes 
than losses and strong purifying selection against genic CNV losses, but not gains, has been 
observed in a eukaryote species77, it was expected that all mouse cohorts would have more 
CNV gains than losses. However, only CL mice were found to have more gains than losses. 
More losses than gains were also found in all but one of 59 sequenced samples assessed in 
a study of wild-caught domesticus and musculus mice (including wild-caught mice bred 
for one or two generations)13. Losses were generally found to be more frequent in studies 
of other organisms as well, including silkworms141, dogs142, goats143, and cattle144, and are 
thought be found more frequently due to mutation mechanism biases and biases in the 
detection technology used141,143. The mouse cohort comparison study also showed the 
median length of CNV losses to be smaller than gains for all cohorts and this length 
difference was larger for Chromosome X CNVs. The reason for this difference in length 
has yet to be determined, although it is possible that large deletions are more likely to be 
deleterious than large gains and therefore are negatively selected against. A study of CNVs 
in wild-caught mice found that, although more numerous, losses generally impacted a 
smaller proportion of the genome than gains, which indicates that many losses are small in 
size13. In humans, the CNV length was found to be associated with pathogenicity, since 
pathogenic CNVs for both gains and losses were longer on average than benign CNVs, 
thereby impacting more of the genome145. Pathogenic CNV losses were also found to 
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outnumber pathogenic gains by ~3-fold while benign CNVs were made up of slightly more 
gains than losses145, further providing support that CNV losses are more likely to be 
deleterious than gains.  
3.4.2.2 CNV recurrence  
The CNV diversity was predicted to be the greatest in the WC cohort because of the 
heterogeneous makeup of the samples in this cohort which included mice from different 
geographical regions and multiple subspecies, and these captured mice were not inbred for 
numerous generations like CL mice. This diversity was reflected in the percentage of 
singleton (non-recurrent) CNVs in this cohort, which is the highest among the three 
cohorts. Likewise, the WC cohort had the highest maximum genetic distance between two 
mice, although the average genetic distance was similar to the WD cohort. In contrast, the 
CL cohort mostly had recurrent CNVs, some of which appear to be specific to a mouse-
strain or lineage and may have resulted from random mutations that arose in the lineage 
and were passed on or they may have been selected for in the generation of a mouse strain 
due to phenotypic impact. An example of this is the Ide gain in C57BL/6J mice78. The high 
level of CNV recurrence in the CL cohort is evident from the pairwise genetic distance 
values which show lower intra-cohort diversity for CL mice than WC or WD mice. WD 
mice had a similar number of singletons as WC mice, indicative of genetic diversity within 
the cohort. However, the WD cohort also had 167 and 166 CNVRs shared with the WC 
and CL cohorts, respectively. These shared CNVs may be the result of shared ancestry or 
they could be variants that arose independently and were positively selected for in the wild 
or laboratory environments. 
The WC and CL cohorts shared more than 3-fold fewer CNVRs than the WD cohort 
shared with either of these cohorts. This suggests that the WD mice are more closely related 
to mice in the other two cohorts, either as a result of shared genealogy or shared 
environmental influence on the genome, while the WC and CL mice had less in common. 
Overall, there were more CNVRs shared by all three cohorts than by any two alone. Some 
of these recurrent CNVs may be specific to mouse subspecies, since multiple subspecies 
or mixtures of subspecies can be found within the cohorts. If shared among all subspecies, 
recurrent CNVs may have arisen in ancient ancestors and could be informative about the 
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evolutionary history of mice. Alternatively, recurrent CNVs may have arisen 
independently in individuals from each cohort in mutation hotspots in the genome.  
CNVRs that overlap large segmental duplications are more likely to contain CNVs 
that are variable in copy number between individuals and overlap environmentally 
responsive genes while CNVRs outside of segmental duplications are more likely to 
contain pathogenic CNVs12,146. Several CNVRs observed in this study have been identified 
in other studies, including the regions that contain the Itln1 and Hjurp (Holliday junction 
recognition protein) genes, which have roles in metabolism and chromosome segregation 
during cell division, respectively12,147. The genomic context of CNVRs and regions with 
unusual CNV distribution patterns should be looked at in depth in future studies to 
determine potential mechanisms of CNV formation and phenotypic impact. CNV 
landscape plots, described in Chapter 3B, can be used to aid in the visual identification of 
major CNVRs and unusual CNV distribution patterns. 
3.4.2.3 Genic content of CNVs and analysis 
The predicted functional impact of genic CNVs differed between mouse cohorts. Similar 
to the DAVID results in the broad survey, the CL mice had CNVs in genes with functions 
relating to immunity like “antigen processing and presentation”, and to epigenetic 
regulation like “nucleosome assembly”. The highest ranking, gene ontology terms for 
CNVs in the WD and WC cohorts, included terms related to olfaction and pheromone 
response, and were also observed for the WC samples in the broad survey. This is 
consistent with a previous study which found that copy number variable regions in wild 
mouse populations generally contained genes relevant to environmental and behavioural 
interactions, such as vomeronasal and olfactory receptor genes12. Pheromone response 
which is important for mouse mate selection, and influencing sexual behaviour and 
reproductive function148, would be expected to be more diverse in natural mouse 
populations where a choice of potential mates is available than in laboratory mice which 
have mates selected for them by humans to create and maintain inbred lines. Likewise, the 
ability to detect a wide range of scents via olfaction is important in the wild for obtaining 
food149,150 and avoiding predators151,152, neither of which is a concern for laboratory mice 
since they live in control environments. Many laboratory mouse strains have been created 
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to express disease-related traits4, so it is expected that immunity-related terms would 
appear in this cohort.  
The G-protein coupled receptor signaling pathway found in the WD and WC mouse 
cohorts is likely to have an important role in adaptation and evolution. The reason for this 
is that these proteins belong to a protein superfamily and their common function is in acting 
as receptors for signals for different biological pathways relating to olfaction, pheromone 
detection, taste, regulation of metabolism, reproduction, development, and more153. Due to 
the numerous functional roles of genes associated with the G-protein coupled receptor 
signaling pathway, genes impacted by CNVs will need to be identified individually to 
determine what specific biological pathways and functions are associated with each cohort 
but broadly fall under the G-protein coupled receptor signaling pathway category.   
3.4.2.4 Genes unlikely to harbour copy-number losses 
Very few CNV losses occurred in genes that were predicted to be unlikely to vary in copy 
number, particularly if the CNV state was zero. Where state-zero-losses of control genes 
did occur, the losses covered 20% or less of the gene. The presence of such losses may not 
have phenotypic consequences if the losses arise during a period where their expression is 
not vital for survival (e.g. after development). The CNV that results in a 20% loss of a gene 
was found in the CL mouse, TSJ/Le, in the Tcf7l2 gene. Had this loss disrupted the gene 
function, the mouse would have been severely hypoglycemic and would have died 
perinatally154. Furthermore, the CNV breakpoints are approximations of the real CNV 
breakpoints so the loss may overlap less than 20% of the gene. Additional experiments 
would be required to confirm that the array is detecting biological events but the low 
presence of CNVs in control genes is consistent with where CNV losses would be less 
likely to occur.  
3.4.2.5 Confirmation of CNV data 
Since the data for this study was produced using publicly available MDGA data from an 
online source, there is no way to directly confirm the array findings using the DNA from 
those specific samples. Instead, the same mouse strains could be tested to identify strain-
specific CNVs, as was done in the broad survey.  
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In the broad survey, Hdhd3 and Glo1 CNV gains were identified in CBA/CaJ and 
DBA/2J samples and confirmed using ddPCR. In the current study, the same gains were 
detected again in these mouse samples. DdPCR was also performed to confirm CNV gains 
in Ide, Fgfbp3, and Skint3, all of which also appeared as gains in the C57BL/6J sample in 
this study. Nlrp1b, B4galt3, and Trim30-ps1 appeared either as a state of two or as gains in 
the eight C57BL/6J mice in the broad survey and as a state of two in the mouse in this 
study. A loss of a copy of Itln1 was found in C57BL/6J samples in both studies.  
Further support for the accuracy of array data is the genetic distance information 
generated from the SNP genotyping data. In the phenogram representing the genetic 
distance relationships between mice, the CL mouse samples cluster together while the WD 
and WC samples are clustered together. Related mouse strains were also found to cluster 
together, which indicates genetic similarity. The WC mouse samples group together by 
mouse subspecies, consistent with a previous study on some of these mouse samples21. One 
WD mouse sample, MOR/RkJ was found to cluster with the C57BL strains, which was not 
expected. However, MOR/RkJ and MOR/Rk mice consistently cluster with C57BL-type 
strains in other SNP-based studies66,155. These findings support the inclusion of C57BL-
type strains in the MOR/RkJ ancestry.  
Two other outliers on the SNP-based phenogram are the CL strains, CE/J and SM/J, 
which are found on their own branches. The background of these two strains likely 
accounts for the increased genetic distance from the other classical laboratory strains. The 
CE/J mouse originated from a wild mutant mouse that was trapped in Illinois in 1920 and 
then inbred for many generations to become a CL strain156. The SM/J mouse was created 
in 1939 using seven different inbred mouse stocks and selectively bred for a small size 
phenotype157. Didion et al (2013) also observed segregation of CE/J and SM/J from the 
other CL strains and attributed this to the highly mixed background of these mice, which 
includes large contributions from a WC mouse in the CE/J strain21.  
The CNV phenogram shows some related mice clustering together but there is not 
a clear distinction between the CL and wild cohorts like there is when using SNP-based 
genetic distance. This lack of clustering based on known genealogy is likely due to 
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insufficient numbers of strain-specific CNVs, which is not an issue with SNP genotype 
data. SNP information is regularly used to determine genetic relationships in a variety of 
organisms.  
3.5 Conclusion 
The microarray is a valuable tool for large-scale analysis and when analyzed with rigour 
can provide insight into SNP and copy number variation. This study provides researchers 
with a CNV detection pipeline that has been tested on a large, publicly available dataset of 
Mus musculus samples and was confirmed using computational and PCR-based 
approaches.   
In the broad survey, differences were found in the genes affected by putative CNVs 
between WC and CL mice, most notably in genes related to lipid, carbohydrate and amino-
acid metabolism, as well as immunity, pheromone response and olfaction. This supports 
the hypothesis that CNVs play a role in increasing genetic diversity and have phenotypic 
impacts that when shaped by selective pressures confer adaptation.  
The mouse cohort study expanded on the findings in the broad survey and identified 
cohort-specific differences in CNV number, state and genes impacted. CNV length is not 
a defining characteristic among the cohorts, suggesting that the CNVs arose in samples 
from the three cohorts via common mechanisms of CNV formation. Further analysis is 
required to determine if there is a biological significance behind the differences in CNV 
number and state between cohorts. The gene pathways impacted by CNVs in CL, WD, and 
WC cohorts have associations consistent with the histories of these mice with respect to 
their environments and breeding histories.  
In future studies, recurrent CNVs could be studied in detail from a cohort and 
subspecies perspective, to identify evolutionary-relevant mutations by finding cohort- or 
subspecies-specific CNVRs and determining if there are dosage-sensitive elements 
contained within those regions that can impact phenotypes. Dosage-sensitivity of a gene 
can be determined by confirming the predicted copy number state through ddPCR and then 
measuring levels of the transcribed product with a gene expression microarray or with RNA 
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sequencing. The mechanism of CNV formation in regions of interest can also be 
determined by sequencing the breakpoint junctions and searching for repetitive or 
homologous regions, or nucleotide deletions and additions that are known to be associated 
with specific mechanisms of CNV formation. Uncharacterized genomic elements in 
recurrent CNVs could be characterized through various functional genomics approaches to 
determine their function and if they are dosage sensitive. For example, a region of interest 
could be sequenced and checked for the presence of transcription-associated sequences like 
open reading frames, followed by measuring levels of predicted transcript and translated 
product. Protein or RNA function can be predicted through ortholog comparisons and 
verified with gene knockout experiments. Any future MDGA-based experiments should be 
carried out on samples where tissues are available for confirmation of microarray results 
using methods not based on hybridization.  
Overall, the two studies in this chapter presented an established CNV detection 
pipeline, introduced a method to visualize the distribution of CNVs across a genome, and 
characterized CNVs in a large variety of M. musculus individuals, including three mouse 
cohorts, from the perspective of CNV number, state, length and genomic context.
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3B Visualizing the Distribution of CNVs across a Genome 
with CNV Landscape Plots 
3B.1 Background 
An informative way to view CNVs across the genomic landscape is to plot them at 
chromosomal base pair positions, similar to the plot presented in Figure 1 of Cutler et al. 
(2007)1. This CNV landscape plot has advantages over Gephi-based visualization of HD-
CNV output in that it shows the genomic locations and copy number states of CNVs in 
each sample with easy recognition of singletons and CNVRs that are specific to a mouse 
strain or cohort, or that are shared by multiple mouse groups. Here, an example CNV 
landscape plot of CNVs detected on Chromosome 17 in the mouse cohort comparison 
dataset is presented alongside the corresponding HD-CNV Gephi image for comparison.  
3B.2 Materials and methods 
The mouse samples used here are described in section 3.2.1. CNV identification was 
performed as described in section 3.2.2. Recurrent and singleton CNVs were determined 
using HD-CNV, described in section 3.2.3. HD-CNV output was converted into a 
chromosome image using the Fruchterman-Reingold layout in Gephi2. To visualize CNV 
recurrence across individual chromosomes, a timeline-style plot was generated in R using 
the geom_curve() function in ggplot2 (v2.1.0).   
3B.3  Results 
3B.3.1 Visualization of CNV spatial landscape of Chromosome 17 
In Figures 3B-1 and 3B-2, several regions with recurrent CNVs, also known as copy 
number variant regions (CNVRs), can be seen. Region A contains CNVs from all mouse 
cohorts, as does region C1. Regions C1 and C2 in Figure 3B-1 flank the ATP-binding 
cassette transporter G1 (Abcg1) and trefoil factor 3 (Ttf3) genes, and correspond with 
region C in Figure 3B-2, which cannot be clearly identified as two separate merge regions 
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at that scale. Region C appears to be a major CNV hotspot in Mus musculus since it is 
present in many mice from all three cohorts. Region D has CNVs that are recurrent mostly 
in the CL cohort, although one WD sample is included as well.  
 
 
Figure 3B-1. Gephi-based visualization of HD-CNV output showing Chromosome 17 
CNV merges and singletons for classical laboratory, wild-derived, and wild-caught 
mouse samples. Each node (circle) represents a CNV and nodes that are connected by 
edges (lines) indicated CNVs that overlap reciprocally by at least 40%. The more CNVs 
that are involved in a merge region, the warmer the node colours are while cool colours 
indicate fewer CNVs in a merge. Merge regions A-D correspond with regions A-D in 
Figure 3B-2.  
 
 
 
 
A 
B 
D 
C1 
C2 
 
 
143 
 
 
 
Genome Position (Mb) 
M
ou
se
 
C
lassical 
W
ild D
erived
 
W
ild C
aught 
B A C D 
 
 
144 
 
Figure 3B-2. Distribution of CNV gains and losses across Chromosome 17 for classical 
laboratory, wild-derived, and wild-caught mouse samples. Regions A-D correspond 
with merge regions A-D in Figure 3B-1. Different colours represent CNV gains (yellow), 
state-one-losses (light blue), and state-zero-losses (dark blue). 
3B.3.2 CNV spatial landscape analyses for autosomes and 
Chromosome X 
A visual inspection of the autosomal landscape plots (data not shown) reveals 21 CNVRs 
that are shared by mice in all three cohorts. There are also six regions where CNVs 
commonly occur in both WD and WC mice. No large multi-sample CNVRs are shared by 
only CL and WD or WC mice, based solely on visual inspection. Nine genomic regions 
were found to have cohort-specific CNVRs, seven of which were unique to the CL cohort 
and were predominantly gains among the CL samples. The X chromosome (Fig. 3B-3) has 
over 10 CNVRs between and within the mouse cohorts, with almost all of these regions 
having CNV gains. CNV losses on the X chromosome are noticeably more common in the 
WD and WC cohorts, in comparison to the CL cohort. CNVRs on the X chromosome are 
difficult to quantify visually due to the large number of CNVs detected on this chromosome 
and would be better suited for HD-CNV analysis. Strain-specific CNVRs were observed 
as well, including a region on Chromosome 9 (Fig. 3B-4) where recurrent gains can be 
found in the 129-type strains.  
The CNV landscape plots also revealed an unusual distribution of CNV occurrence 
on five autosomes of the PWK x Domesticus F1 sample, where many CNVs were found 
somewhat uniformly distributed either in regions of an autosome or across the entire 
autosome. Such a pattern can be observed in other samples within the dataset, like on 
Chromosome 8 (Fig. 3B-5A) of the RDS10105 WC sample, but only PWK x Domesticus 
F1 has this pattern on multiple chromosomes. Other CNV distribution patterns can be 
observed as well, such clustered gains made up of two or more closely-spaced, large CNV 
gains (Fig. 3B-5B) and paired, small CNV gains and deletions where a CNV gain is located 
almost immediately next to a CNV loss or vice versa (Fig. 3B-5C).  
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Figure 3B-3. Distribution of CNV gains and losses across Chromosome X for classical 
laboratory, wild-derived, and wild-caught mouse samples. Different colours represent 
CNV gains (yellow), state-one-losses (light blue), and state-zero-losses (dark blue). 
M
ou
se
 
C
lassical 
W
ild D
erived
 
W
ild C
aught 
Genome Position (Mb) 
 
 
146 
 
 
Figure 3B-4. Distribution of CNV gains and losses across Chromosome 9 for classical 
laboratory, wild-derived, and wild-caught mouse samples. Different colours represent 
CNV gains (yellow), state-one-losses (light blue), and state-zero-losses (dark blue). 
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Figure 3B-5. Examples of three CNV distribution patterns (A-C) across a mouse 
chromosome. Different colours represent CNV gains (yellow), state-one-losses (light 
blue), and state-zero-losses (dark blue). Dark red asterisks indicate a gain closely followed 
by a loss. Light green asterisks indicate a loss closely followed by a gain. 
3B.4  Discussion 
When CNVs from the mouse cohort comparison study are plotted on CNV landscape plots, 
several CNVRs that involved a large number of CNVs are revealed. In total, there are at 
least 21 of these CNVRs shared among M. musculus samples in all three cohorts, as well 
as over 15 regions that are specific to two cohorts, one cohort, or a mouse strain. HD-CNV 
analyses detected far more CNVRs (see section 3.3.2.2), but it is not possible to visually 
identify all these CNVRs from the CNV landscape plot. In general, the CNV landscape 
plot is more useful in identifying major mutation hotspots and CNVRs in a large dataset, 
such as Regions A and D on Chromosome 17. The plot is also highly informative about 
general CNV distribution patterns across the mouse genome. HD-CNV Gephi images are 
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most helpful in visualizing the number of singletons and recurrent CNVs but they are not 
informative about the nature of the CNVs nor do they allow for visual identification of 
CNV occurrence patterns along the chromosome landscape. Following CNVR 
identification in the mouse cohort comparison dataset, the next step would be to examine 
the genomic context of the CNVRs in order to determine the mechanisms of CNV 
formation and impact on phenotype or biological relevance.  
Given a sufficient sample size for pattern observation, the CNV landscape plot can 
be used for data visualization with any genome and for any mutation type, provided that 
the genomic positions of the CNVs are known. Furthermore, the CNV landscape plot can 
be used in conjunction with HD-CNV output to visualize merged regions and singletons 
across each chromosome. In all, the CNV landscape plot is a useful tool in assisting with 
visual identification of mutation hotspots in a genome and CNVRs relevant to adaptation 
and evolution. This type of CNV plot may also prove to be valuable in identifying mutation 
signatures in disease studies involving unstable genomes, such as cancer, and in mutagen 
exposure studies, such as exposure to ionizing radiation which is known to cause increased 
CNV formation3.  
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Chapter 4  
4 Somatic Mosaicism and de novo CNVs in a C57BL/6J 
Mouse Family  
4.1 Background 
The presence of two or more genetically distinct cell populations within an individual, is a 
common phenomenon known as mosaicism, which can impact phenotypes, in some cases 
causing deleterious effects. Somatic mosaicism, which occurs postzygotically in somatic 
cells1 via multiple mechanisms, including imperfect DNA replication, and exogenous and 
endogenous mutagen exposure2,3, has been shown to be widespread in normal human 
tissues4–6. Mosaicism can also occur in the germline, in which case it is referred to as 
germline mosaicism7. Unlike somatic mutations, mutations in the germline can impact 
offspring. The proportion of cells with a given de novo (i.e. postzygotic) mutation is largely 
dependent on when the mutation arose. CNVs in mice were observed to arise as early as in 
the first division following zygote formation, and although CNVs were not found in all 
preimplantation embryos, there was a general pattern of increasing CNV numbers as 
preimplantation embryos continued to grow in cell number and develop8. Similarly, 
chromosomal mosaicism was found in approximately half of human embryos, with a 
pattern of increasing frequency of mosaic embryos with embryo progression through the 
developmental stages9. A mutational event that occurs when a two-cell embryo is formed 
can result in genotypic differences between half of an individual’s cells, if the mutation 
does not reduce cell fitness, and could have potential phenotypic implications for the 
affected individual if genes or regulatory regions are impacted10,11. Early-occurring 
mutations may lead to mosaicism in both the soma and germline if arising prior to the 
separation of the soma and germline7, resulting in gonosomal mosaicism. In such a case, 
there is potential for the phenotype to be impacted in both the affected individual and the 
individual’s offspring7. Due to its association with different diseases, mosaicism has been 
commonly studied from a human disease perspective. There are comparatively fewer 
studies on mosaicism occurring with normal development in healthy individuals. 
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Mosaicism can lead to several potential consequences depending on several factors 
including but not limited to the mutation type, location (i.e. genomic content), and 
proportion of cells affected12,13. With respect to mutation type, aneuploidy mutations are 
more likely to cause severe phenotypic consequences than smaller genome alterations or 
point mutations since they affect a larger region of the genome that includes numerous 
genes and regulatory elements. One of the most commonly known examples of aneuploidy 
in humans is Trisomy 21 and it can be found in a mosaic form. The severity of the affected 
person’s symptoms is dependent on the proportion of cells containing the extra 
Chromosome 21 and if a full third chromosome or partial copy, similar to a CNV gain, is 
present14,15. Other chromosomal aneuploidies can be lethal when inherited but can produce 
less severe consequences if a small proportion of the person’s cells are affected, as is the 
case with trisomy 18 mosaicism16. Smaller genomic alterations like CNVs are also 
contributors to genome mosaicism between17,18 and within6 normal human tissues and do 
not always result in negative phenotypes. De novo CNVs are estimated to affect 
approximately 30% of normal human skin fibroblast cells and between 13-40% of human 
frontal cortex neurons4,6, making somatic mosaicism a common phenomenon in normal 
human tissues.  
The observation that CNV mosaicism can occur in normal tissues without 
phenotypic consequences can be explained by several reasons. First, some genes have 
tissue-specific or time-specific expression and are not needed in the tissue or during the 
time point when the CNV arises. For example, of 19,628 putative protein coding genes in 
humans for which there is transcriptome data available in major organs and tissue types, 
7,367 genes are expressed in all tissues and 7,835 have tissue-specific or related tissue 
group-specific expression patterns19. Even if CNVs overlap genic or non-coding elements 
that are expressed, the elements might not be dosage sensitive (i.e. expression is dependent 
on copy number), so there may not be any impact on phenotype for gains or partial losses. 
Individual cells that acquire mutations that disrupt vital cell functions will die or stop 
dividing, resulting in the loss of these mutant cells from proliferating cell populations20,21. 
Furthermore, the presence of cancer-causing mutations does not always result in the 
development of cancer. An example of this was observed in the human eyelid where more 
than 25% of cells in the normal human eyelid epidermis were found to contain known 
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cancer-causing mutations as a result of UV exposure, yet still appeared to be maintaining 
normal functions22. Although the reason for why the cells are not presenting malignant 
phenotypes was not determined in the study, it has been proposed that the cellular 
microenvironment is an important factor the development of cancer and genetic mutations 
alone, within the context of the eyelid epidermis, are not sufficient to cause cancer23. The 
microenvironment is an important area of study in cancer research and multiple studies 
have shown the impact of the microenvironment on both allowing and preventing cancer 
initiation and progression24,25.  
In contrast to mutations that do not impact phenotypes because of their timing or 
location in a specific cell type or tissues, some mutations are linked to different diseases 
because they generate different phenotypes depending on the cell or tissue type and the 
developmental timing of the origin of the mutation. For example, a study sampling brain 
and skin tissue from individuals with Sturge-Weber syndrome found that a specific 
nonsynonymous point mutation in the guanine nucleotide-binding protein G(q) subunit 
alpha (GNAQ) gene is associated with this neurocutaneus disorder and likely occurs early 
in fetal development26. This same mutation occurring later and in a different cell type, 
melanocytes, is linked to uveal melanoma risk27.  
When attempting to find a genetic link to a phenotype, it is important to account for 
possible somatic mosaicism. If the mutations are tissue-specific in tissues that are hard to 
access, such as the brain, then the mutations might not be detected when a sentinel tissue 
such as blood, saliva or skin is used for disease testing. In one case, a CNV gain present in 
approximately 20% of neurons, was enough to cause brain dysfunction (i.e. 
hemimegalencephaly)28. This CNV gain was discovered in a post-mortem brain and likely 
would not have been discovered in the living individual if sentinel tissues were tested 
instead of the brain tissue. It is possible that many disease-causing mutations are missed 
even when the appropriate tissue is selected, because of low-level mosaicism that is below 
the detection threshold of the technology used.  
De novo CNV discovery is heavily dependent on the technology used, making the 
true number of de novo CNVs present in an individual’s tissues and cells difficult to 
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ascertain. Estimates of the minimum detectable level of mosaicism using SNP microarray 
technology range from <5-20% depending on the array resolution and probe types, 
algorithms used, amount of tissue or number of cells examined, the heterogeneity level of 
the cell population, and type of mutation being assayed29–32. Alternatively, sequencing 
strategies offer high depth of coverage and single-nucleotide resolution allowing for the 
detection of rare, low frequency events in cell population or even individual CNV events 
in a single cell6,33,34. While there are multiple CNV mosaicism detection approaches 
available, the most appropriate choice will be dependent on cost limitations and what 
research question needs to be answered. There are also several additional challenges when 
studying mosaicism in humans, including but not limited to, the low availability of multiple 
human tissues, limitations to conducting family studies, and the difficulty in controlling for 
the subject’s environment and genetic background.  
For this study, a cost-effect MDGA approach is used to identify somatic mosaicism in 
multiple healthy tissues from the parents and sons of a C57BL/6J mouse family. The 
MDGA has not been used previously in a study of somatic mosaicism occurring with 
normal development in a mouse family. The C57BL/6J strain was selected as it is a highly 
inbred strain that is commonly used by mouse researchers and it is most compatible with 
the MDGA, which was built based on the C57BL/6J reference genome35. With a family 
study, genetic variants can be compared between parents and siblings to help establish 
when the variants may have arisen. The use of multiple tissues for each individual can help 
identify tissue-specific mutations, and examining tissues derived from different 
developmental germ layers can help establish when the variants arose. Overall, this study 
will establish what a normal CNV profile looks like across the genomes of multiple healthy 
tissues in a C57BL/6J mouse family. 
4.1.1 Research goal, central hypothesis, and specific objectives 
Research goal: The purpose of this study is to characterize the CNV landscape in multiple, 
normal tissues of family members of a commonly used laboratory mouse strain to 
determine the contribution of CNVs to somatic mosaicism occurring with normal 
development. 
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Central hypothesis: CNVs that are inherited in family members or arise spontaneously 
within an individual mouse during postzygotic development can be detected using MDGA 
analysis.  
The specific objectives of this chapter are:  
1. To detect and characterize putative CNVs in both parents and three sons of a single 
C57BL/6J mouse family across four tissues in the parents and six tissues in the sons. 
Predictions: Based on CNV data from eight C57BL/6J tail samples, presented in the broad 
survey in Chapter 3 and Locke et al.36, there should be an average of 11 CNVs per mouse 
for the mouse family tail samples. This average increases to 14 if Chromosome X CNVs 
are included. It is also predicted that there will be more gains than losses since 57% of 
autosomal CNVs detected in the eight samples were gains.  All the Chromosome X CNVs 
found in the eight C57BL/6J samples were gains and are therefore predicted to be gains in 
the C57BL/6J mouse family in this analysis. Considering previous findings in C57BL/6J 
samples, copy number gains of the Ide gene are likely to be found since these mouse 
samples also came from The Jackson Laboratory.  
2. To determine what the level of de novo CNV occurrence is within an individual mouse 
and to determine if there are tissue-specific CNVs. 
Predictions: Most CNVs detected are predicted to be recurrent across different tissues 
within an individual mouse. Given that somatic mosaicism is a common phenomenon, it is 
predicted that the MDGA will detect some de novo CNVs given that a sufficient clonal size 
is present, but it is unknown if tissue-specific CNVs will be detected. Recurrent CNVs are 
expected to be shared among members of the mouse family due to inheritance.  
3. To confirm the presence of select candidate CNVs in the biological samples using 
ddPCR. 
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4.2 Materials and methods 
4.2.1 Samples 
All mouse housing, care and animal use procedures were approved by Western 
University’s Animal Care Committee (Appendix 3I).  One family of C57BL/6J mice, 
consisting of a sire (identifier number 1), dam (identifier number 2), and three adult sons 
(numbers 3-5), was used in this study. The mice were euthanized by CO2 asphyxiation 
according to approved protocols and exsanguinated via cardiac puncture. Tissues were 
harvested, frozen in liquid nitrogen and stored at -80°C. The tissues chosen for this study 
were selected based on collectively representing different compositions of cells derived 
from different embryological germ layers. The selected tissues were hippocampus 
(ectoderm), lung (endoderm), bladder (mesoderm), and tail (mesoderm and ectoderm) for 
all five mice, and in addition, kidney (mesoderm), and pancreas (endoderm) from the three 
sons. A tail sample from a C57BL/6J mouse not related to the family, a tail sample from a 
CBA/CaJ mouse, and a DBA/2J brain sample (provided by Dr. Shiva Singh), were also 
included in this study for comparison to the mouse family and were used for ddPCR 
confirmation of select candidate CNVs.  
4.2.2 DNA extraction 
The DNA was extracted according to the Wizard® Genomic DNA Purification Kit protocol 
(Promega, Madison, Wisconsin, USA), with two modifications: 1) tissues were digested 
by proteinase K for 24-48 hours, and 2) RNAse digestion was used for all tissues. DNA 
quantity and purity were assessed using a NanoDrop 2000c spectrophotometer (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). DNA preparation and hybridization to 
the Mouse Diversity Genotyping Array were performed according to the standard  
protocol37 at the London Regional Genomics Centre (Robarts Research Institute, London, 
Ontario, Canada). MDGA hybridization data were outputted in a CEL file format.  
4.2.3 Genotyping and CNV detection 
Genotyping was performed using Affymetrix Power Tools’ (APT)38 BRLMM-P algorithm, 
and default parameters as specified by Genotyping Console39, which includes quantile 
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normalization.  Following a summarization step using APT, the Log R Ratio (LRR) and B 
allele frequency (BAF) values were generated using the PennAffy package40. CNV calls 
were made using PennCNV41 with GC model correction. The GC model file was generated 
using in-house scripts and KentUtils42, and was based on the mouse reference genome 
(UCSC:mm10). CNV calls on the X chromosome were generated separately using the –
chrX option in PennCNV. The first round of genotyping and CNV calling used a reference 
set of 313 mice36 to create a canonical genotype clustering file for use with the PennAffy 
package, as well as the Population Frequency of B Allele (PFB) file used with PennCNV. 
However, only eight of twenty-six samples had a log-R ratio standard deviation (LRR SD) 
that met the cutoff by having values below 0.35, for the autosomes (Appendix 4A). The 
samples passing the LRR SD cutoff were also below the B-allele frequency drift (BAF drift 
<0.01) and waviness factor (WF <0.05) cutoffs. Confirmation of select CNVs based on this 
dataset was low (see section 4.3.1), so CNV calling was performed again with 
modifications so that data did not produce false positive calls, based on the ddPCR results.  
The quality of the calls was improved when using a different reference set (214 
classical laboratory mice with more females), and only SNP probes. With those 
modifications, all samples passed the LRR SD and WF cutoffs but only nine samples were 
below the BAF drift cutoff (Appendix 4A). All SNP genotype call rates were above 99% 
for every sample and CNVs that failed to be confirmed by ddPCR did not appear in this 
dataset. The CNV dataset created using the 313 sample reference file will be referred to as 
dataset 1 and the CNV dataset created using the 214 sample reference file will be referred 
to as dataset 2. 
4.2.4 DdPCR confirmation 
DdPCR was performed using nine TaqMan® Copy Number Assays (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA), selected based on results from dataset 1: Hoxa1 
(Mm00563305_cn), Hoxa2 (Mm00563310_cn), Hoxa3/5 (Mm00736986_cn), Hoxa13 
(Mm00563296_cn), Glo1 (Mm00735212_cn), Ide (Mm00496897_cn), Fgfbp3 
(Mm00630217_cn), Skint3 (Mm00735949_cn), and Itln1 (Mm00534147_cn). Six 
additional gene assays were selected to confirm CNVs from dataset 2: Slamf9 
(Mm00736858_cn), Lama2 (Mm00307917_cn), Ebf1 (Mm00734275_cn), Loxl2 
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(Mm00611995_cn), Mum1l1 (Mm00631824_cn), and Map3k7 (Mm00735116_cn). The 
transferrin receptor gene (Tfrc) was used as the diploid copy number reference and no-
template controls were used in all assays. Gene assays were selected to test a mixture of 
CNV gains, losses, singletons and recurrent CNVs. Control samples with no expected gains 
or losses, according to the MDGA results, were used for each gene assay in addition to 
samples for which a CNV was called.   
DNA quantity and quality were assessed prior to ddPCR, using a NanoDrop 2000c 
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and diluted 
to approximately 8 ng/μl. Then, the DNA was fragmented by centrifuging 140 μl of DNA 
sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo, Limburg, 
Netherlands).  
The PCR mixture for a single reaction contained 5 μl of DNA template, 5 μl of 
PCR-grade water, 12.5 μl of the ddPCR™ Supermix for Probes (Bio-Rad, Hercules, 
California, USA), 1.25 μl of the FAM™ dye-labelled TaqMan® assay for the gene target of 
interest, 1.25 μl of the VIC® dye-labelled TaqMan® reference assay. Additional water was 
used instead of template DNA or gene assay solution for controls. 20 μl of the PCR mixture 
was used for droplet generation and PCR. Droplets were generated by a QX200™ droplet 
generator (Bio-Rad, Hercules, California, USA). PCR was carried out in a C1000 Touch™ 
thermal cycler (Bio-Rad, Hercules, California, USA) with the following program: 1 cycle 
at 95°C for 10 min, 45 cycles of denaturation at 95°C for 30 s, annealing and extension at 
60°C for 1 min and enzyme deactivation at 98°C for 10 min. Droplets were read using a 
QX200™ droplet reader and analyzed with QuantaSoft™ software (Version 1.7.4.0917; 
Bio-Rad, Hercules, California, USA). 
4.3 Results 
4.3.1 CNVs detected and ddPCR confirmation 
From dataset 1, 112 autosomal and 25 Chromosome X CNVs were detected (Appendix 
4B). From this dataset, nine genic regions were selected for ddPCR confirmation. The 
genic regions included targets within the Hoxa cluster, which is predicted to be present as 
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a copy number loss, and targets confirmed as CNVs in Chapter 3 that were also predicted 
to be CNVs in the mouse family samples. Losses were predicted in a region on 
Chromosome 6 that spans several Hoxa cluster genes in the pancreas and bladder of mice 
4 and 5, with the CNV loss starting at Hoxa2 or Hoxa3, depending on the sample, and 
ending at Hoxa13. Hoxa1 ddPCR assays consistently showed a state of two in tested 
samples (Fig. 1). Copy number states for Hoxa2 and Hoxa3/5 were between 1.5 and 2, 
while copy number states for Hoxa13 were generally between 1 and 1.5. There was a trend 
of decreasing copy number state with increasing gene proximity to Hoxa13, observed for 
mice 1 and 5 (Fig. 1). For three mice (C57BL/6J, DBA/2J, and CBA/CaJ) not related to 
the C57BL/6J mouse family, the copy number state for Hoxa13 was lower than an expected 
default state of two and ranged between 1.5 and 1.77.  
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Figure 4-1. DdPCR-based copy number states for Hoxa genes in multiple tissues from a C57BL/6J mouse family and three 
unrelated mice.  Hoxa13 (H13) results are shown in dark green while ddPCR states for Hoxa1 (H1), Hoxa2 (H2), and Hoxa3/5 (H3) 
are shown in light green. Individual mice are represented by a number if they are members of the C67BL/6J family, where 1, 2 and 3 to 
5 represent the sire, dam and three sons, respectively. Letters are used to indicate individuals not related to the mouse family (B for 
C57BL/6J, C for CBA/CaJ, and D for DBA/2J). The letters above the bars indicate samples for which no MDGA data were available 
(n), samples for which a copy number state of two is expected based on array findings (t), and samples for which a copy number state 
of one is expected based on array findings (o). The bars show the average state of two technical replicates, with the exception of bars 
marked with an asterisk which represent one assay. Error bars represent standard deviation and were used when the average was 
calculated from two, three (bold lowercase letter), or four (bold, underlined lowercase letter) separate ddPCR assays for the same gene 
and sample.  
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CNV losses that overlapped Glo1 and Itln1 were also detected by the array in several mouse 
samples, yet all tested samples showed a default copy number state of two (Fig. 4-2). Likewise, a 
Skint3 gain that was identified in the lung of mouse 3, could not be confirmed with ddPCR. Copy 
number gains for the Ide and Fgfbp3 genes were confirmed in mouse 2. An Ide gain was also 
identified in the kidney of mouse 5, although it was not identified as a CNV by the MDGA. 
Overall, the confirmation rate for CNV gains and losses for non-Hoxa regions was 23.5%. Hoxa 
gene assay results are excluded from the confirmation rate because the copy number state for most 
samples is neither a one nor a two.  
 For dataset 2, 70 autosomal and 38 Chromosome X CNVs were identified (Appendix 4C). 
CNVs from dataset 1, that failed to be confirmed by ddPCR, were not present in dataset 2. Six 
CNV gene regions were selected for confirmation. These regions represented a mixture of copy 
number states and were found to differ between tissues or mouse samples. Four of the selected 
genes (Ebf1, Lama2, Map3k7, and Slamf9) were predicted as copy number losses but none could 
be confirmed by ddPCR (Fig. 4-2). Mum1l1 (chr. X) was predicted as a gain in the lung of mouse 
3 and kidney of mouse 5. Like the CNV losses, this gain could not be confirmed as a CNV using 
ddPCR.  
A CNV gain was detected on Chromosome 14 in all tissues of every mouse family member. 
This CNV overlapped Synb and Entpd4 but as no assays were available for these genes, a gene 
neighbouring this CNV region, Loxl2, was selected for confirmation. Loxl2 could not be confirmed 
as a gain. In all, no CNV gains or losses from dataset 2 could be confirmed. 
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Figure 4-2. DdPCR-based copy number states for eleven genes in multiple tissues from mice of a C57BL/6J family. Gene assays 
were selected based on either the first set of MDGA results (dark blue) or the second set of results (light blue). Individual mice are 
represented by a number if they are members of the C67BL/6J family, where 1, 2 and 3-5 represent the sire, dam and sons, respectively. 
Bolded letters represent genes Fgfbp3 (F), Skint3 (S), and Map3k7 (M). The letters above the bars indicate confirmed copy number 
states that matched predicted MDGA states (a), ddPCR copy number states that did not match the predicted MDGA copy number state 
(b), samples for which no MDGA data were available (n). All bars show the average state of two technical replicates for an assay, with 
the exception of bars marked with an asterisk which do not have replicates. Error bars represent standard deviation and were used when 
the average was calculated from two separate ddPCR assays each with replicates, for the same gene and sample. A bolded lowercase 
letter indicates that two separate ddPCR assay values were averaged but one assay had two technical replicates and the other did not 
have replicates.  
a b a a n a
b
b* b* a b b b b b b a a a b a b b b* a b a* a a a b a a a b a a a a a a b a b b b a
a
a
a b a b
0
1
2
3
4
5
Hi
pp
oc
am
pu
s
Ta
il
Hi
pp
oc
am
pu
s
Lu
ng
Pa
nc
re
as Ta
il
Ki
dn
ey
Hi
pp
oc
am
pu
s
Lu
ng
Pa
nc
re
as
Hi
pp
oc
am
pu
s
Ki
dn
ey
Lu
ng Ta
il
Ki
dn
ey
Lu
ng
Bl
ad
de
r
Hi
pp
oc
am
pu
s
Lu
ng
Pa
nc
re
as
Lu
ng
Pa
nc
re
as Ta
il
Bl
ad
de
r
Hi
pp
oc
am
pu
s
Lu
ng Ta
il
Lu
ng
Lu
ng
Ki
dn
ey
Pa
nc
re
as
Lu
ng
Lu
ng
Ki
dn
ey
Pa
nc
re
as
Lu
ng
Ki
dn
ey
Lu
ng
Lu
ng
Ki
dn
ey
Lu
ng Ta
il
Ki
dn
ey
Hi
pp
oc
am
pu
s
Bl
ad
de
r
Ki
dn
ey
Lu
ng
Lu
ng
Lu
ng
Ki
dn
ey
Lu
ng
Lu
ng
Ki
dn
ey
2 2 5 1 2 3 4 5 3 4 5 3 1 2 3 1 2 4 1 3 4 5 2 3 2 3 1 2 3 4 5
Fgfbp3 Ide Glo1 Itln1 Skint3 Ebf1 Lama2 Loxl2 Map3k7 Slamf9 Mum1l1
C
op
y 
N
um
be
r S
ta
te
Gene Assay and Mouse Sample 
  F  n Ide Glo1 Itln1 S Ebf1 Lama2 Loxl2 M  Slamf9 Mum1l1 
 
 
161 
 
4.4 Discussion  
Among the tail samples, the highest average number of CNVs was for dataset 1 when 
counting both autosomal and Chromosome X CNVs. This average number of CNVs was 
six, which is much lower than the predicted average of 14 CNVs per C57BL/6J tail 
sample36. However, the lowest number of CNVs detected for one of the eight C57BL/6J 
samples was also six, indicating that an average of six CNVs for the mouse family could 
be within the normal range. More mouse samples would be needed to firmly establish the 
normal range of the number of CNVs present in healthy C57BL/6J mice.  
 Predictions for the proportion of gains to losses were met for dataset 1. It was 
predicted that the majority (57%) of CNVs detected would be gains for the autosomes and 
that all Chromosome X CNVs would be gains. For dataset 1, 61% of autosomal CNVs 
were gains and all Chromosome X CNVs were gains. For dataset 2, 50% of the autosomal 
CNVs were gains and all Chromosome X CNVs were gains. 
Unfortunately, several arrays failed to pass quality control criteria and the CNV 
confirmation rate was low for both sets of data.  The CNVs that were confirmed, like gains 
of Ide and Fgfbp3, are already known to be widespread in C57BL/6J mice43, so it was a 
possibility that they would be present in the mouse family. Gains of Ide were confirmed to 
be a copy number of four in the dam (mouse 2) and the sire (mouse 1) likely had a copy 
number state of two for Ide since one son (mouse 5) was found to have an Ide copy number 
of three. Further ddPCR experiments would be required to confirm the copy number status 
of Ide in the other two sons and the sire.  
 Although there were issues with the quality of the data, an unexpected biological 
event was discovered. A Hoxa13 loss was detected in dataset one and ddPCR assays for 
this gene consistently returned copy number states that were in-between one and two, for 
all samples tested except bladder of mouse 4, which had a copy number state of one. A 
similar pattern was observed in tissues from three unrelated mice of different backgrounds 
(C57BL/6J, CBA/CaJ, and DBA/2J). A copy number state between one and two is 
consistent with the presence of a mixed cell population where some cells have a Hoxa13 
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loss and some cells have two copies of Hoxa13. Hoxa13 is unlikely to be inherited as a full 
loss because it can cause embryonic lethality44. Surviving Hoxa13-/- mice have been 
recovered when the genetic contribution of the C57BL/6J background in the mice is at least 
87.5%, however, these mice are infertile, and exhibit hypodactyly, syndactyly, and stiffness 
when walking45. Mice with a high contribution of C57BL/6J to the genetic background and 
one functional Hoxa13 copy do not exhibit visible autopod skeletal defects and are capable 
of producing offspring. In 129/SV strains of mice or in mice with lower background 
contributions of C57BL/6, varying degrees of hypodactyly and syndactyly of the forelimbs 
and hindlimbs have been observed with a Hoxa13+/- genotype, with greater disruption of 
Hoxa13 function being associated with increased phenotype severity44. All of the mice in 
the C67BL/6J family appeared phenotypically normal, and it is likely that the mice 
inherited two normal copies of Hoxa13 which, based on array findings, may have been lost 
in a subpopulation of cells as an example of postzygotic somatic mosaicism.  
 An emergent hypothesis that is consistent with findings is that Hoxa13 losses may 
have occurred early in development, after limb development, as a non-random, 
“programmed” deletion. Programmed genomic deletions, which typically occur in the form 
of chromatin diminution or elimination, are known to occur in over 100 multicellular 
animal species from nine taxonomic groups, as well as single-cell ciliates and can serve 
different purposes46. In sea lampreys and the nematode Acaris suum, ~20% and ~13% of 
the somatic genome, respectively, is deleted during early development to create distinct 
genomes and transcriptomes between the germline and soma47,48. Many of the deleted 
lamprey genes have roles in germline development and pluripotency47. Similarly, 85% of 
the deleted genes in A. suum are expressed during gametogenesis (65%) or early 
embryogenesis (20%)48. Sciarid flies undergo three tissue-specific types of chromosome 
elimination which serve to determine the sex of the embryo and to develop gametes49. Like 
many eliminated genes, Hoxa13 has functions important for organism development, and 
has been shown to be required for autopod development44 and placental function50 in mice. 
It is unknown what biological purpose it would serve for Hoxa13 or neighbouring Hoxa 
genes to be deleted in somatic cells during early development. An alternative explanation 
for the Hoxa13 deletions is that there is no programmed modification of Hoxa13, but rather, 
this region is a mutational hotspot that is susceptible to replication- or transcription-induced 
 
 
163 
 
deletions. The presence of low copy repeats like segmental duplications and self-chains, 
for example, can facilitate repeat-induced replication errors leading to CNV formation51. 
On the other hand, repetitive DNA sequences are also commonly associated with 
programmed chromosome diminution, as the majority of eliminated DNA sequences are 
repetitive46.   
To determine the mutational mechanism for CNV losses in the Hoxa cluster, the 
breakpoint junctions of the CNVs need to be identified and sequenced. Given that all 
Hoxa1 ddPCR assays indicated a copy number state of two, it can be assumed that one 
breakpoint junction occurs between Hoxa1 and Hoxa13. For some samples, Hoxa2 and 
Hoxa3 had lower copy number states than Hoxa1 but higher than Hoxa13 which may 
suggest the presence of multiple deletion initiation or end points within the Hoxa cluster 
region.  
 Initial Hoxa13 ddPCR results for mice not related to the C57BL/6J family suggest 
that the occurrence of Hoxa13 losses might be a widespread phenomenon in M. musculus. 
Further testing of multiple tissues from individuals of different strains and subspecies will 
need to be conducted to determine how prevalent Hoxa13 losses are in mice. Detailed 
analysis of different tissues can also assist in delineating the cell lineages affected and the 
developmental timeline. Screening mouse embryos at different developmental stages for 
Hoxa13 losses would help establish if Hoxa13 losses occur early in development and are 
present as a minority cell population in all germ layer lineages or if the deletions are more 
likely to independently arise numerous times, in multiple cell populations. Early Hoxa13 
losses might not result in a deleterious phenotype if not enough cells are affected for gene 
expression levels to meet a phenotypic threshold. No study to-date has observed intra-tissue 
losses of this gene in multiple tissues in all members of a mouse family. Further work can 
be extended to determine the mutational mechanism and purpose of Hoxa13 deletions and 
to determine what proportion of the mouse genome regularly undergoes such alterations. 
4.5 Conclusion  
Ultimately, this study was unable to examine somatic mosaicism in a mouse family due to 
technical issues that may have occurred during the DNA preparation or hybridization 
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process. To gather the data again will require DNA from the mouse family members to be 
hybridized to new set of MDGA arrays. Alternatively, different technology like sequencing 
could be used to identify somatic mosaicism in mice. Since this study was completed, there 
has been significant progress in the methods used to study how mutations arise in cell 
lineages of mice. By using CRISPR technology to insert known DNA sequences called 
“barcodes” into mouse embryos, deletion and insertion mutations can be tracked through 
cell lineages and developmental germ layers of a whole mouse52. In the future, the mouse 
family study could be expanded upon by using methods with higher resolution and 
sensitivity, and including more families, a greater variety of tissues and subpopulations of 
cell, and more mouse strains or subspecies. 
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Chapter 5  
5 Characterization of the CNV Landscape in a Mouse 
Model of Breast Cancer with Lung Metastasis in the 
Presence and Absence of Rhamm 
5.1 Background 
Although the MDGA was designed to detect genetic variation in normal mouse tissues1, it 
may prove to be a useful tool in detecting genetic variation associated with cancer. 
Currently, its application in detecting structural variation in tissues with genomic 
instability, like cancer tissues, has been limited2. Conversely, numerous human, SNP 
microarray-based studies have been conducted to study genomic structural alterations, like 
copy number alterations and aneuploidy, in cancer3–6. Like with human studies, the use of 
SNP-based microarrays in mouse models of cancer may help expand our understanding of 
the role of genetic alterations in cancer. Copy number alterations cause the disruption of 
normal cell function by increasing, decreasing, or preventing the expression of dosage-
sensitive genes, and thereby contributing to various cancer characteristics like initiation 
timing and location, tumour cell metabolism, tumour growth, ability to metastasize, and 
response to treatment7–12.  
Numerous mouse models of human cancer have been developed to help fill in gaps 
in human studies and the design of mouse models of cancer has been constantly improving 
to help increase the predictive value when compared to human-based studies13. Mouse 
models of human breast cancer are among some of the most common animal cancer models 
and can be generated in several ways, the earliest being generated through a transgenic 
approach where foreign, oncogenic DNA is integrated into the genome14,15. One example 
of an oncogenic transgene is a mouse mammary tumour virus (MMTV) promoter paired 
with a polyoma middle T-antigen (PyMT) gene, which is used to model luminal breast 
cancer with lung metastasis16. MMTV is active in estrogen-sensitive tissues such as the 
mammary epithelium where it drives the expression of the oncogenic PyMT which 
simulates growth signaling pathways, resulting in unregulated cell division and the 
development of mammary gland primary tumours and secondary tumours in the lungs16–
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18. Other cancer models can be generated through the use of various combinations of 
promoters and oncogenes. The whey acidic protein (WAP) promoter for example, drives 
gene expression in the mouse mammary gland epithelium like MMTV, but unlike with 
MMTV which is activated during puberty16, WAP is responsive during pregnancy under 
the influence of multiple lactogenic hormones and continues after weaning19. WAP can be 
used to create a model of breast cancer when paired with the simian virus 40 (SV40) T/t 
antigen, a protein which inactivates the tumour suppressors p53 and Rb20. Ectopic 
expression of the SV40 T/t antigen has been used to create over 20 different transgenic 
cancer models affecting the bladder, liver, retina, skin, intestines, stomach, and mammary 
glands20. Mouse cancer models can also be created in several other ways that do not require 
the introduction of a transgene, including but not limited to mutagen or carcinogen 
exposure, knockouts of tumour suppressor genes, and the use of human tumour 
xenografts15,21.  
Cancer cells routinely exhibit several common properties termed “hallmarks”. 
Three of these hallmarks are sustained proliferation, genomic instability, and escape from 
apoptosis22. It was proposed by Macheret and Halazonetis (2015)22 that DNA replication 
stress should be included as another hallmark of cancer. DNA replication stress is 
connected to the previous three hallmarks since sustained cellular proliferation induces 
DNA replication stress which in turn can lead to genomic instability, such as the formation 
of CNVs, and some of these de novo mutations may alter normal cell phenotypes allowing 
them to escape from apoptosis22. DNA replication stress in yeast has been observed to 
induce high rates of both large (e.g. aneuploidy and CNVs) and small genomic alterations 
(point mutations and small insertions/deletions), with tandemly repeated genes like 
ribosomal RNA genes being particularly susceptible to deletions23. The observed genomic 
alteration preferentially occurred in regions with slow-moving replication forks, with some 
alterations conferring a selective growth advantage to cells23. Cancer-associated copy 
number alterations that confer an advantage for growth are important for the development 
of some cancer types while passenger mutations can help elucidate the mechanisms behind 
genomic instability22.  
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The roles of genomic alterations in certain cancers are thought to be important to 
tumorigenesis and cancer progression since multiple recurrent and syntenic copy number 
alterations have been found between a mouse model of T-cell lymphoma and multiple 
human cancers, suggesting the existence of genetic modifications and biological pathways 
that are common between cancers across and within species24. This finding is further 
supported by Rennhack et al. (2018) who found that copy number alterations are very 
common in 27 major models of breast cancer and although there is a high degree of 
heterogeneity, there are many conserved gene copy number alterations within and between 
mouse and human tumors that are associated with tumour progression and secondary 
tumour characteristics like histological appearance, metastatic potential, and oncogenic 
singalling25. It was also noted that not all mouse models had equal amounts of genomic 
instability, which differed based on the cancer driver, promoter, and mouse strain used25.   
Copy number alteration differences are known to exist between primary and 
secondary tumours26–28. For some cancers, there are greater mutation constraints in the 
primary tumours, possibly due to microenvironment effects or requirements to maintain 
specific functional pathways29. Depending on how early or late in primary tumour 
development metastasis-capable cells develop and metastasize, and on how quickly new 
subpopulations arise in the primary and metastatic tumours, more or fewer genetic 
similarities may be detected between the two tumour types30. If only one subpopulation of 
a primary tumour is capable of metastasizing, the initial metastatic tumour cell population 
will have less genetic diversity than the primary tumour31. The level of heterogeneity in a 
metastatic tumour may increase as the tumour continues to grow and acquire mutations, 
leading to increased genetic distance between the primary and metastatic tumours31. In a 
study of human colorectal cancer with liver metastasis, the discordance in average copy 
number between the primary tumour and metastases was 22%, leading the authors to 
proposed that due to substantial genomic differences, different treatment strategies may be 
required for primary tumors and metastasis tissue26. 
In this study, the MDGA is used to assess the CNV landscape of mammary gland 
primary tumours and lung with metastasis in an MMTV-PyMT mouse model of luminal 
breast cancer, in the presence and absence of the receptor for hyaluronan-mediated motility 
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(Rhamm) gene. RHAMM is a receptor for hyaluronan (HA) and has intracellular and 
extracellular functions relating to normal cellular function and cancer. Inside the cell, one 
important function of RHAMM is to localize to the centromeres during mitosis and 
maintain mitotic spindle integrity32. RHAMM normally resides intracellularly but it can be 
exported to the cell surface to bind HA in response to wounding and cytokine signalling33. 
Extracellularly, RHAMM can promote cell motility and invasion through the use of MEK1 
and ERK1/2 kinases via association with CD44, the main HA receptor, and subsequent 
activation of MEK1 and ERK1/2 kinases34,35. Elevated RHAMM expression is associated 
with poor clinical outcome in the majority of breast cancers36 and high levels of HA binding 
to RHAMM are associated with increased breast cancer invasiveness and lung metastases, 
but lower proliferation37.  
A lack of Rhamm  expression in cells causes multi-pole mitotic spindles, aberrant 
chromosome segregation, and inappropriate cytokinesis during mitosis38. Crossing Rhamm 
knockout mice to the MMTV-PyMT mouse model of luminal breast cancer leads to a 
significant increase in the number of metastasis nodules in the lung compared to wild-type 
MMTV-PyMT mice (unpublished). The increased metastases observed in Rhamm-/- mice 
suggests that elevated genomic instability in the absence of Rhamm expression is a driver 
for tumour progression. The association between loss of Rhamm expression and genomic 
instability makes this cancer model suitable for studying genome structural alterations.  
The MDGA has been used previously to study copy number alterations in a mouse 
model of breast cancer. Standfuss et al.2 found that there was an increase in copy number 
alterations in primary tumours in transgenic mice that developed breast cancer in 
comparison to mammary gland tissue from two non-transgenic mice, of the same strain, 
that did not develop cancer. Transgenic mammary gland tissue that was collected prior to 
tumour development showed fewer copy number alterations than tumour samples but more 
alterations than normal tissue. 
There are several differences between the Standfuss study and this study. Standfuss 
et al. used a WAP-SVT/t-driven cancer model with outbred mouse strains and included 
WAP-SVT/t breast cancer derived cell lines, while this study used an MMTV-PyMT 
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cancer model in inbred mouse strains with Rhamm-/- and wild-type genotypes. The results 
of the Standfuss study and this study are not expected to be very similar since cancer 
models using different oncogenic drivers have been observed to have different CNV 
profiles, and even when the same cancer driver is used in a mouse model of breast cancer, 
the use of different background strains can produce copy number differences25. Similarities 
between the two studies include the use of a small sample set of six mice and neither study 
used adjacent normal tissue for comparison to cancer tissue. However, the Strandfuss study 
assessed copy number alterations at different stages of tumorigenesis up to the 
development of primary tumours, while our study assesses genetic differences occurring 
with different Rhamm genotypes and between primary tumours and metastasis in the same 
animal. The study in this chapter advances beyond Standfuss et al. by being the first to use 
both SNP probes and IGPs for CNV detection with the MDGA, which increases the MDGA 
resolution and genic representation. The increased resolution, as well as the use of filtered 
probe lists is expected to allow for the more reliable detection of CNVs, particularly of 
genic CNVs, as well as help in the detection of smaller CNVs that can be missed at a low 
resolution. 
5.1.1 Research goal, central hypothesis, and specific objectives 
Research goal: The purpose of this study is to 1) assess the utility of the MDGA in the 
context of tumorigenesis and metastasis, specifically in an MMTV-PyMT mouse model of 
breast cancer using wild-type and Rhamm-/- mice, and 2) to analyze CNV differences with 
different Rhamm-/- genotypes and cancer tissue types (primary tumour or tissue with 
metastases). 
Central hypothesis: Given that genomic instability is a hallmark of cancer, primary 
tumours and lung tissue with metastases will have more CNVs than normal tissues. If 
metastatic capabilities are specific to a subset of primary tumour cells with a given 
genotype, then the primary tumor will have more CNV diversity than metastatic tumours 
and there will be more inter-animal variability in CNV profiles of primary tumours versus 
metastatic tumours. Given the phenotype of increased metastases in Rhamm-/- mice, 
primary tumour and metastatic tumour samples will have Rhamm genotype-specific CNV 
profiles which may include increased genomic instability.   
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The specific objectives are:  
1. To identify CNV differences between primary tumours and lung with metastasis in 
wild-type and Rhamm-/- MMTV-PyMT mouse samples. 
2. To confirm the presence of select candidate CNVs in the biological samples using 
ddPCR. 
5.2 Materials and methods 
5.2.1 Samples 
Mouse MDGA CEL files and DNA samples were provided our collaborator, Dr. Eva 
Turley. All six mice used in this study are female, carry an MMTV-PyMT transgene, and 
are of a mixed FVB/N and C57BL/6 background (E. Turley, personal communication). 
Three of the mice have a Rhamm-/- genotype and are represented by numeric identifiers: 
10.4, 45.2, and 63.1. The three wild-type mice are represented by the numeric identifiers 
36.1, 36.2, and 76.3. All mice developed mammary gland primary tumours that 
metastasized to the lungs. For each mouse, DNA was isolated from a primary mammary 
gland tumour and from normal lung tissue that contained metastatic tumours. In total, there 
are four sample groups in this study: wild-type primary tumour (WP), wild-type lung with 
metastasis (WM), Rhamm-/- primary tumour (RP), and Rhamm-/- lung with metastasis 
(RM). The metastasis samples also contain surrounding normal tissue since it was not 
feasible to extract only the individual metastasis nodules.  
5.2.2 MDGA hybridization 
Mouse DNA was prepared by C. Tolg. MDGA hybridization was performed at the London 
Regional Genomics Centre (Robarts Research Institute, London, ON) according to 
instructions in the Affymetrix® Genome-Wide Human SNP Nsp/Sty 6.0 manual39. The 
resulting CEL files were then used for SNP genotyping and CNV identification.   
5.2.3 SNP genotyping and CNV identification 
M.E.O. Locke generated SNP genotypes and CNV calls by using the BRLMM-P algorithm 
implemented in Affymetrix® Power Tools40 using default clustering parameters as 
specified by Genotyping Console, and included median normalization and artifact 
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reduction, as recommended for cancer samples by the Affymetrix® Genotyping Console 
4.0 User Manual41. Analysis was limited to a stringent probe list42. A canonical genotype 
clustering file42 was used to calculate Log R Ratio (LRR) and B allele frequency (BAF) 
values using the PennAffy package43. A GC model file, containing the percent GC content 
of the 1 Mb region surrounding each marker (or the genome-wide average of 42% if this 
could not be calculated) was generated using KentUtils44 and an in-house script based on 
the reference genome (UCSC:mm9). CNVs were detected with PennCNV using default 
parameters, a Population Frequency of B Allele (PFB) file based on a collection of 
reference strains42 and GC model correction45. Calls were not filtered based on length or 
number of markers, as all passed the minimum criteria of at least a 500 bp length and more 
than 10 markers underlying the call. Samples were not excluded based on the standard 
deviation of the LRR values or B allele frequency drift. The CNV calls are available in 
Appendix 5A. 
5.2.4 Select genic CNV confirmation by droplet digital PCR 
(ddPCR) 
A recurrent CNV region located on Chromosome 7, was selected for confirmation by 
ddPCR in all 12 samples. Two TaqMan® Copy Number Assays (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) for the Ilk/Rrp8 (Mm00216640_cn) and Taf10 
(Mm00232271_cn) genes, which overlap the CNV region, were used for confirmation. 
Additionally, a Rhamm TaqMan® Copy Number Assay (Mm00344889_cn) was used to 
confirm the copy number state of Rhamm in each mouse sample. The transferrin receptor 
gene (Tfrc) was used as the diploid copy number reference for the Ilk, Taf10 and Rhamm 
assays. No-template controls were used in all assays and there were two technical replicates 
for each assay.  
DNA quantity and quality were assessed prior to ddPCR, using a NanoDrop 2000c 
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and diluted 
to approximately 8 ng/μl. Subsequently, the DNA was fragmented by centrifuging 140 μl 
of DNA sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo, Limburg, 
Netherlands).  
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Each PCR reaction, with the exception of negative controls, contained 5 μl of DNA 
template, 5 μl of PCR-grade water, 12.5 μl of the ddPCR™ Supermix for Probes (Bio-Rad, 
Hercules, California, USA), 1.25 μl of the FAM™ dye-labelled TaqMan® assay for the gene 
target of interest, 1.25 μl of the VIC® dye-labelled TaqMan® reference assay. 20 μl of the 
PCR mixture was used for droplet generation and PCR. Droplets were generated by a 
QX200™ droplet generator (Bio-Rad, Hercules, California, USA). PCR was carried out in 
a C1000 Touch™ thermal cycler (Bio-Rad, Hercules, California, USA) with the following 
program: 1 cycle at 95 °C for 10 min, 45 cycles of denaturation at 95 °C for 30 s, annealing 
and extension at 60 °C for 1 min and enzyme deactivation at 98 °C for 10 min. Droplets 
were read using a QX200™ droplet reader and analyzed with QuantaSoft™ software 
(Version 1.7.4.0917; Bio-Rad, Hercules, California, USA). 
5.2.5 SNP and CNV phenogram construction 
SNP distance was calculated by totaling the number of loci where pairs of samples did not 
share the same genotype call and dividing by the total number of SNP loci. Loci where 
both mice had a No Call genotype were not counted as a difference. For pairwise CNV 
distance calculations, SNP and IGP markers were assigned the copy number state (0, 1, 2, 
or 3+) that they called as their “genotype”. The total number of CNV genotype differences 
between pairs of samples was divided by the total number of SNP and IGP loci to obtain 
CNV genetic distance values. SNP and CNV distance matrices are available in Appendix 
5B. The genetic distance matrices were used to construct a phenogram file using the BIONJ 
function of the APE package (version 3.3) for R (version 3.2.2), which implements the 
algorithm described by Gascuel et al46.  The phenogram file was saved in Newick format 
and uploaded to Figtree (v1.4.2) to generate coloured phenogram images.   
5.2.6 Tissue-specific CNVs  
Tissue-specific CNVs within a mouse were identified using inhouse scripts. If a CNV in 
one mouse tissue overlapped to any degree with another CNV in a different tissue of the 
same mouse, regardless of copy number state, it was considered to be recurrent within the 
mouse. Conversely, CNVs that did not overlap any CNVs in a different tissue within the 
same mouse were considered to be tissue-specific CNVs (i.e. somatic mutations). It is 
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important to note that the inherited copy number state is unknown. Therefore, in cases 
where the copy number state of the same locus differs between two tissues of the same 
mouse, either one or both of the tissues sampled may contain a de novo CNV. 
5.2.7 Recurrent gene gains and losses and IPA networks 
Genic annotation used to identify the genic content of CNVs was obtained from Ensembl’s 
BioMart (Ensembl genes 67, NCBIM37). Protein-coding genes, non-coding genes, and 
pseudogenes that completely overlapped CNVs of the same state, in all three samples of a 
group (shared Rhamm genotype and tumour type), were considered to be recurrent within 
that group (Appendix 5C). Lists of recurrent gene gains and losses were made for each of 
the four groups. The four sample groups were wild-type primary tumour (WP) samples, 
wild-type metastasis (WM) samples, Rhamm-/- primary tumour (RP) samples, and     
Rhamm-/- metastasis (RM) samples.  
Each gene list was inputted into the Ingenuity® Pathway Analysis (IPA) Core Analysis 
(Qiagen, Venlo, Limburg, Netherlands) program. IPA identifies relevant relationships, 
functions and pathways for inputted datasets such as gene lists. IPA parameters were set to 
include: direct and indirect relationships with a maximum of 35 focus molecules per 
network, mouse genes only, an “experimentally observed” confidence level, and the 
Ingenuity Knowledge Base Genes only reference set. “Endogenous Chemicals” was not 
selected since the focus of this study is on genetics aspects rather than metabolomics.  
5.3 Results 
5.3.1 CNVs detected 
Across 12 cancer samples, 665 CNVs were identified (Appendix 5A). CNV genetic 
distances do not show samples clustering together by mouse or genotype (Fig. 5-1). There 
is no readily apparent relationship between the samples. In contrast, SNP distances are 
greater between different mice than between two tissues of the same mouse and the samples 
also cluster by genotype (Fig. 5-1). 
Primary tumours in Rhamm-/- and wild-type mice have greater inter-animal 
variation in the number of CNVs detected than do metastatic tumour samples (Table 5-1).    
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Rhamm-/- metastatic tumour samples have 1.4-fold more CNVs on average, with more 
inter-animal variation in the number of CNVs, than wild-type metastatic tumour samples. 
Cancer samples range from having 1.6- to 3.2-fold more CNVs, on average, than normal 
tail samples which have an average of 25 CNVs per sample (Table 5-1). In contrast to 
normal samples, which have slightly more gains than losses on average, all cancer samples 
have more losses than gains (Table 5-1; Fig. 5-2).  
Rhamm-/- primary tumour samples have the smallest CNVs, with the average length 
being less than half the size of CNVs found in any other cancer sample group, and closest 
in size to C57BL/6J normal tail tissue samples (Table 5-1). By plotting the length 
distribution of the CNVs for each sample, it is evident that only the Rhamm-/- primary 
tumour samples all consistently have a high proportion of smaller CNVs and this is not 
seen with the metastasis samples and only seen in one wild-type primary tumour sample 
(Fig. 5-3). Wild-type primary tumour samples were found to have the longest average CNV 
length but also had the greatest inter-animal variation (Table 5-1). The average CNV size 
of metastasis samples is similar between genotypes (Table 5-1; Fig. 5-3). All cancer groups 
have longer CNVs, on average, than do normal tissues (Table 5-1).  
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CNV        SNP 
                   
Figure 5-1. Phenograms representing CNV- and SNP-based pairwise genetic distance between mouse samples from four groups: 
Rhamm-/- primary tumour, Rhamm-/- lung with metastasis, wild-type primary tumour, wild-type lung with metastasis. Rhamm-/- 
primary tumour (RP) and lung with metastasis (RM) samples are coloured in blue while green indicates wild-type primary tumour (WP) 
and lung with metastasis (WM) samples. The numeric values in the sample labels represent the individual mouse identifier number.  
Scale bars represent genetic distance.
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Table 5-1. Summary of averages for CNV numbers, length, state, and genic classification, in cancer and normal sample 
groups. 
Sample group 
Number 
of 
samples 
Average number 
of CNVs per 
mouse 
Average CNV  
length (bp)  
per group 
Gains 
(%) 
Genic 
(%) 
Genic gains 
(%) 
Rhamm-/- primary 
tumour 3 79 ± 46 91,239 ± 16,525 3.16 ± 4.03 62.08 ± 7.57 3.25 ± 3.61 
Wild-type primary 
tumour 3 46 ± 42 272,356 ± 134,633 14.86 ± 23.90 71.46 ± 4.31 15.82 ± 26.01 
Rhamm-/- lung with 
metastasis 3 56 ± 21 235,703 ±77,512 14.15 ± 6.93 75.79 ± 7.98 8.11 ± 3.47 
Wild-type lung with 
metastasis 3 41 ± 9 229,280 ± 46,936 11.94 ± 3.93 74.92 ±  6.56 8.22 ± 4.18 
114 classical laboratory 
mouse normal tail 
tissue42 
114 25 ± 14 52,490 ± 18,840 51.28 ± 17.54 23.87 ± 11.23 59.11 ± 28.94 
C57BL/6J normal tail 
tissue42 8 11 ± 4 76,469 ± 19,760 57.54 ± 13.76 43.66 ± 11.65 58.12 ± 15.36 
FVB/NJ normal tail 
tissue42 1 28 46,279 53.57 17.86 40 
 
Averages are presented along with standard deviation.  
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Figure 5-2. Number of CNV gains and losses detected in primary tumour and lung 
with metastasis samples from three wild-type and three Rhamm-/- mice. Gains are 
shown in dark blue while losses are shown in light blue. Each mouse is represented by a 
numeric identifier.  
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Figure 5-3. CNV length distribution for primary tumour and lung with metastasis 
samples from three wild-type and three Rhamm-/- mice. Primary tumour data are 
coloured in blue and lung with metastasis data are coloured in green. Individual mice are 
represented by the numeric identifiers at the top of the figure.  
Cancer samples have a similar percentage of genic CNVs on average at around 71-
76%, except for Rhamm-/- primary tumour samples, which have 62% genic CNVs (Table 
5-1). In contrast, 18-44% of CNVs in normal tissues are genic, depending on the sample 
group (Table 5-1). A high proportion of genic CNVs in cancer samples are losses, ranging 
from 84-97% genic losses, depending on the sample group. For normal tissues, more genic 
CNV gains than losses were observed in 64% of the 114 mouse samples. 
Here, a CNV is defined as tissue-specific if it is present in only one of two tissues 
of an individual mouse. The majority of CNVs (68-97%) in the wild-type and Rhamm-/- 
mice are tissue-specific within an individual mouse (Fig. 5-4). The proportion of tissue-
specific CNVs detected in a particular tissue type, did not appear to be dependent on 
genotype.  
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Figure 5-4. Tissue-specific CNVs in the primary tumour and lung with metastasis 
tissue of wild-type and Rhamm-/- mice. Dark green bars represent primary tumour data 
and light green bars represent lung with metastasis data. Each mouse is represented by a 
numeric identifier. Values over each bar indicate the number of CNVs represented by the 
bar.  
5.3.2 Droplet digital PCR confirmation of select genic CNVs 
The ddPCR results confirmed that the Rhamm gene was knocked out in Rhamm-/- samples 
and was present as a copy number state of two in wild-type samples (Fig. 5-5). Based on 
MDGA results, Ilk and Taf10 were predicted to have a copy number state of two in all 
samples except in Rhamm-/- primary tumours. These genes were not confirmed to be a copy 
number state of one in Rhamm-/- primary tumour samples. Instead, there appears to be a 
mixture of genotypes present in the cell population with a subset of cells carrying the 
deletion. Furthermore, several other samples also appear have lost copies of Ilk and Taf10 
in a subset of the cell population sampled within the tissue sample.   
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Figure 5-5. Copy number state of Ilk, Taf10, and Rhamm genes as detected by ddPCR in wild-type primary tumour, wild-type 
lung with metastasis, Rhamm-/- primary tumour, and Rhamm-/- lung with metastasis mouse tissues.  Bars are coloured according 
to sample group (genotype and tumour type). Each mouse is represented by a numeric identifier on the x-axis and primary tumour and 
metastatic tumour tissues are represented by “P” and “M”, respectively. 
0.0
0.5
1.0
1.5
2.0
2.5
36
.1
36
.2
76
.3
36
.1
36
.2
76
.3
10
.4
45
.2
63
.1
10
.4
45
.2
63
.1
36
.1
36
.2
76
.3
36
.1
36
.2
76
.3
10
.4
45
.2
63
.1
10
.4
45
.2
63
.1
36
.1
36
.2
76
.3
36
.1
36
.2
76
.3
10
.4
45
.2
63
.1
10
.4
45
.2
63
.1
P M P M P M P M P M P M
Wild Type Rhamm-/- Wild Type Rhamm-/- Wild Type Rhamm-/-
Ilk Taf10 Rhamm
C
op
y 
N
um
be
r S
ta
te
Gene Assayed, Sample Genotype, Tumour Type and Mouse Identifier Number
Il f Rha
-/- Rhamm-/- -/-
0
 
 
 
185 
5.3.3 CNV genic analysis 
Genic CNVs, especially genic losses, are found in the majority of cancer samples which is 
in contrast to normal tissue samples where the majority of CNVs detected are not genic 
(Table 5-1). For each of the four cancer sample groups, recurrent CNV-affected 
pseudogenes, non-coding genes and protein-coding genes can be found that are common 
to all samples within the groups (Appendix 5C). Rhamm-/- primary tumour samples have 
more genes in common that are impacted by CNVs than wild-type primary tumour samples 
do. More specifically, Rhamm-/- primary tumour samples had eight recurrent CNV regions 
overlapping 48 protein-coding or non-coding genes, while only six protein-coding or non-
coding genes, all in one CNV region, were affected by CNVs in the three wild-type primary 
tumour samples.  
The top IPA network for the 48 shared Rhamm-/- genes is “connective tissue 
development and function, tissue morphology, cellular growth and proliferation” (Table 5-
2). Vascular endothelial growth factor B (Vegfb), a regulator of Rhamm is found in this 
network but Vegfb-containing CNVs were also found in some wild-type samples. Only 
three genes, integrin-linked kinase (Ilk), ribosomal RNA processing 8 methyltransferase 
homolog (yeast; Rrp8), and TATA-box binding protein associated factor 10 (Taf10), were 
unique to Rhamm-/- primary tumours as copy number losses and not found to vary in copy 
number in any other sample. These genes were completely encompassed by a single CNV, 
which also partially overlapped the dynein heavy chain domain 1 (Dnhd1) and tripeptidyl 
peptidase I (Tpp1) genes. Wild-type primary tumour samples did not have any group-
specific genes.  
Although an Ilk loss was not observed in Rhamm-/- metastasis samples, the top 
canonical pathway for this cancer group in IPA was “ILK Signaling” (p = 1.43 x 10-5) and 
included insulin receptor substrate 3 (Irs3), protein phosphatase 1 regulatory inhibitor 
subunit 14B (PPP1R14B), ribosomal protein S6 kinase polypeptide 4 (RPS6KA4), and 
VEGFB. Rhamm-/- metastasis samples shared CNVs affecting 31 genes in six genomic 
regions. Wild-type metastasis samples shared 20 genes, also in six genomic regions. In 
Rhamm-/- metastasis samples, only snoMe28S-Cm3227 (snoRNA) was unique to that 
 
 
 
186 
group, while in wild-type metastasis samples, AC161763.1 (miRNA), ABCE maturation 
factor (LTO1), and cyclin D1 (Ccnd1) were unique and not found in Rhamm-/- metastasis 
samples. The top Rhamm-/- metastasis network is immune-related cell signaling (Table 5-
2), and the top wild-type metastasis network is cell function related to cancer and injury 
response. The remaining top networks for both metastasis groups only had one associated 
focus molecule. 
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Table 5-2. Top three Ingenuity Pathway Analysis “diseases and functions” terms for 
gene networks describing recurrent genic CNVs within each cancer sample group.  
Group IPA Scorea 
Number 
of Focus 
Moleculesb 
Top Diseases and Functions 
Rhamm-/- 
primary 
tumour  
39 17 
Connective Tissue Development and Function, 
Tissue Morphology, Cellular Growth and 
Proliferation 
12 7 
Digestive System Development and Function, 
Hepatic System Development and Function, 
Inflammatory Response 
2 1 Carbohydrate Metabolism, Small Molecule Biochemistry, Post-Translational Modification 
Wild-type 
primary 
tumour  
3 1 Amino Acid Metabolism, Post-Translational Modification, Small Molecule Biochemistry 
3 1 Cancer, Gastrointestinal Disease, Hepatic System Disease 
2 1 
Cell-To-Cell Signaling and Interaction, 
Hematological System Development and Function, 
Immune Cell Trafficking 
Rhamm-/- 
metastasis  
14 6 
Cell-To-Cell Signaling and Interaction, 
Hematological System Development and Function, 
Immune Cell Trafficking 
3 1 Tissue Morphology, Organ Development, Reproductive System Development and Function 
3 1 Cancer, Cell-To-Cell Signaling and Interaction, Immunological Disease 
Wild-type 
metastasis  
16 7 Cellular Function and Maintenance, Cancer, Organismal Injury and Abnormalities 
3 1 Tissue Morphology, Cellular Development, Tissue Development 
3 1 Amino Acid Metabolism, Post-Translational Modification, Small Molecule Biochemistry 
 
a The IPA score is equal to -log10 of the p-value 
b Number of genes that were inputted into IPA by the user and are present in the top diseases 
and functions network
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5.4 Discussion 
The MDGA was able to provide information regarding the number, size, state and gene 
content of CNVs in cancer samples. Comparisons of CNVs in cancer tissues and normal 
tissues revealed differences in cancer CNV profiles from normal CNV profiles with respect 
to CNV number, length, state, and genic content. Contrary to predictions, there is no clear 
association between the number of CNVs detected in either the presence or absence of 
Rhamm expression. However, the absence of Rhamm expression is associated with 
alterations to the primary tumour genome that were not observed in metastasis tissue or 
with a wild-type genotype, particularly in respect to the high proportion of smaller CNV 
losses. With respect to CNV length only, Rhamm-/- primary tumour CNVs are more similar 
to normal tissues than to other cancer samples. Rhamm-/- primary tumours also have 
multiple genic CNVs shared between samples within the group that are associated with 
IPA disease and function terms relevant to cancer while the wild-type primary tumours 
have more diversity in genic CNVs impacted, suggesting that Rhamm-/- absence in the 
microenvironment leads to selection for specific phenotypes resulting from genotypic 
changes. This genotype-specific difference was not observed with metastasis samples, 
possibly because of the presence of normal tissue and a difference in the lung verses 
mammary gland microenvironment. As predicted, confirmation of select CNV targets 
revealed that there are SNP microarray sensitivity limitations for genetically heterogeneous 
samples, such that small mutant clones cannot be detected. Ideally, tumour subpopulations 
should be isolated and characterized for CNVs using CNV-detection methods appropriate 
for small sample sizes. Regardless of its limitations, the MDGA provided important leads 
to follow up on relating to the influence of Rhamm-/- on the CNV landscape, possibly 
through tissue microenvironment changes that lead to selection for specific phenotypes 
associated with the detected genotypes.  
5.4.1 CNVs detected 
The genetic distance between cancer samples can differ greatly based on which mutation 
types are used in the calculations (e.g. SNPs or CNVs), the algorithm or model used, and 
if the sample is genetically heterogeneous or if more homogeneous cell subpopulations are 
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used47. When using SNPs, the genetic distance between cancer samples reflected the 
known genetic relationships between the samples. On the other hand, CNV genetic distance 
showed that the genetic variation acquired by the cancer samples exceeds the shared, 
inherited genetic variation in a way that the known relationships are not observed when 
looking at the CNV phenogram. The absence of sample clustering by animal in the CNV 
phenogram would suggest that there is high intra-animal copy number variation in 
cancerous tissues, regardless of Rhamm genotype. However, the SNP genetic distance 
values are larger than CNV genetic distance values, which means that there is a larger 
contribution from SNPs to genetic differences between the samples than there is from 
CNVs.  
Differences between SNP and CNV genetic distance values and how closely they 
represent known genetic relationships are a result of SNP and CNV frequency in the 
genome and how that is applied to genetic distance calculations. SNP genetic distance is 
calculated for hundreds of thousands of single-nucleotide loci while CNV genetic distance 
is dependent on CNV number, length and state. Assuming that the majority of the genome 
is a copy number state of two in all individuals, a sample would need to have a great number 
of small CNVs with mixed states to achieve a high level of uniqueness and thereby 
distinction from other samples – similar to SNPs. Within a mouse, the CNV landscape 
between two tissues would have to be very similar for the tissues to cluster together since 
genetic distance can be greatly impacted by small differences in CNV number, length or 
state. If there is a high incidence of de novo or tissue-specific CNVs in tissue samples, as 
can occur with cancer or mutagen exposure, the genetic distance will be greater than for 
tissues that only contained inherited CNVs.  
The number of CNVs detected in the cancer samples exceeded what is typical of 
normal mouse tissues, in some cases by more than four-fold. This observation of high CNV 
levels in cancer is not found in all cancer studies as mutation profiles can vary based on 
cancer type10,48. In a study on human colorectal cancer49, the median number of CNVs was 
found to be similar between individual tumours (480 CNVs, with a range of 7-969 CNVs) 
and matched normal tissue (383 CNVs, with a range of 3-762 CNVs). A large range in 
CNV number was also found in the cancerous tissues of the six mice, unlike the CNV range 
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for normal mouse samples, which was far smaller. In the human colorectal cancer study49, 
there were more than 4-times the number of CNVs detected overall in cancer samples than 
normal samples - similar to the findings in the mouse study presented here. A larger sample 
size of primary and secondary tumour samples with matched normal tissue will be needed 
in future experiments to determine if the high CNV loads detected in the MMTV-PyMT 
mice are representative of this particular cancer model or if these six mice are outliers and 
other mice would have lower CNV loads.  
Tissue-specific copy number alterations were detected in all tissues of this study 
and are a common occurrence with cancer tumorigenesis and metastasis29,50. The number 
of mutations that arise in a tissue can depend on many factors including, but not limited to, 
which genes are affected (e.g. mutation repair genes), tissue type, and microenvironment. 
Ben-David et al51 found that aneuploidy and large copy number alterations become 
dominant as non-invasive lesions progress to invasive carcinomas in SV40 Tag-induced 
cancer, but that an increase in chromosomal aberrations is not associated with PYMT-
related metastasis development. The authors also found recurrent copy number alterations 
that are unique to specific breast cancer drivers51. Recurrent CNVs should be studied at a 
cell subpopulation level within the primary tumours and compared to isolated metastasis 
tumours to identify chromosomal changes that promote tumorigenesis and metastasis. 
However, higher resolution technology is required to study cell subpopulations since the 
MDGA only reports the most abundant copy number state. 
One of the most striking differences when comparing cancer samples to normal 
tissues is the high number of CNV losses observed with cancer. Generally, genic losses are 
more likely to be deleterious than gains, particularly when there is a loss of genes necessary 
for cell function. Therefore, CNV losses are not expected to be prevalent in healthy tissues. 
However, sometimes losses are advantageous. In hematopoietic cancer stem cells from a 
Pten-/- mouse model of leukemia, loss of ribosomal DNA regions was counterintuitively 
associated with increased cell proliferation, rRNA production and protein synthesis52. 
Alternatively, copy number losses could be neutral, they could contain tumour suppressor 
genes that would contribute to tumour progression if gene copies are lost, or they could 
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confer minor fitness disadvantages to cells but are linked to a strong cancer driver and are 
therefore not selected against.  
 Although there were no clear genotype-specific differences regarding the number of 
CNVs detected by the array, genotype-specific differences were observed when looking at 
the length of CNVs in primary tumour samples. In the absence of Rhamm, primary tumour 
CNV losses were found to be smaller than in wild-type primary tumours, but still larger 
than CNVs in healthy mice. This difference was not seen in metastatic tumour samples, 
possibly because of the presence of some normal tissue and a different microenvironment 
in the lung than in the mammary gland. Alternatively, it is possible that the successfully 
metastasizing cells had a genotype that did not contain many of the CNV losses present in 
the primary tumour samples. Small losses that are genotype specific may share a common 
mechanism. The mechanisms known to generate smaller deletions include: double-strand 
breaks associated with elevated reactive oxygen species and this being more likely with 
open DNA53. Therefore, the wild type and Rhamm-/- groups could be examined for 
differences in chromatin structure which may result from differing levels of transcription 
or influences on histone activity. The level of DNA accessibility and susceptibility to 
damage can be determined using a DNase I footprinting assay. Other assays could be 
applied to test for genotype-specific, mutation repair deficiencies. 
Aneuploidy was not detected by the MDGA, even though it is known to occur in 
the absence of RHAMM38. Aneuploidy would not be detectable by the array unless a large 
proportion of the cells had the same chromosomal gain or loss.  
5.4.2 Droplet digital PCR confirmation of select genic CNV regions 
Confirmation of selected recurrent CNVs revealed a limitation of microarrays when used 
with cancer samples or any sample that is a composite of subpopulations with different 
CNV genotypes. The MDGA is only capable of calling whole number CNV states from 
zero to four while ddPCR can detect a mixture of copy number states, such as a state of 
1.5. In a genome, a copy number state can only exist as a whole number. A state of 1.5 
could appear if there is mosaicism in a population of cells where some cells have a CNV 
loss while others do not, so an averaged copy number state is detected. In this event, ddPCR 
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would make a copy number call in between whole-number states, while the MDGA would 
round the state up or down to a whole number. CNV detection is often more problematic 
in cancerous tissues than in normal tissues because of the heterogeneous genetic makeup 
of tumours54,55.  
 The MDGA has the capability to detect a knockout of Rhamm since there are probes 
present in that region of the genome. However, no state zero CNVs were detected in the 
entire dataset. This may have occurred for a few reasons such as uneven or excessive 
staining, or it could be due to highly variable fluorescence intensities that can occur with 
cancer samples or can arise from unequal sample application during hybridization56–58. 
Visual images of the arrays showed hybridization abnormalities like the presence of curved 
line artifacts across the arrays which would likely cause high variation in fluorescence 
intensities. Therefore, as with any technology based on massively parallel hybridization, 
conclusions drawn from the array data require additional experimental confirmation. In this 
study, ddPCR analysis did successfully confirm the Rhamm genotype of the samples.  
5.4.3 CNV genic analysis 
Due to the heterogeneous nature of cancer tissues and microarray limitations, additional 
confirmation of the results is required, particularly when attempting to assign cancer-
related roles to genes. For examples, the CNV region containing Ilk, Rrp8, and Taf10, 
which are genes that have been implicated in cancer, was identified by the MDGA as a 
copy number loss in Rhamm-/- primary tumour samples. However, ddPCR results suggest 
that the samples contain cell populations with mixed copy number states of two or lower. 
This intra-sample heterogeneity cannot be captured by the MDGA, which is limited to 
calling whole-number CNV states.  
Ilk, Rrp8, and Taf10, are found contiguously and partially overlapping each other 
on Chromosome 7 and were detected as a copy number state of one in all three Rhamm-/- 
primary tumour samples using MDGA analysis. This CNV confirmed as a copy number 
state of less than two, but more than one, by ddPCR in all Rhamm-/- primary tumour 
samples. Although other samples also had a copy number state less than two for this region, 
there was no other sample group wherein all the samples showed this loss. Ilk, Rrp8, and 
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Taf10 may impact cancer proliferation, apoptosis resistance, and growth, respectively, and 
might contribute to some Rhamm-/--specific phenotypes like increased lung metastases. 
 During mitosis, ILK forms a complex with an integrin receptor, α-Parvin and 
Dynactin-2/1 to orient mitotic spindles59.When Ilk is knocked out, mitotic spindles become 
more randomly oriented leading to changes in the axis of mitosis and subsequently 
allowing cells to grow outside of their normal cell layer. With less cell-cell contact limiting 
cell division, cells are able to proliferate more rapidly and spread outside of their normal 
layers. ILK has overlapping regulatory pathways with RHAMM as they both act as 
regulators of ERK1/2 Map kinases38,60, which are commonly involved in cancer61. ILK and 
RHAMM are also involved in fibronectin (FN1) regulation. RHAMM is an up-regulator 
of Fn1 when associated with E2F162, and ILK is required for the induction of FN1 
fibrillogenesis63. Fibronectin is important for cell adhesion and invasion64, including for 
metastatic breast cancers65. What impact the combination of ILK reduction and RHAMM 
absence has on fibronectin and cell behaviour remains to be determined.  
Ribosomal RNA-processing protein 8 (RRP8) is thought to be a methyltransferase 
in the energy-dependent nucleolar silencing complex (eNoSC). One established function 
of eNoSC involves sensing the energy status in a cell, and when energy levels are low, it 
will suppress rRNA transcription and ribosome biogenesis through histone acetylation and 
methylation to prevent energy deprivation-dependent apoptosis66. Rrp8 heterozygous 
deletions have been found in several different cancers and reduced expression is thought 
to play a role in tumor formation and poor survival in breast cancer67. 
TAF10 is also involved in transcriptional regulation and required for mouse 
embryogenesis and cell cycle progression68, and erythropoiesis69. TAF10 is a component 
of multiple complexes including TFIID, a general transcription factor which binds TATA 
boxes, and TATA box-binding protein-free TAF-containing complexes like TRTC, PCAF, 
and STAGA, which also have roles in regulating transcription70–72. In addition, TAF10 can 
directly associate with estrogen receptors (ER) and when it is knocked down, there is a 
significant reduction in estradiol-induced repression of the folate receptor-α (Folr1) P4 
core promoter73. With Taf10 deleted in the Rhamm-/- primary tumour cells, Folr1 repression 
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through ER would be reduced. Since Folr1 expression helps triple negative (ER-, PR-, 
HER2-) breast cancer cells increase folate uptake and grow in vitro, it was suggested that 
Folr1 could be targeted in cancer treatments74.  
The CNV loss encompassing Ilk, Rrp8 and Taf10 could not have been inherited as 
a complete loss (copy number = 0) since at least one copy of Taf10 is required for mouse 
embryogenesis68. Whether or not a loss of this region plays an important biological role in 
the MMTV-PyMT model studied here remains to be seen. An L1-family LINE located 
between exons in Dnhd1, as well as several SINEs and LTRs may provide mechanisms for 
CNV formation in this region.  
Wild-type primary tumours had many mouse-specific CNVs, as the three primary 
tumour samples only shared one CNV, and this shared CNV was not unique to this cancer 
group. The high level of unique CNVs in wild-type primary tumours and the contrasting 
high levels of CNV recurrence in Rhamm-/- primary tumours may indicate 
microenvironment differences that result in selection for phenotypes, produced by specific 
CNV genotypes, in the absence of RHAMM. The idea that Rhamm absence or presence 
can influence the tumour microenvironment is plausible since there is emerging evidence 
that suggests the tumour microenvironment can be modified by different gene alleles75. 
Furthermore, the tumour microenvironment is hypothesized to be involved in the 
development of highly malignant cells through a combination of selection and education 
(characteristic alteration) of tumour cells76. A larger sample size and additional 
experiments would be required to ascertain if the microenvironment influences the 
genotype of the cells and what advantages are conferred to the primary tumour as a result 
of the selection for specific genotypes.  
In Rhamm-/- metastasis samples, no CNVs containing protein-coding genes were 
unique to the group. SnoMe28S-Cm3227 was unique to Rhamm-/- metastasis samples but 
its association with cancer has not been studied. In wild-type metastasis samples, 
AC161763.1, LTO1, and Ccnd1 were unique to the group and observed as losses. 
AC161763.1, also known as brain cytoplasmic RNA 1 or Bc1, is a lincRNA77 that promotes 
TGF-β-induced smooth muscle cell differentiation when knocked down and acts as a 
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suppressor of differentiation when overexpressed78. Overexpression of LTO1 but not 
under-expression,  as would be expected with a loss, has been commonly observed in 
cancer79. Ccnd1 is a cell cycle regulator whose reduced expression has been linked to 
resistance to breast cancer80 and reduced tumour incidence in teratoma-susceptible mice81. 
The role that genic CNVs play in relation to cancer in this study’s metastasis samples 
cannot be determined solely from SNP microarray data, especially because the metastasis 
samples contain a mixture of normal and cancerous tissue.   
5.5 Conclusion 
In this study, cancer samples differed in CNV landscape in comparison to normal, healthy 
tissues. Primary tumour samples had a greater inter-animal variability in the number of 
CNVs detected than did metastasis samples. The absence of Rhamm is associated with the 
presence of small CNVs in primary tumours but not in lung tissue with metastasis or in the 
wild-type tissue samples. This is suggestive of different CNV mutation mechanisms in the 
primary tumour tissue in the presence and absence of Rhamm. Based on CNV recurrence 
and genic analysis, an absence of Rhamm is now hypothesized to produce a 
microenvironment where there is selection for a specific cell phenotype.  
This study was designed as a pilot study to determine if the MDGA could be used 
for CNV detection with cancer samples and if it could be used, then the goal was to identify 
and characterize differences between wild-type and Rhamm-/- cancer tissue. Although 
microarray technology is limited in its ability to detect copy number variants in tissue 
samples composed of heterogeneous cell populations, the MDGA was able to identify 
differences in comparison to normal tissues and between cancer groups in regard to CNV 
number, size, state, recurrence and genic content. To explore the CNV landscape in more 
depth, larger sample sizes, the use of normal tissue adjacent to assayed tumour samples, 
higher resolution technology, and focusing on cell subpopulations within tumours is 
recommended. This study shows the utility of the MDGA in searching for general mutation 
patterns, between cancer groups, that could be further investigated to identify mutational 
mechanisms and genes associated with specific cancer phenotypes. 
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Chapter 6  
6 Summary and Discussion  
The overall goal of this thesis was to identify CNVs in inbred and wild mice, using the 
Mouse Diversity Genotyping Array (MDGA), and to explore the CNV landscape of Mus 
musculus from the perspectives of evolution and adaptation, normal development, and 
cancer. To accomplish this goal, a CNV detection pipeline for the MDGA needed to be 
developed and tested on a sample dataset. Once a reliable pipeline was established, the 
MDGA could be used to characterize the CNV landscape in different mouse subspecies, 
multiple normal tissues within an individual mouse, and in primary tumour samples 
compared to metastasis tissue. The outcome of the first thesis aim of developing a CNV 
detection pipeline, was the generation of lists of filtered probe lists recommended for use 
in CNV detection, updated probe annotation files, and the collection of a list of genes, 
predicted have conserved copy number states, for use in the assessment of CNV call 
reliability. It was also shown that the MDGA probes were not designed as carefully as the 
Genome-Wide Human SNP Array 6.0 probes. However, filtering of the MDGA probes 
increases SNP genotyping performance and is predicted to improve CNV genotyping. 
Cross-species MDGA hybridization data showed that MDGA use is not limited to M. 
musculus but has the potential to be a SNP and CNV detection tool for Mus genus samples 
and may be of more limited use for genotyping distantly related rodents like H. glaber. 
Cross-species hybridization studies using the MDGA would require identifying which 
probes are usable in the species of interest by determining which probe sequences are 
present in the reference genome, and reannotation of the probe genomic positions is 
necessary for accurate CNV genotyping in a species other than M. musculus.   
The developed MDGA CNV detection pipeline was first used in a broad, mouse 
survey study where CNVs were shown to commonly occur in the genomes of M. musculus 
individuals, with 9,634 CNVs being detected in 334 mouse samples. The reliability of the 
pipeline for CNV detection was established by putative CNV confirmation by ddPCR. 
Indirect confirmation of CNVs on strain-matched samples suggests that some CNVs may 
be strain-specific. CNVs were also found to impact different genes and biological pathways 
in classical laboratory strain and wild-caught mouse cohorts that appear to be linked to 
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differences in their respective environments and mate selection. As predicted, these data 
imply that some adaptive traits can be conferred through variation in gene copy number, 
although experiment confirmation of these findings is required. The discovery of CNV 
differences between the classical laboratory strains and wild-caught mice led to the 
development of the mouse cohort study to further explore mouse cohort differences in CNV 
landscapes.  
The mouse cohort study compared the CNV landscapes in classical laboratory, 
wild-derived, and wild-caught mouse cohorts. The differences in gene pathways between 
the classical laboratory strains and wild-caught mice were similar to findings in the broad 
survey study. The wild-derived strain cohort, which was not assessed for CNV genic 
content in the broad survey study, was found to have gene pathway overlap between both 
the classical laboratory and wild caught cohorts. These data may show how CNV-affected 
gene pathways are altered through the process of creating inbred laboratory strains.  A 
useful tool that came out of this study to assist with future identification of cohort-specific 
CNVs and mutation hotspots in the mouse genome was the CNV landscape plot. Given a 
sufficient sample size for pattern observation, the CNV landscape plot can be used for data 
visualization with any genome and for any mutation type, provided that the genomic 
position is known. Furthermore, the CNV landscape plot can be used in conjunction with 
HD-CNV output to visualize merged regions and singletons across each chromosome.  
After looking at CNV differences between mice, where all the data originated from 
tail samples, the next aim was to characterize the CNV landscape between multiple tissues 
of individual mice. However, low data quality provided too many false positives to 
accurately characterize the CNVs in the sample tissues from members of a C57BL/6J 
mouse family. A ddPCR confirmation of some of the putative CNVs detected may have 
uncovered a mutational hotpot or programmed deletion in the Hoxa gene cluster, which 
always included Hoxa13. This deletion was not only present in all tested C57BL/B6 mice 
and tissue samples, but also appeared to be occurring as somatic mosaicism at the intra-
tissue level. Evidence of Hoxa deletion mosaicism was also found in two other M. 
domesticus laboratory strains and in a C57BL/6J mouse unrelated to the mouse family. The 
significance of a Hoxa13 gene loss is that it is unlikely to be inherited without causing 
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embryonic lethality or some level of abnormal development, depending on if the deletion 
is a copy state of zero or one, respectively, and depending on the mouse genetic 
background. The emergent hypothesis from this data is that this deletion is a case of 
nonstochastic somatic mosaicism. Future testing of is required to determine if the data 
show a developmentally-programmed deletion in a developmentally-relevant gene, within 
the context of specific tissues. 
The final thesis aim was to study CNVs in the context of tumorigenesis and 
metastasis. Using an MMTV-PyMT mouse model of breast cancer with either a knockout 
of Rhamm or a wild-type genotype, the CNV profile was characterized for mammary gland 
primary tumours and lung tissue with metastasis for six mice. CNV profiles in cancer 
samples were found to differ from normal tissues and have greater numbers of CNVs, 
particularly genic losses. Among the four cancer tissue groups, the CNV profiles of 
Rhamm-/- primary tumour samples were unique in having smaller CNV deletions than the 
other groups. This would suggest that different mutational mechanisms are forming CNVs 
in the presence and absence of Rhamm. Furthermore, the higher frequency of recurrent 
CNVs, or greater genetic homogeneity, among Rhamm-/- primary tumour samples 
compared to samples with a wild-type genotype suggests that Rhamm absence may be 
altering the microenvironment so that certain cancer cell genotypes are selected for. In the 
absence of positive selection for a specific phenotype and genotype, primary tumours 
would be expected to have greater genetic heterogeneity. Overall, this study shows the 
utility of the MDGA in cancer research and provides further leads to explore relating to the 
impact of Rhamm absence on the CNV landscape of the cancer genome, particularly in the 
mechanisms of CNV formation and role of recurrent, genic CNVs. 
6.1 Study limitations 
There are several limitations for the studies described in this thesis that could be improved 
upon in future studies. When the MDGA probe lists were filtered, the impact of the filtering 
was assessed indirectly via SNP genotype call rate changes without additional biological 
confirmation. Following filtering and overall increases in SNP genotype, some poorly 
performing SNP probes that returned only “No Calls” remained. This could result from 
probe properties that were not filtered, like the presence of mononucleotide repeats or GC 
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content, or for other reasons like low sequence complementarity between the probes and 
sample DNA. Since the probe filtering was performed to improve CNV calling, SNP 
probes that are suitable for SNP genotyping but not for CNV calling, would have been 
removed. Thus, the use of the recommend filtered probes provided in Locke et al1 is more 
suited for CNV studies than SNP studies.  
When testing the ability of the MDGA to provide genotype calls for the genus Mus 
and for H. glaber samples, it was found that samples that are distantly related to mice can 
artificially be made to appear more closely related if genotyped together with mouse 
samples. Therefore, it is important that genotyping is performed using species-appropriate 
reference files and genotyping groups. Likewise, the sample size of the species of interest 
should be sufficiently large so that distinct genotype clusters can be generated. Lastly, 
because the genotyping output for cross-species hybridization experiments was observed 
to differ greatly depending on the approach used, biological confirmation is essential to 
ensure that the correct approach is being applied to detect biological events and minimize 
false calls.  
For the broad mouse survey study and the mouse cohort study, the greatest limitation 
is that the tissue that was used to generate the CEL files was not available for CNV 
confirmation. Although mouse-specific CNVs cannot be confirmed without the sample 
tissue, it may be possible to confirm strain-specific CNVs in a different member of the 
same strain. For identification of strain-specific and subspecies-specific CNVs to be 
possible, the sample size for each group should be increased so that recurrent CNVs can 
be identified. Using the same mouse subspecies for classical laboratory, wild-derived, and 
wild caught mouse cohort comparisons would help identify cohort differences that result 
from life in a laboratory environment or in a natural environment without any confounding 
effects from the inclusion of multiple subspecies.  
When using the MDGA to study somatic mosaicism, it is important to keep in mind 
that microarrays have limited sensitivity and resolution. This means that the CNVs that 
are most likely to be detected in a tissue sample are those that have a clonal size that meets 
the required detection threshold. For large clonal sizes to be present in normal tissue, the 
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CNV event either arose early in development or in a tissue with a high cell turnover rate 
where there is more opportunity for CNV formation to occur via replication errors2. The 
MDGA’s resolution limit does not allow for exact CNV breakpoint identification, so 
sequencing of the predicted breakpoint regions is required to locate the exact CNV start 
and end. Sequencing of these regions may also uncover the potential mechanisms by which 
CNVs arose. In the mouse family study, sequencing is required to determine if the Hoxa 
cluster deletions involve the same mechanism and CNV breakpoints in all members of the 
mouse family.  
The inclusion of adjacent normal tissue is needed to establish which CNVs in the 
cancerous tissues are associated with tumorigenesis and metastasis and which CNVs 
constitute the normal background genotype. The high amount of genetic heterogeneity 
present in cancerous tissues3 poses a challenge in CNV detection since CNVs will only be 
detected if they are present in a sufficient clonal size. Therefore, experimental confirmation 
of putative CNVs is necessary to identify biological events and determine false positive 
rates. Due to genomic instability in cancer, the CNVs found in cancerous tissues may be 
byproducts of an unstable genome without being contributors to cancer phenotypes. 
Therefore, confirmed CNVs need to be characterized through further experimentation to 
determine their role in cancer formation and development, metastasis, and treatment 
resistance. Another caveat of the cancer study described here, is that the CNV landscape 
that was observed is specific to the cancer model used here and could differ with the use 
of different cancer models, mouse strains, and mouse habitat conditions4–6. Likewise, the 
results observed in mouse models may not be reproducible in human studies due to 
biological differences between the species7.  
6.2 Future extensions 
The experiments conducted in this thesis all used filtered probe lists for SNP and CNV 
genotyping. To further improve on the probe lists used, a future study should be conducted 
to provide biological confirmation of the impact of probe filtering on genotyping. The 
impact of probe list filtering on CNV calling reliability can be assessed by using known 
CNVs (i.e. samples with known genotypes) to compare if CNV calling is more accurate 
before or after probe filtering. Similarly, the impact of probe list filtering on SNP genotype 
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calling can be assessed with PCR-based genotyping of samples to determine if the filtered 
probe list provides more reliable SNP genotype calls than the unfiltered list. Since 
algorithm selection and the composition of the dataset can influence SNP and CNV 
genotyping, experimental confirmation can be used to determine the best approach for 
detecting SNPs and CNVs with accuracy. Further experiments can be performed to assess 
the variant detection abilities of the MDGA in cross-species hybridization experiments. 
These experiments would need large sample sizes with species-appropriate model files, 
probe filtering based on a reference genome to identify and annotate useable probes in the 
species of interest, and biological confirmation of the results. Overall, these experiments 
would greatly improve the reliability of the MDGA in SNP and CNV detection in mice and 
possibly provide a SNP and CNV detection tool for studies where there is not a microarray 
available for the species of interest.  
6.2.1 Evolution and adaptation studies 
There are also multiple future extensions possible for the broad mouse survey study and 
the mouse cohort study. Future studies can be designed to investigate the role of CNVs in 
different mouse strains, and in mouse evolution and adaptation to different environments. 
At a mouse strain level, study extensions could include characterizing mouse strain-
specific CNV differences to assist with phenotype characterization and the determination 
of appropriate background strains to use in mouse model studies. From the perspective of 
evolution, evolutionary differences would be observable by studying different mouse 
subspecies and populations to find and characterize CNVs that contribute to phenotypic 
differences among these groups. A study that would be particularly relevant to the 
evolution of M. musculus subspecies is the role of CNVs in reproductive isolation, 
speciation, and hybrid sterility, since genetic incompatibilities leading to hybrid sterility 
are known to occur between M. musculus subspecies8. These CNV studies would first 
require characterization of the mating outcome of subspecies crosses and the fitness of 
offspring. Then CNV studies can be performed to identify differences between samples 
where mating was unsuccessful, or offspring fitness was reduced, in comparison to samples 
where cross-subspecies mating was successful and offspring fitness was not affected. For 
all future experiments, CNVs detected with microarray approaches would require 
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experimental confirmation, and the impact of a CNV on phenotype can only be established 
following additional functional genomics experiments that focus on the impact of the CNV 
on transcription, translation, gene expression regulation, protein or RNA functions and 
interactions, cell function, and organism development and fitness.  
In the mouse cohort study, CNV differences between mouse cohorts were indirectly 
studied but can be expanded upon using a more informative direct experimental approach. 
Further extensions would include identifying recurrent CNVs and characterizing them for 
phenotypic impact and to sequence the breakpoint junctions to identify the mechanisms of 
CNV formation. The mouse cohort study can be improved by using the same mouse 
subspecies for each cohort to reduce subspecies-related confounding factors. Ideally, CNV 
changes related to environmental adaptation would be studied by characterizing CNV 
profiles in wild caught founder populations and then observing how the CNV landscape is 
altered following the generation of inbred strains from the founding population, under 
laboratory housing conditions. The generated inbred strains would not contain genetic 
modifications like gene knockouts or selection for disease-related phenotypes since 
targeted genetic modifications may be confounding factors when studying CNV landscape 
alterations over generations. The goal would be to ensure that a different environment is 
the only or predominant factor influencing the CNV landscape in the mice. Conducting 
additional broad CNV survey studies across various mouse groups would also be of great 
value. Broad survey studies with single nucleotide resolution of CNV breakpoint junctions 
would be informative about common mechanisms of CNV formation in the mouse genome 
and where mutation hotspots are located. Furthermore, these studies could help identify 
which genomic regions highly conserved regardless of environment, and which are copy 
number variable allowing for different phenotypic traits.  
6.2.2 Study extensions for genome mosaicism in healthy tissues 
and cancer  
In this thesis, the contribution of CNVs to mosaicism was studied from the perspective of 
healthy tissues (mouse family study) and cancerous tissues. The mouse family study will 
need to be repeated due to problems with the data quality, and there are several 
modifications that can be included in the repeat experiments. First, the tissue samples that 
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are selected for study should include samples that represent only one germ layer rather than 
a mix of germ layers. This will allow for the determination of when a CNV arose in somatic 
tissue. Blood should also be included in the study to assess its usefulness as a sentinel 
tissue. More C57BL/6J mouse families, as well as other strains, can be included in future 
studies to generate CNV profiles are representative of most laboratory strains and to ensure 
that the data are not biased due to small sample sizes. In addition, somatic mosaicism 
experiments can be performed using wild mouse populations to determine if CNV 
mosaicism levels are influenced by the level of genetic diversity in a population and by an 
individual’s environment.   
Although reliable CNV profiles could not be generated for the mouse family study, 
the suggestive occurrence of a nonstochastic, postzygotic HOXA gene cluster deletion 
opened an unexpected area for confirmation and hypothesis testing related to a 
developmentally-programmed mutational event. Future studies can be performed to 
determine if the occurrence of the deletion is a wild-spread phenomenon in Mus, and if the 
deletions are programmed or occur due to being in an area susceptible to structural 
mutations. Sequencing of the Hoxa gene region will provide information on the exact 
genomic position and surrounding genomic context of the deletion in different tissues, 
which can be used to determine the mutation’s origin and mechanism of formation. If the 
Hoxa cluster is a mutation hotspot, then it is likely that germ cells are affected as well as 
the soma. Therefore, germ cells could be included in future studies to determine the 
frequency of Hoxa deletion occurrence and what are the impacts on reproduction success 
and offspring health.  
When studying mosaicism in cancer, the genetic heterogeneity of the cancerous 
tissue created challenges in microarray-based CNV detection. To better characterize the 
CNV landscape in tumours with respect to improved resolution and sensitivity, a 
sequencing-based approach would be recommended in combination with isolation of cell 
subpopulations. Comparisons between CNV profiles of primary tumour cell populations to 
metastasis cells and normal adjacent cells could provide insight into mechanisms of 
tumorigenesis and successful metastasis. The use of large sample sizes would be required 
to be able to identify patterns and statistically significant differences between sample 
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groups. To attribute functional roles to CNVs of interest, functional genomics and 
phenotypic impact experiments would be required. Future aims for the MMTV-PyMT 
Rhamm cancer study include conducting additional experiments to determine phenotypic 
impacts of genic CNVs, determining if Rhamm genotype influences that mechanism of 
CNV formation, and establishing if there is positive selection for cells with a specific 
genotype due to microenvironment changes in the absence of Rhamm. 
The MDGA may also prove useful in studying how the CNV landscape is altered 
in a mouse or specific tissues of a mouse following mutagen exposure. Normal CNV 
profiles from somatic mosaicism studies can serve as a baseline for comparison to 
mutagen-exposed samples, while some cancer profiles may represent the extreme end of 
genomic instability. There is also potential for using the MDGA as a biomonitoring tool 
for laboratory and natural mouse populations with the goal of monitoring levels of genetic 
diversity and checking for environmental mutagen exposure. In conclusion, the work 
presented in this thesis provides researchers with a CNV detection pipeline compatible with 
MDGA data, with potential use in studying the CNV landscapes of Mus musculus and 
closely related species from the perspective of evolution and adaptation, and genome 
mosaicism in healthy and disease-afflicted individuals.     
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Appendices 
Appendix 2A: Genome-Wide Human SNP Array 6.0 filtered probe list. (Online)  
Appendix 2B: Genome-Wide Human SNP Array 6.0 filtered probe list including 
flanking regions. (Online) 
Appendix 2C: 874 HapMap3 CEL files. (Online) 
Appendix 2D: Sample Affymetrix Power Tools commands for using Birdseed 
version 1 and version 2 algorithms for SNP genotyping with the apt-probe-genotype 
program. 
#Birdseed v1 example  
apt-probeset-genotype \ 
-o Output_Directory/ \ 
-c GenomeWideSNP_6.Full.cdf \ 
-s Probe_list.txt \ 
--special-snps GenomeWideSNP_6.Full.specialSNPs \ 
--read-models-birdseed GenomeWideSNP_6.birdseed.models \ 
-a birdseed \ 
--cel-files CEL_Files.txt \ 
--verbose 2 
 
#Birdseed v2 example  
apt-probeset-genotype \ 
-o Output_Directory/ \ 
-c GenomeWideSNP_6.Full.cdf \ 
-s Probe_list.txt \ 
--chrX-probes GenomeWideSNP_6.chrXprobes \ 
--chrY-probes GenomeWideSNP_6.chrYprobes \ 
--special-snps GenomeWideSNP_6.Full.specialSNPs \ 
--read-models-birdseed GenomeWideSNP_6.birdseed-v2.models \ 
-a birdseed-v2 \ 
--cel-files CEL_Files.txt \ 
--verbose 2 
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Appendix 2E: 351 Mouse Diversity Genotyping Array CEL files from The Center for 
Genome Dynamics at The Jackson Laboratory and sample ID. (Online) 
Appendix 2F: List of Mouse Diversity Genotyping Array SNP probes from filtered 
probe list that produced a No Call genotype in all 351 mouse samples. (Online) 
Appendix 2G: List of genes unlikely to vary in copy number. (Online) 
Appendix 3A: Mouse sample information for 351 Mouse Diversity Genotyping Array 
CEL files. (Online) 
Appendix 3B: Mouse sample cohort, subspecies and origin information for 215 Mouse 
Diversity Genotyping Array CEL files. (Online) 
Appendix 3C: Autosomal CNVs detected for 351 mouse samples. (Online) 
Appendix 3D: Chromosome X CNVs detected for 351 mouse samples. (Online) 
Appendix 3E: Summary of autosomal and Chromosome X CNVs detected for 351 
mouse samples. (Online) 
Appendix 3F: CNVs detected for 210 mouse samples. (Online) 
Appendix 3G: Summary of autosomal and Chromosome X CNVs detected for 210 
mouse samples. (Online) 
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Appendix 3H: Summary of the predicted and experimental ddPCR copy number (CN) states for nine genic copy number 
variant regions (CNVRs) in three classical laboratory mouse strains.  
a The CNVR start and end positions are determined by the earliest start position and latest end position in a group of overlapping 
CNVs for CNVs detected in C57BL/6J, CBA/CaJ and DBA/2J mice 
b These genes partially overlap the CNVR 
c The number of mice where the observed CNV only partially overlapped the gene of interest is underlined 
CNVR 
gene 
target 
TaqMan® Copy 
 Number 
Assay ID 
CNVR locationa 
CNVR 
size 
(bp) 
Number 
probes in 
CNVR 
(SNP, IGP) 
Predicted CN state summary 
(number of mice) ddPCR CN state summary 
C57BL/6J 
(n = 8) 
CBA/CaJ  
(n = 1) 
DBA/2J  
(n = 1) 
C57BL/6J 
(n = 5) 
CBA/CaJ 
(n = 5) 
DBA/2J 
(n = 4) 
B4galt3b Mm00735212_cn chr1:173206026-173208119 2,093 2, 18 2 (5), 3 (3)
c 2 2 2 2 2 
Fgfbp3 Mm00630217_cn chr19:36990335-37045706 55,371 12, 38 2 (5), 3 (3) 2 2 2 and 3 2 2 
Glo1 Mm00735212_cn chr17:30593663-31058945 465,282 61, 273 1(6), 2 (2) 3 3 2 4 4 
Hdhd3 Mm00553493_cn chr4:62157378-62185081 27,703 3, 33 2 (8) 4 3 2 6 6 
Ide Mm00496897_cn chr19:37317974-37451133 133,159 31, 54 
2 (2), 3 
(5,1) 2 2 2 2 2 
Itln1 Mm00534147_cn chr1:173391344-173508077 116,733 12, 43 1 (8) 2 2 2 2 2 
Nlrp1bb Mm00635379_cn chr11:71014664-71099017 84,353 3, 29 
2 (1), 3 (2), 
4 (5) 2 2 2 2 2 
Skint3 Mm00735949_cn chr4:111745396-112064463 319,067 0, 61 4 (2,6) 2 2 2 0 0 
Trim30e-
ps1 Mm00657977_cn 
chr7:111681502-
111683670 2,168 0, 7 2 (5), 4 (3) 2 2 2 0 0 
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Appendix 3I: Western University ethics approval for animal use in research. 
 
 
2009-033::6: 
AUP Number: 2009-033 
AUP Title: Mutational Mechanisms 
 
Yearly Renewal Date: 10/01/2015 
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2009-033 has been approved and will be 
approved for one year following the above review date. 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the 
ACVS office. 
Health certificates will be required. 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are 
familiar with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components 
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have 
received all necessary approvals. Please consult directly with your institutional safety officers. 
Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee 
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Appendix 3J: CNV and SNP genetic distance matrices. (Online) 
Appendix 3K: Ingenuity Pathway Analysis core analysis of genes overlapping CNV 
regions for different copy number states and two mouse cohorts. (Online) 
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Appendix 3L: DdPCR confirmation of CN state in 14 mice of three different inbred strains for nine select genic CNVRs 
detected using the Mouse Diversity Genotyping Array. 
Gene assay  
ddPCR CN state  
C57B/6J mouse  CBA/CaJ mouse DBA/2J mouse 
1 2 3 4 5 1 2 3 4 5 1 2 3 4 
B4galt3 
1.99 1.80 2.01 1.90 1.94 2.04 2.09 2.02 1.97 1.89 2.01 1.94 1.94 1.97 
1.87 1.87 1.87 1.99 2.00 2.02 2.17 2.00 1.85 1.96 1.87 1.90 2.02 2.03 
Fgfbp3a 
1.97 2.92 2.06 2.07 2.12 2.02 2.11 2.00 1.99 2.11 2.11 2.09 2.00 2.05 
2.04 2.89 2.03 2.04 2.04 2.05 2.03 2.15 2.00 2.05 1.99 2.02 1.97 2.00 
Glo1a 
1.89 2.04 2.05 1.94 1.94 3.94 3.88 3.84 3.97 3.99 3.86 4.12 3.87 3.90 
2.01 1.97 1.97 2.01 1.99 3.93 3.94 3.99 4.00 3.99 3.96 4.10 3.94 3.74 
Hdhd3a,c  
1.93 1.78 1.98 1.98 1.96 5.85 5.87 5.93 6.02 5.86 5.66 5.90 5.90 5.70 
1.96 1.71 1.95 1.98 1.96 5.80 5.80 6.01 5.78 5.81 5.69 5.71 5.89 5.90 
Ide 
1.89 1.86 1.92 1.88 1.87 1.91 1.90 1.94 1.89 1.94 1.97 1.94 1.86 1.99 
1.94 1.89 1.93 1.92 1.89 1.94 1.91 2.01 1.94 1.90 1.99 1.94 1.96 1.97 
Itln1a,b  
1.96 1.89 1.95 1.95 2.06 1.94 1.92 1.98 1.93 1.92 1.95 1.89 2.01 1.94 
1.90 1.90 2.03 2.02 1.97 1.9 1.93 1.96 1.88 2.06 2.01 1.94 1.99 1.92 
Nlrp1b 
2.09 2.01 2.01 1.99 1.86 1.98 1.96 1.95 1.92 1.99 2.09 2.11 2.04 2.06 
2.09 1.97 1.89 1.99 1.97 1.99 2.01 2.04 1.99 2.02 1.96 2.04 1.98 1.99 
Skint3  
2.09 2.19 1.91 2.08 2.09 0 0 0 0 0 0 0 0 0 
2.02 2.04 2.02 1.98 1.99 0 0 0 0 0 0 0 0 0 
Trim30e-ps1 
2.07 1.88 1.98 2.10 1.94 0 0 0 0 0 0 0 0 0 
2.00 1.91 1.94 2.01 1.99 0 0 0 0 0 0 0 0 0 
a The gene is entirely within the CNV observed in each mouse 
b All DBA/2J and CBA/CaJ samples had multiple droplet populations between the lowest amplitude negative droplet population and 
the highest amplitude Itln1 postive droplet population. This may be caused by strain-specific genetic variation affecting amplification 
efficiency 
c For C57BL/6J mouse 2, the CN is likely two but ddPCR values were lower than expected for a CN of two, possibly because the 
duplicate regions are very close in proximity and further fragmentation of the sample is required to accurately detect the CN state
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Appendix 3M: List of CNVs found overlapping genes that are unlikely to vary in copy 
number. (Online) 
Appendix 4A: Log R ratio, B allele frequency, and waviness factor values for 26 
mouse tissue samples and two PennCNV runs. (Online) 
Appendix 4B: CNV calls for first PennCNV dataset. (Online) 
Appendix 4C: CNV calls for second PennCNV dataset. (Online) 
Appendix 5A: CNV calls for six mammary gland primary tumour samples and six 
lung with metastasis samples from three MMTV-PyMT Rhamm-/- mice and three 
MMTV-PyMT Rhamm+/+ mice. (Online) 
Appendix 5B: CNV and SNP genetic distance matrices. (Online) 
Appendix 5C: Copy number state, position and genic content of CNV regions that are 
recurrent in all three samples with a shared Rhamm genotype and tumour type. 
(Online) 
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